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ABSTRACT 
Annually more than 3.45 million new cases of cancer are registered in Europe which makes cancer 
one of the most deadly diseases. Current strategies to diagnose, image and treat cancer still lack 
efficiency, is invasiveness and are provoking uncomfortable side-effects for the patient. While 
still in an early stage of development, gold nanoparticle-based diagnostics and therapeutics could 
potentially alleviate these shortcomings. The wide-based interest for these gold nanoparticles 
originates from their unique optical and thermal properties appearing at a nanometer scale. These 
properties form basis for their use as an imaging (e.g. photoacoustic imaging) and therapeutic 
(e.g. photothermal therapy) agent. As a consequence these gold nanoparticles can be used as a 
theranostic agent combining both their imaging and therapeutic capabilities into one nanoparticle.  
In this PhD work we used gold nanostars as a theranostic agent for HER2 expressing tumor 
masses, since they have stronger optical properties compared to other anisotropic gold 
nanoparticles. To be used in clinical conditions, these nanostars have to meet critical requirements 
including the absorption of light in the NIR-region, a hydrodynamic diameter below 100 nm and 
to be highly stable under physiological conditions.  Optimizing the existing synthesis and 
functionalization procedure resulted in the desiring nanostars. In vitro and in vivo experiments 
(by intratumoral injection) confirmed their theranostic properties while they end up in vesicular 
structures in the tumor cells. However the final goal is to target these tumor masses by the 
nanostars after intravenous injection. Two targeting strategies are explored, either passively 
where the nanostars diffuse into the tumor interstitium or actively where the nanostars are 
functionalized with a biological molecule, which recognizes an overexpressed receptor on the 
tumor cells. While passive targeting showed an effective nanostar uptake in the tumor cells in 
vitro, by changing the end-group of the self-assembled monolayer on the nanostar surface, in vivo 
the nanostars did not accumulate at the tumor masses. Active targeting could increase this uptake 
where the nanostars were functionalized with a nanobody targeting the HER2 receptors on the 
tumor cells. Specific uptake of the nanobody functionalized nanostars in the tumor cells was 
realized in vitro and in vivo after blocking the protein corona formation by deactivating the 
chemically active groups on the nanostar’s surface.  
Developing gold nanostars as a theranostic agent for cancer is a multidisciplinary research task 
where chemistry, biology and nanotechnology encounters. This study contributed to important 
improvements on both studying the theranostic properties of the nanostars as well as on 
optimizing the targeting strategies of the nanostars to tumor masses.  
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SAMENVATTING 
Jaarlijks is kanker nog altijd één van de belangrijkste doodoorzaken in Europa waarbij  nog steeds 
3.45 miljoen nieuwe kanker patiënten geregistreerd worden. Huidige kanker diagnose-, 
beelvormings-  en therapiestrategiën missen nog altijd efficientie en zijn invasief waardoor het 
veel neveneffecten heeft voor de patient. Ondanks dat het onderzoek rond gouden nanopartikels 
in een startende fase zit, zouden deze nanoparticles deze noden kunnen voldoen door hun unieke 
optische en thermische eigenschappen. Deze eigenschappen zijn de basis voor hun beeldvormings 
(bv: fotoakoestische beeldvorming) en therapeutische (bv: fotothermale) capaciteiten. Bijgevolg 
kunnen ze zelf gebruikt worden als een theranostische agentia waarbij hun beeldvorming en 
therapeutische capaciteiten gecombineerd worden. 
In deze doctoraatsthesis hebben we gouden nanosterren gebruikt als een theranostische agentia 
voor HER2 expressie brengende tumorcellen. Deze nanosterren zijn gekozen door hun sterkere 
optische eigenschappen in vergelijk met andere anistrope nanosterren. Voor ze gebruikt kunnen 
worden in klinische condities moeten deze nanosterren voldoen aan een paar voorwaarden zoals 
het licht absorberen in het NIR gebied, een hydrodynamische diameter hebben onder 100 nm en 
stabiel zijn in fysiologische condities. Dit werd gerealiseerd door bestaande synthese en 
functionalisatie processen te optimaliseren. Met behulp van in vitro en in vivo experimenten 
(intratumorale injectie) werd hun theranostische eigenschappen bevestigd waarbij de opname van 
de nanosterren in vesiculaire structuren van de tumor cel werd gevisualiseerd. Voor de finale 
toepassing, moeten de nanosterren specifiek opstalen in de tumor massa’s na intraveneuze 
toediening. Hiervoor zijn er twee strategiën beschreven, zowel de passieve targeting waarbij de 
nanosterren diffuseren in het tumor interstitium, of de actieve targeting waarbij de nanosterren 
gefuntionaliseerd worden met een biologisch molecule dat een kankerspecifiek ligand herkent op 
de tumorcellen. Ondanks dat voor de nanosterren een effectieve opname in de tumor cellen is 
waargenomen in vitro, afhankelijk van de eindgroep op de chemische stabiliserende laag, kon 
deze resultaten in vivo niet geraliseerd worden. Actieve targeting van de HER2 receptors zou deze 
nanoster opname in de tumorcellen kunnen verhoren met behulp van nanobodies. Specifieke 
opname van deze biologisch gefunctionaliseerde nanosterren werd in vitro and in vivo 
gerealiseerd na het deactiveren van de actieve groepen op de oppervlakte van de nanosterren 
waardoor de protein corona diameter geminimaliseerd werd rond de nanosterren. 
Het gebruik van nanosterren als een theranostische agentia voor cancer is een multidisciplinair 
onderzoek op de grens van chemie, biologie en nanotechnologie. Deze studie heeft bijgedragen 
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op het vlak van de theranostische eigenschappen als ook op de geoptimaliseerde targeting 
strategie van de nanosterren in tumor massa’s. 
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1 INTRODUCTION 
 
Currently, cancer is still one of the most deadly diseases in the world.  In Europe 3.45 million 
new cases of cancer and 1.75 million deaths as a result of cancer are registered annually1. In view 
of these high numbers, various imaging and therapeutic techniques are currently employed as a 
standard of care for these patients. These techniques face still severe limitations to be practical 
and their usage depends on the actual cancer disease2. Therefore new approaches are needed to 
develop a target delivered therapy that can be monitored by imaging. Hereby solutions could be 
offered by the bionanotechnology field where nanoparticles may play a crucial role3.  
 
1.1 Cancer 
 
The conception of cancer has changed over the last decades. While previously tumors were seen 
as masses of proliferating cancer cells, nowadays they are noted as complex tissues consisting of 
different cell types participating in several cell interactions. The tumor cells interact specifically 
with other cells, ranging from immune to epithelial cells, resulting in an unique tumor 
microenvironment 4.Contributing to this microenvironment, ten essential hallmarks are defined, 
where each one is crucial for cancer development.  The follow up of these hallmarks defines the 
neoplastic characteristics of each tumor5.    
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Each hallmark is characterized by the down or up regulation of specific biological molecules due 
to genetic mutations. One example is the human epidermal growth factor 2 receptor (HER2) 
showing an overexpression in 20-30 % of breast cancer which is assigned to the hallmark of 
sustaining proliferative signaling. This overexpression is associated with tumor aggressiveness 
and an increased probability for recurrent disease6. The main reason for this cause of 
aggressiveness is the role of the tyrosine kinase receptor as a transducing growth stimulator to the 
cell interior, enhancing cell proliferation. Having an over-expression, tumor cells are hyper-
responsive to ambient levels of growth factors that normally would not trigger cell proliferation.  
This overexpressed receptor is an ideal target for cancer therapies, such as the monoclonal 
antibody Herceptin targeting HER26.   
 
Overall, the hallmark of metastasis formation, the spread of the tumor cells of the primary tumor 
to other organsq is responsible for 90% of the human cancer deaths. Diagnosing and treating the 
tumor before the formation of metastases is still one of the main challenges in current cancer 
treatment5.  
 
1.1.1 Diagnosis of cancer 
 
Until today, there is no single test that can diagnose cancer. Rather a combination of various 
techniques ranging from biomarker tests, histopathology after tumor biopsy and medical imaging 
techniques are required to verify if a patient has cancer. These imaging techniques are described 
as the visualization of the interaction of electromagnetic radiation or sound waves with an object 
as a tumor7. Since each imaging technique has its own key strengths and limitations, they are 
often complementary used for diagnostic imaging.     
 
In the clinic, three imaging methods are often used for cancer diagnosis: magnetic resonance 
imaging (MRI), X-ray computed tomography (CT) and position emission tomography (PET)8.  
Contrast in MRI is based on the relaxation time of hydrogen proton spins after applying an 
external magnetic pulse (Figure 1.1). Having different hydrogen relaxation times in soft tissue 
with and without contrast agents, MRI is commonly used as a soft tissue contrast imaging tool 
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ideally for cancer imaging9. Still, MRI is an expensive technique necessitating long scanning 
times for generating high spatial resolution. Conversely, CT uses the X-ray attenuation properties 
of tissues/bones for generating contrast (Figure 1.1). With faster scanning times and broadly 
available instrumentation, CT is commonly used for diagnosing particular cancers, e.g. 
mammography for breast cancer10.  At last, PET is based on the detection of ionizing radiation 
emitted by a radioactive contrast agent/ tracer (Figure 1.1). The radioactive label is typically part 
of a biologically active molecule (e.g. glucose) having a higher uptake or accumulation in specific 
cells such as tumor cells. These agents provide highly sensitive functional / metabolic imaging 
with limited anatomical information. This technique is routinely used for detecting 
tumors/metastasis using e.g. fluorodeoxyglucose or radiolabeled amino acids9.  
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Figure 1.1. Schematic overview of the non-invasive imaging techniques. (A) Magnetic Resonance 
Imaging (B) X-ray Computed Tomography (C) Positron Emission Tomography (D) Ultrasound (E) 
Fluorescence Imaging (F) Photoacoustic imaging. 
 
 Less commonly used imaging techniques for cancer have gained particular interest in the field of 
biomedical research during the last years. Ultrasound, imaging the interaction of ultrasound waves 
with biological tissues, is commonly used for maternity imaging and in cardiology (Figure 1.1). 
By using microbubbles targeting cancer, this technique could be applied as a sensitive and cost 
efficient cancer imaging technique. Optical imaging techniques (fluorescence, bioluminescence, 
and Surface Enhanced Raman Imaging) rely on the emission of photons by specific molecules 
(Figure 1.1). Having high sensitivity due to the use of optical agents but low penetration depth, 
these techniques focus rather on preclinical imaging in small animals or as guidance during 
surgical removal of tumor lesions (interventional imaging). At last, photoacoustic imaging, a 
combination of optical and ultrasound imaging is making its way in the (pre-) clinical field (Figure 
1.1). This technique relies on the thermo-elastic expansion of a contrast agent after laser 
irradiation with a nanosecond pulse. Consequently, it combines the benefits of both imaging 
techniques11. 
 
1.1.2 Therapy of cancer 
 
The most critical step in cancer treatment is the actual therapy itself. This stage is highly 
dependent on the type and stage of the cancer.  
  
Current common cancer treatment techniques are surgery, radiotherapy and chemotherapy, which 
are applied as single techniques or in combination12. Surgical removal is used when a non-
metastasized tumor is located in non-crucial parts of organs. In the best case, all the tumor cells 
are removed during surgery, affecting healthy cells as least as possible13. For tumors located close 
to complex organs, radiotherapy is often opted. With this therapy ionizing radiation causes DNA 
damage that can be repaired efficiently by cells, but not by tumor cells. By applying the right 
radiation dose, tumor cells will be affected while healthy cells are able to recover. Still, 
radiotherapy efficiency is dependent on the amount of cells the radiation has to pass and an 
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efficient local application of the radiation14.  Another common treatment technique for 
metastizing tumors in the clinic is chemotherapy, where specific cytotoxins are applied to inhibit 
growth or even kill fast proliferating cells like cancer cells. Unfortunately, next to cancer cells, 
other cells such as bone marrow, leukocytes etc. are also affected. In many cases a combination 
of chemotherapy is applied, where a cocktail of medicines is used to limit side effects and spread 
the toxicity over the whole body instead of over only one organ, and to limit the resistance against 
specific medicines.  Overall these techniques are rather invasive, resulting in a long and complex 
recovery for the patient after therapy15.   
 
Because current cancer treatment approaches clearly have limitations and disadvantages, there is 
a huge interest in new therapeutic strategies, such as targeted delivery and hyperthermia. During 
hyperthermia treatment, heat is applied to the tumors resulting in a specific cell death.  This heat 
can be applied on a local level at the tumor site or to the whole body. Currently this heat is applied 
by external fluid applied around the body, ultrasound, fluctuating magnetic fields or laser based 
therapy16. Moreover this heat can be used for thermally triggered drug release which can result in 
a specific cancer therapy17.    
1.1.3 Theranostics 
 
In the last decade, major efforts have been intiated to develop more specific and individualized 
therapies to particular sub-types of tumors by combining the diagnostic and therapeutic 
capabilities into one agent9. Since cancer is such a complex disease, current therapies are only 
effective for a limited amount of patients in a specific stage of the disease. It is generally believed 
that by the integration of diagnostic and therapeutic capabilities into one agent, a more controlled 
and specific therapeutic protocol per individual could be achieved. This concept of combining 
diagnosis and therapy is called ‘theranostics’3. 
 
Table 1.1 Examples of nanoparticles used as a cancer theranostic agent 
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Nanotechnology plays a crucial role within this emerging research field to combine therapy and 
imaging into one agent, a so-called nanoparticle. Several types of nanoparticles have been studied 
ranging from solid nanoparticles (magnetic, gold etc.) to polymeric structures such as liposomes18. 
Those nanoparticles can be coupled with targeting moieties like antibodies, nanobodies or small 
molecules 19. Therapy can be achieved by either the properties of the core particles themselves or 
by linking or loading the nanoparticles with chemotherapeutic agents20,21. The interest in solid 
nanoparticles as a theranostic agent is also illustrated by several companies starting within this 
field (Table 1)22. In this work, the focus is on gold nanoparticles and their tumor targeting 
capabilities as a nanotheranostics agent.   
1.2 Nanoparticles 
 
A nanoparticle is defined as “a particle with all three external dimensions in the nanoscale”23. 
When one of the dimensions is greater than 100 nm, or at least significantly larger than the other 
two, the name nanofiber is more appropriate. Potentially, nanoparticles have applications in a 
wide range of fields, such as medicine engineering, energy and many more24,25. 
 
Within this medical field, a huge range of different nanoparticles are either studied or either 
currently used as a standard of care. A main division within this field of nanoparticles can be 
Trade Name Description of Nanoparticle Cancer targeted by the Nanoparticle Phase of Development
Resovist Carboxydextran-coated SPIO
MRI contast agent for imaging 
hepatocellular carcinoma
Approved
Nanotherm Aminosilane-coated SPIO
Local ablation of glioblastoma 
multiform
Approved
Nanotherm Aminosilane-coated SPIO Pancreatic and prostate cancer Phase 1
Aurimmune
Gold nanoparticle loaded with tumor 
necrosis factor
Solid tumors Phase 1
AuroShell
Near-infrared irradiation with gold 
nanoshells (localized thermal ablation)
Head an Neck Cancers Phase 0 (pilot study)
C-dots PEG-coated SiO2 Melanoma IND approved
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made between organic and inorganic nanoparticles. Organic nanoparticles consist of biological 
molecules where the most studied ones are bilipid layered structures called micelles. Inorganic 
nanoparticles comprise a huge variety of nanoparticles such as quantum dots, iron oxide, silica, 
gold nanoparticles etc. All these types of nanoparticles have their advantages and disadvantages 
to use them in the medical field26,27.  
 
Within the field of inorganic nanoparticles, noble metal nanoparticles have fascinated scientists 
since long times because of their specific properties in comparison to their bulk material. A main 
difference between noble metal nanoparticles and the noble metal bulk material is the bright color 
of nanoparticles. This is the result of a plasmon absorption band, which is lacking in the bulk 
material28.  
 
1.2.1  Localized Surface Plasmon Resonance  
 
The plasmon absorption band is seen when metal nanoparticles are exposed to light which causes 
the ‘localized surface plasmon resonance’ (LSPR) effect. Here the electromagnetic field of the 
light induces a resonant coherent oscillation of the free electrons of the metal conduction band 
(Figure 1.2). This results in a charge separation around the nanoparticle surface, perpendicular to 
the incoming electromagnetic field, causing a dipole moment along the axis of the 
electromagnetic field. When the frequency of the light is in resonance with the eigenfrequency of 
the electron oscillations of the nanoparticles, the amplitude of the oscillation will be maximal.  
This results in a strong absorption band at the ‘plasmon frequency’. The decay of the surface 
plasmon is fast and happens radiative, by emission of a photon, and non-radiative, by the creation 
of electron-hole pairs. The former results in elastic/Rayleigh scattering, the latter in absorption, 
followed by a conversion to heat29.  
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Figure 1.2. Schematic drawing of the LSPR effect. 
 
The LSPR effect was theoretically explained by Mie in 1908 by solving the Maxwell’s 
electromagnetic equation for the interaction of light with spherical nanoparticles30. For 
nanoparticles smaller than the wavelength of the incident light (λ >>2R < 25 nm), only the dipole 
absorption of the Mie equation contributes to the extinction cross section of the nanoparticles29. 
This results in the following equation:  
 
𝐶𝑒𝑥𝑡 =
24𝜋2𝑅3𝜀𝑚3 2
⁄
𝜆
𝜀𝑟
(𝜀𝑖 + 2𝜀𝑚)2 + 𝜀𝑟2 
 
 
In this equation Cext is the extinction cross section (nm2), R is the radius of the metallic (nm) 
nanoparticle, λ is the wavelength of the incident light (nm), εm is the dielectric constant of the 
medium of the nanoparticle, εr and εi are the real and imaginary compound of the nanoparticle's 
dielectric function, respectively. The εr determines the position of the surface plasmon resonance, 
the εi the width of this band. As can be derived from the simplified Mie equation, will the 
absorption maximum will be attained when εr = -2 εm. The real part of this equation determines 
the wavelength position of the resonance, the imaginary part determines the bandwidth. As a 
result of this, spherical golden nanoparticles display a typical absorbance band around 520 nm. 
The exact location of this absorbance band is dependent on multiple factors, as described below31.  
 
1.2.1.1 Effect of the nanoparticle material 
 
The material effect of LSPR in the Mie function can be explained by the (εr + 2εm) part of the 
dipole approximation. Most noble metal nanoparticles (e.g. lead, mercury, tin and cadmium 
Chapter 1: Introduction 
 
 
 
Antoine D’Hollander   9 
 
 
 
nanoparticles) show an absorbance band in the UV range, and therefore do not exhibit strong 
color effects32. An exception to nanoparticles with a LSPR band in the UV-Vis range are the 
coinage metals: copper (Cu), silver (Ag) and gold (Au)33. Due to the d-d band transition, the 
absorbance band of these coinage metal nanoparticles is in the visible region of the spectrum. 
Copper nanoparticles with a diameter of 20 nm show an absorption band around 620 nm, while 
silver at 400 nm and gold around 520 nm, respectively. For biological studies, gold nanoparticles 
(AuNPs) are preferred due to ease of synthesis, higher stability, limited toxicity, and higher 
biocompatibility31,34.    
 
1.2.1.2 Effect of the nanoparticle size 
 
The Mie equation shows only a size dependence of the extinction cross intensity but not of the 
plasmon resonance. However, there is still a strong size dependence on the plasmon bandwidth 
and position with nanoparticles smaller than the wavelength of the incoming electromagnetic 
wave.  Supposedly, this dependence is attributed to the dielectric function, εm. This size-
dependence is called the intrinsic size effect.   
 
For larger nanoparticles (diameter (2R) > 25 nm), the extrinsic size effect occurs. In this case, 
higher order oscillations and scattering should be taken into account for solving the Mie equation. 
These higher order oscillations are explained by an inhomogeneous polarization of the 
nanoparticles when their size is comparable to the wavelength. By superposition of the dipole 
oscillations and higher order oscillations, such as quadrupole and octopole, a broadening of the 
plasmon band occurs. Furthermore, the higher order oscillations and scattering are explicitly size-
dependent and therefore a red shift occurs as the particle size increases. This increase in extinction 
coefficients by increasing size is mainly due to the relative contribution of the scattering 
coefficient31,35.   
 
1.2.1.3 Effect of the surrounding medium 
 
It is known that the total extinction coefficient is sensitive to the dielectric properties of the 
surrounding medium, explained by the εm factor36. More specific the refractive index close to the 
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material plays a crucial role. An increase in the refractive index will cause a red shift of the 
plasmon band, where a linear increase has been found for some nanoparticles with increasing 
refractive index.   
 
1.2.1.4 Effect of the nanoparticle shape 
 
The shape of the nanoparticles has a notable effect on the position of the LSPR band, even more 
than the material, size and surrounding medium37. Next to changing the position of the absorption 
plasmon band into the NIR region, changing the shape can also increase the cross extinction 
coefficient. In addition to spherical particles, rod-, shell-, cage-, cross, hollow- and star-shaped 
particles have been synthesized, each shape having their specific optical properties38. 
 
In the case of elongated nanoparticles, such as rods, the direction of the plasmon oscillation 
depends on the orientation of the particle axis with respect to the oscillating electric field of the 
incident light. This results in two plasmon bands, one for the longitudinal absorption and one for 
the transverse absorption (Figure 1.3)32. The relative position of these bands depends on the ratio 
of long to short axis, the so-called aspect ratio. When the aspect ratio increases, the wavelength 
difference between the two bands will be larger39. 
 
 
 
Figure 1.3. A. TEM picture of nanorods having different aspect ratio. B. LSPR spectra of nanorods 
with increasing aspect ratio by using lower gold seed concentration during synthesis. 
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Gold nanocages represent a new type of nanoparticles with a hollow interior and a thin porous 
wall. By changing the thickness and porosity of the walls, their absorption band can be tuned into 
the near infrared region (NIR; Figure 1.4). During synthesis, the basis silver cubes are replaced 
by hollow gold nanocages with pores. By increasing the gold concentration during synthesis, the 
wall thickness will increase shifting the plasmon band to longer wavelengths40,41.  
 
 
Figure 1.4. A. SEM picture of the nanocages starting from silver cubes (A) to gold nanocages (D). As 
inset a TEM picture where the hollow shape of the nanocages is shown. B. LSPR spectra of the 
nanocages after addition of different volumes of gold salt resulting in thicker gold walls. Different 
colors are observed for these nanocages as seen on the photograph 
 
Also for star-shaped nanoparticles is the plasmon band red-shifted compared to spherical 
particles, typically resulting in a plasmon band in the near infrared region (NIR). This shift mostly 
results from the sharpness and length of the branches, and less from the size of the particles. When 
the branches increasing in length, a shift towards the NIR is measured (Figure 1.5)42,43.  
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Figure 1.5. A. SEM picture of the nanostars having an increasing length of their branches. B. LSPR 
spectra of these nanostars having a different LSPR maximum. 
 
1.2.2 Required properties for in vivo use 
 
To apply these nanoparticles in vivo as a theranostic agent against cancers, they need to comply 
with a number of requirements ranging from the position of the LSPR band, size and stability in 
physiological conditions.  
  
1.2.2.1 The biological window 
 
As a first requirement, the maximum LSPR band of the gold nanoparticles must be tuned to the 
NIR region for maximum depth penetration. Within this region, the light can penetrate up to a 
few centimeters inside the human (or animal) body. This pronounced effect is caused by the lower 
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absorption of light by water and hemoglobin at this specific wavelength zone compared to other 
wavelength zones (Figure 1.6). Consequently this region is called, the biological window44.   
 
 
Figure 1.6. Schematic drawing of the biological window (650-900 nm) where hemoglobin and water 
show minimal absorption 
 
Gold nanoparticles can be tuned to have their maximum of the LSPR band in the NIR region by 
changing their shape. Several special shaped gold nanoparticles have been introduced such as 
nanorods, nanocages, nanoshells, hollow nanospheres, nanostars etc  18. 
 
1.2.2.2 Enhanced Permeability and Retention Effect 
 
To deliver the nanoparticles to the therapeutic site like a tumor, the particles have to overcome 
biological barriers like the one between the vasculature to the interstitial space. A crucial 
parameter to overcome this barrier is the size of these nanoparticles, which has to be small enough 
to passively diffuse through the vascular pores of the tumor masses. Particles with a size between 
20-600 nm have been shown to passively diffuse more easily into the tumor due to the Enhanced 
Permeability and Retention Effect (EPR)45. This effect can be explained by the leaky vasculature 
of the tumor compared to the healthy tissue (Figure 1.7). Due to this defective tumor vascular 
architecture, which results in fenestrations, there is no constant blood flow and the lymphatic 
drainage is inefficient which leads to enhanced retention into the tumors. This is typical for 
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tumors, but can also appear in several other organs, such as the sinus endothelium of the liver. 
Nanoparticles can accumulate inside the interstitial space by escaping the blood vessel through 
pores in the endothelial cell layer. This effect can be observed in almost all human cancers, with 
the exception of hypovascular tumors such as prostate cancer or pancreatic cancer46. If the 
nanoparticles are smaller than 20 nm, a more widespread distribution in all other organs will occur 
47. 
 
Figure 1.7. Schematic representation of the enhanced permeability and retention effect in the tumor 
 
1.2.2.3 Retention time 
 
The blood retention time of nanoparticles (after intravenous (i.v.) injection) is a crucial parameter 
for its systemic delivery. Having a long retention time will increase the possibility of the 
nanoparticles to accumulate inside the tumor.  Several determining factors for the blood retention 
time have been described48. The first factor is that not only tumors, but also the spleen and liver 
are characterized by fenestrae instead of vascular tight junctions. Materials up to 600 nm can pass 
through these gaps, ending up in these organs. Second, the reticuloendothelial system (RES) has 
a crucial role to phagocyte xenobiotic materials, such as nanoparticles circulating in blood and 
lymphatic systems26. This system is composed of different cells including monocytes, reticulum 
cells, Kupffer cells etc. The first step in the recognition of the nanoparticles by the cells is the 
opsonization process49. Here, plasma proteins are adsorbed on the surface of the nanoparticles to 
facilitate phagocytosis. This phagocytosis will lead to the elimination of these nanoparticles from 
the blood stream. 
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Figure 1.8. Schematic overview how polyethylene glycol prevents uptake by the RES (A) 
Nanoparticles (A1) are coated with opsonin proteins (A2) and associate with macrophages (A3) for 
transit to the liver (A4). Macrophages stationary in the liver, known as Kupffer cells, also participate 
in nanoparticle scavenging. (B) Nanoparticles coated with PEG coating (B1) prevents this 
opsonization (B2), resulting in decreased liver accumulation (B3) and increased availability of the 
AuNP for imaging or therapy. 
 
For increasing the retention time, the size, coating and charge of the nanoparticles play a 
determining role. Within the diameter size range for nanoparticles between 40 and 600 nm, 
nanoparticles with larger diameters show a smaller blood retention time. Larger particles are more 
easily recognized by the RES, resulting in an increased uptake in liver and spleen50. Changing the 
shape compared to spherical shapes also has a profound effect on the blood retention time and 
organ distribution over time. For example, nanorods or discoidal shaped particles show less 
accumulation in liver since they avoid accumulation by non-specific cells. As a consequence, they 
show a longer blood-retention time which could result in a higher tumor accumulation51,52. By 
changing the coating of the nanoparticles, the opsonization process can be reduced. Nanoparticles 
functionalized with a hydrophilic coating such as PEG coating and a neutral charge show the least 
uptake by the RES system53–55. Neutral charges have been proven to reduce the interaction with 
the RES by reducing the interaction with the plasma proteins. The hydrophilic PEG layer on the 
other hand, improves the stability of the nanoparticles, preventing them from aggregation and 
interaction with the RES (Figure 1.8). Due to the PEG coating, the particles will show a longer 
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blood retention time. The thickness of the PEG layer is a crucial factor for diminishing the 
opsonization process56.  
 
1.2.2.4 Targeting 
 
Having the right properties, nanoparticles can passively accumulate in the tumor by the EPR effect 
as described above45,46. Due to a longer retention time these nanoparticles have more chance to 
diffuse inside the tumor masses. This targeting technique is called passive targeting. The 
disadvantage of this targeting strategy is that nanoparticles are located in the tumor peripheum 
but their uptake by tumor cells will not be promoted.  An alternative strategy, to enhance binding 
or uptake of nanoparticles by tumor cells, is to link these particles with biomolecules (peptide, 
antibody, aptamers etc.) recognizing over-expressed receptors on the tumor site to improve tumor 
targeting19. This active targeting may change the intratumoral accumulation of these 
nanoparticles, resulting in a more efficient uptake over time. Hereby, a biological ligand is chosen 
which targets either an over-expressed receptor on the tumor cells itself such, as HER2 or a target 
on the tumor vasculature, such as VEGFR. The latter has the advantage that there is no extra 
boundary of passive diffusion of these nanoparticles to the tumor cells. Still a debate is ongoing 
if active targeting will result in a more efficient targeting to the tumor or if it just has a minor 
effect on the intratumoral distribution of the nanoparticles57,58. 
 
Choosing the right biological molecule can be crucial to succeed in active targeting. Size, activity 
and stability are crucial parameters within this decision. Nanobodies are chosen in this thesis as 
the biological ligand, which is the antigen-binding region of the functional heavy-chain only 
antibody of camelids. 
 
Conventional antibodies are Y-shaped and consist of two identical heavy and two identical light 
chains 59. These heavy chains consist of three or four constant regions (counting from the N 
terminus: CH1, CH2, CH3 and possible CH4) and one variable region (VH), while the light chains 
have only one constant region (CL) and one variable region (VL). Disulfide bonds will link the 
heavy chains to each other but also each heavy chain with one light chain. The two variable 
domains associate and determine the antigen binding specificity 60. Heavy-chain antibodies on the 
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other hand don’t have these light chains, so that the antigen will be bound by only one variable 
domain. Thus the variable domain of these heavy chains represent the complete binding domain 
of the antibody and are called nanobodies (Figure 1.9)59.  
 
 
 
The nanobodies have shown to be completely functional in antigen binding, due to small 
adaptation in the variable region compared to conventional variable region. These adaptations 
generate benefits ranging from increased stability in gastric and jejuna fluid, thermal stability, 
possibility of multimerization and ability to bind into clefts and cavities which can be of great 
therapeutic use since it can interfere with biological interactions 61. 
1.2.3 Gold nanoparticle synthesis and functionalization 
 
With these specific requirements in mind, many methods have been optimized to generate metal 
nanoparticles in the last decades62. Generally, there are two strategies to obtain these 
nanoparticles. Bottom-up methods where nanoparticles are produced from the reduction of ions 
and top-down method where material is removed from the bulk material, resulting in the desired 
nanoparticles28,63. While the latter one has minimum size limitations due to the restrictions of 
lithography, by using the bottom-up method all sizes and shapes could be synthesized but at rather 
low yield. Still, for mixing different materials on one particle the top down synthesis is preferred.  
 
 The bottom up synthesis technique for gold nanoparticles is based on the reduction of positive 
gold ions with chemicals in well-defined quantities and under controlled temperature and 
Figure 1.9 (a) Conventional antibody with two heavy and two light chains. (b) heavy-chain only 
antibody from a camelid that comprises only two identical heavy chains. (c) Nanobody that consists of 
the variable domain of one heavy chain of such a heavy chain only antibody (VHH). 
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pressure28. For bottom up synthesis, one can differentiate between an in situ (one step) and ex situ 
(multiple steps; Figure 1.10). By using the in situ method monolayer-forming materials are mixed 
with nanoparticle- forming materials to create functional nanoparticles in a single reaction.  For 
the ex situ method, nanoparticles are synthesized first and in a second step monolayer-forming 
materials (e.g. polyethylene glycol (PEG) layer) are added to the mixture. A monolayer is then 
formed upon the freshly synthesized particles. The most standard ex situ procedure for gold 
nanoparticle synthesis is the citrate reduction method also named the Turkevitch method62. 
Hereby, citrate is used as the reducing agent and after proper mixing well defined spherical gold 
nanoparticles will be generated.  The citrate will also function as a capping agent forming a well-
defined layer around the nanoparticles. Nanoparticles with a different shape (such as nanorods, 
nanostars etc.) can only be synthesized by ex situ methods by adding extra capping agents as 
CTAB, BSPP, PVP, etc 64–66.  
 
 
Figure 1.10. Schematic drawing of the synthesis and functionalization of AuNPs either using in situ 
or ex situ strategy. 
 
 The monoforming layer can range from polymers, silica to organic molecules with a thiol group, 
having a high affinity for gold28. These layers must increase the stability of the nanoparticle, 
which is crucial for later biomedical applications, like increasing the blood retention time. A 
common monoforming layer used for gold nanoparticles is the self-assembled monolayer (SAM). 
SAMs provide a unique opportunity to stabilize metal nanoparticles based on steric and 
electrostatic repulsion to prevent agglomeration67. SAMs will form a layer on top of the gold 
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nanoparticles with a charge at the end of the SAM. These SAMs must meet specific standard 
requirements68.  First, the SAM molecules must form a densely ordered layer and should have 
high affinity for the used nanoparticles. Second, they must be suspendable in water and have the 
ability to increase the circulation time when used for in vivo purposes. Third, when used in vivo, 
one should choose a SAM with as little aspecific binding as possible. Fourth, for targeting 
biological molecules SAMs should have a functional chemical end group on which a biological 
ligand can be coupled. This is a necessity for specific coupling onto tumor cells69.    
 
 A commonly used standard SAM molecule contains, in the following order, a thiol end group, 
an alkyl chain group, a polyethylene glycol (PEG), and a functional end group (Figure 1.11). The 
sulfur atom of the thiol molecule will bind chemically on the gold atoms of the nanoparticle. This 
thiol group has a higher affinity than the COOH group of the citrate capping agent and will 
preferentially bind to the gold nanoparticle surface62. The alkyl chain is the backbone of the SAM, 
creating an ordered monolayer through van der Waals forces between the methylene groups. This 
alkyl chain should preferentially be longer than 10 methylene units to efficiently stabilize the gold 
nanoparticles69. To increase the water solubility of the SAM-gold nanoparticle complex, a PEG 
chain is included in the long thiol molecule. Furthermore, poly-ethylene glycol (PEG) units are 
known to minimize the non-specific adsorption of proteins due to their hydrophilic nature, 
increasing the blood circulation time of nanoparticles56. At last, the functional end group will 
enable the binding with biological ligands.   
 
 
 
Figure 1.11. Schematic drawing of self-assembled monolayer around the AuNPs with their specific 
subunits. 
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1.3 Gold Nanoparticles as a theranostic agent 
 
Gold nanoparticles can be used for diagnosis, assessment of particle delivery to the tumor and 
therapy18. As for diagnosis, several imaging techniques are described where gold nanoparticles 
can be used as an imaging technique as SERS, CT, PAI. Using these techniques, the particle 
delivery of the nanoparticles could be monitored which is crucial criterion in cancer research. At 
last these nanoparticles can be used for hyperthermia using a laser which is called photothermal 
therapy (PTT) but also for photodynamic therapy or drug release by hyperthermia22.  
 
1.3.1 Photoacoustic imaging 
 
Photoacoustic effects are based on the thermo-elastic expansion of an agent after laser irradiation 
with a nanosecond pulsed laser (Figure 1.12)70. Due to the combination of optical and ultrasound 
imaging, it combines the spectral selectivity of molecular excitation by the laser with the high 
resolution of the ultrasound imaging71.  
 
 
Figure 1.12. Schematic representation of PAI using gold nanoparticles as a contract agent 
 
To generate significant PA signals, two conditions must be met, referred to as the thermal and 
stress confinement. First the thermal confinement defines that the pulse width of the laser light 
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should be shorter that the time required for diffusing the heat.  Second, the time that the absorbant 
expands in volume must be smaller than this pulse width which is described as the stress 
confinement72. Fulfilling these two conditions, the pressure raised by the pulsed laser can be 
described as:   
𝑝𝑜(𝑟) =  
𝛽𝑐2
𝐶𝑝
𝜇𝑎𝐹 =  𝛤𝐴 
where 𝛽 is the isobaric volume expansion coefficient in K-1, 𝐶𝑝 is the specific heat in J/(K kg), 
𝜇𝑎 is the absorption coefficient in cm-1, F is the local light fluence in J/cm2, A is the local energy 
deposition density in J/cm3: A=µaF, and Γ is referred to as the Grüneisen coefficient expressed as 
Γ =βc2/Cp 70.  
 
The optical absorption needed for the pressure raise in PAI can either be performed by both 
internal and external contrast agents. A typical endogenous contrast agent is (oxy-) hemoglobin 
showing a high specific absorption spectrum in the visible-NIR region. Therefore PAI has shown 
to be a powerful tool for blood vessel imaging and oxygenation of the blood in preclinical and 
clinical applications73. Next to endogenous contrast agents, exogenous agents can be divided in 
two classes. Either nanoparticles as gold nanoparticles are used having a high absorption 
coefficient due to the LSPR effect or NIR organic dyes are chosen, showing lesser absorption 
capabilities. As a consequence, gold nanoparticles show a higher sensitivity compared to NIR 
dyes74. 
 
 Since PAI is based on the optical absorption of light by the gold nanoparticles, the absorption 
cross section is a determining factor for photoacoustic sensitivity. A study by Hu et al compared 
different gold shaped nanoparticles for their absorption and scattering properties and their 
potential theranostic application75. These capabilities have been compared between nanoshells, 
nanorod and nanocages with their peak of the LSPR band at 800 nm. For all three nanoparticles, 
the absorption cross section is higher than their scattering cross section, which is crucial for PAI. 
The nanorods and nanocages have a much larger absorption and scattering cross section then 
nanoshells75.  Another study by Van de Broek et al has proven that nanostars have even a larger 
absorption cross section then nanorods, which could increase the sensitivity of these nanostars as 
a photoacoustic contrast agent65. This difference in absorption cross sections is resulting in a 
minimum limit of detection concentration for PAI for the nanorods at 24 pM, for the nanocages 
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at 4.5 pM and for the nanostars at 1 pM20,76 . Due to these low detection concentrations, these 
nanoparticles are introduced into the preclinical field for cancer theranostics.   
 
Within the class of nanorods, the first proof of principle has been published in 2007 using gold 
nanorods as specific agent for prostate cancer, targeting HER2. With these nanorods, a first proof 
of principle of in vivo PAI is shown after implementation of a gel loaded with nanorods77. Li et al 
showed the multiplexing capability of PAI in vitro and in vivo by using two different nanorods, 
absorbing the light at a different wavelength (785 and 1000 nm), targeting either HER2 or 
EGFR78. This active targeting application using nanorods visualized by PAI has been confirmed 
by other groups76,79. For increasing the PA signal per particle, these nanorods can be plated with 
a certain thickness of a silica layer. With this layer an three-fold increase of PA signal could be 
achieved80,81. With these silica-coated nanorods, the first steps are accomplished for specific 
targeting of cancer cells and in vivo PAI using a passive targeting strategy (Figure 1.13)82,83.  
 
 
Figure 1.13. Overview of the PA main results with silica coated nanorods. Left. Active targeting of 
two different cell lines using silica coated nanorods either having their absorption maximum at 780 
nm (yellow) or red (830 nm). On top the ultrasound picture, where in the middle the PA signal at 830 
nm indicates which cell type contains silica coated nanorods. At the bottom the unmixing of both 
different nanorods, showing the selectivity of these nanorods for the cancer cells. Right. On top the 
3D ultrasound of the tumor before and after i.v. injection of non biofunctionalized nanorods and on 
the bottom the PA signal, where an increase of signal is measured after nanorod injection. 
 
 Next to nanorods, both nanocages and nanostars have gained interest as a photoacoustic agent 
for in vivo cancer imaging. In 2008 Song et al. has shown the applicability of these nanocages as 
a photoacoustic agent for lymph node mapping on a rat model using a home-build photoacoustic 
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set-up84. Kim et al. has shown that using active targeting, PAI shows a 300 % signal increase 
compared to passive targeting 6h after intravenous injection of the nanocages84. For the nanostars, 
a first in vivo photoacoustic experiment has been performed where the accumulation of the 
nanostars in the lymph nodes have been mapped85. A recent study has shown the use PAI after 
active targeting of the vasculature of the tumor and the follow-up of the disrupture of this 
vasculature20.  
 
1.3.2 Surface Enhanced Raman Scattering 
 
One of the emerging optical techniques is SERS which is based on the Raman scattering of 
molecules86. This Raman Effect describes the inelastic scattering of the light that occurs with the 
vibration of the molecule. This vibration results in a loss or gain of the light's energy, causing a 
frequency shift of the scattered light. However, this Raman Effect is exceedingly weak compared 
to other optical effects. For example, the Raman cross section of the molecule is around 10-30 and 
10-25 cm2, while with fluorescence the cross section is around 10-17 and 10-16 cm2 87. 
 
When bringing these molecules in close contact to a gold surface, the intensity of the inelastic 
scattering light will be enhanced by approximately 10-10-10-12 .This enhancement is due to two 
effects, namely the electromagnetic and chemical effect. The electromagnetic effect is caused by 
the LSPR effect of the gold nanoparticles88. When the Raman molecule is in close contact with 
the surface of the gold nanoparticle, they will experience the enhanced electrical field by the 
LSPR field. As a consequence, the incoming light and Raman scattered signal will be enhanced 
by the LSPR effect. This electromagnetic effect is the main contribution factor for the signal 
enhancement of SERS. The second effect has a more chemical origin but is still not completely 
understood. One of the theories is the inelastic tunneling of the excited electron from the highest 
occupied molecular orbital of the metal to the lowest unoccupied molecular orbital of the 
chemisorbed molecule88,89. When this electron returns to its initial state, a Raman-shifted photon 
is emitted.    
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 The total SERS signal can be described by90:  
 
𝑃𝑆𝐸𝑅𝑆~𝑁 𝐼𝐿 |𝐴(𝜈𝐿)|2|𝐴(𝜈𝑆)|2𝜎𝑎𝑑𝑠𝑅  
 Where 𝑁 is the number of molecules involved in the SERS process 𝐼𝐿  the excitation intensity 
and the effective cross section 𝜎𝑆𝐸𝑅𝑆described by the two field enhancement factors for both the 
excitation 𝐴(𝜈𝐿) and scattered 𝐴(𝜈𝑆) enhancement and the chemical SERS effect, described by 
the increased Raman cross section of the adsorbed molecules as 𝜎𝑎𝑑𝑠𝑅 . 
   
Since SERS depends on the specific vibration of chemical groups in the molecule, a specific 
fingerprint spectrum will reflect the identity of the molecule91. This gives the opportunity to 
identify these molecules at small quantities. Hereby, several molecules have been examined for 
their capacity of an ideal SERS molecule fulfilling requirements such as the ability to bind on the 
gold surface and a high Raman cross section. As a result, up to pico- and femtomolar 
concentration, these Raman labeled gold nanoparticles are still detectable76,92. Therefore, SERS 
is appealing for biophysical and biomedical applications ranging from the detection of specific 
molecules on histological sections, pH sensing inside the cell to intraoperative imaging during 
surgical removal of a tumor76,93,94. 
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Figure 1.14. In vivo cancer targeting and Surface Enhanced Raman detection by biofunctionalized 
gold nanospheres recognizging the biomarker EGFR. SERS spectra are shown for the tumor and the 
liver by using targeted (A) and non-targeted (B) nanospheres. C. Photographs showing the laser beam 
focusing on either the liver or the tumor for obtaining the SERS spectrum. 
 
Compared to other imaging techniques, very few examples are described on using gold 
nanoparticles (-sphere, rod, star) as an in vivo SERS diagnostic imaging agent. Qian et al showed 
in 2008 the first in vivo application of tumor SERS imaging using Raman labeled gold 
nanospheres by active targeting. An SERS spectrum could be deducted from the tumor site 
corresponding to the nanospheres inside the tumor (Figure 1.14)95. Next to nanospheres, nanorods 
have been shown as a specific SERS contrast agent for imaging a tumor overexpressing HER2 
where a 30 times stronger signal is measured compared to HER2 targeting nanospheres96. The 
SERS contrast imaging capabilities using nanorods have been further examined by other groups 
from in vitro to in vivo 76,97. Also the nanostars as a SERS diagnostic agent have been extensively 
studied by two groups led by Liz-Marzan and Von-Dinh. Due to the spikes of the nanostars, a 
four times higher SERS signal could be measured compared to nanospheres, where the sharpness 
and size of the nanostars are the crucial factors 43. With these unique properties, SERS has been 
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shown as an ideal tool to image the uptake of nanostars intracellularly by passive targeting98–101. 
Still no in vivo data has been published of using nanostars as a SERS imaging contrast agent.   
 
 Switching over from Raman spectroscopy to 2D Raman imaging, Gambhir et al. utilized SERS 
as a powerful tool for intraoperative imaging using either nanorods or nanospheres. Using the 
high specificity of the SERS signal, the tumor border can be well defined during surgery, resulting 
in a more effective surgical removal of the tumor 76.  
 
1.3.3 Computed Tomography 
 
CT is one of the most commonly used clinical imaging modalities nowadays. This technique is 
based on the X-ray attenuation by different tissues, providing high-resolution images of electron 
dense materials such as bones and metal implants.  However, it is difficult to distinguish subtle 
difference between soft tissues. Consequently, exogenous contrast agents are required for better 
delineation of the specific soft tissues using iodine or barium sulfate suspensions102.   
 
An X-ray image is based on the degree of the attenuation of these electromagnetic waves. This 
attenuation is caused by absorption or scattering of these waves by an object. The degree of X-
ray attenuation is described by:  
 
𝐼 = 𝐼𝑂𝑒∑ −𝜇𝑖𝑖 𝑥𝑖 
Where I is the intensity of the transmitted X-ray, IO is the intensity of the incident X-ray, µ is the 
mass attenuation coefficient of the object, and x is the thickness of the object.   
 
During X-ray imaging there are three types of interactions between the X-ray and the object: 
Compton scattering, coherent scattering and the photoelectric effect. The last effect is the 
dominant factor for the attenuation of the X-ray waves. Here the incident X-ray photon transfers 
its energy to the inner-shell electrons, resuling in ejection from the atom. The resulted vacancy of 
the electron (typically K or L shell) is filled by outer-shell electrons, producing characteristic X-
ray photons in random directions. An important criteria is that the X-ray energy is slightly higher 
than the binding energy of the inner-shell electron, resulting in a higher effectiveness102. 
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Figure 1.15. In vivo X-ray CT of mouse before injection (A), 6 hours after injection of either 
untargeted nanospheres (B) or targeted nanospheres (C). The last one show clear tumor 
accumulation while the untargeted doesn't. CT-values are quantified for the tumor, liver and kidney 
confirming the CT images 
 
The most commonly used contrast agents for CT are iodine, barium sulfate or gold. Iodine-based 
contrast agents are usually suspensions of small molecules which show a high excretion by the 
kidney and a non-specific distribution. By coupling these molecules to polymers, micelles or 
liposomal contrast agents, better contrast has been obtained at specific tissues. Compared to 
iodine, gold nanoparticles show a 2-fold signal increase for CT102. This is due to the high atomic 
number of gold (Z=79) and the k-edge value (80,7 keV) compared to idione, which has an atomic 
number of Z=53 and its k-edge value is 33,2 keV. Since higher resolution is possible with X-rays 
at higher energy, gold nanoparticles will show a better sensitivity than iodine103.  
With this in mind, several studies have used gold nanoparticles as an effective CT contrast agent 
for cancer imaging. Most studies have been performed with gold nanospheres since CT contrast 
does not depend on the shape/ LSPR absorbance of the gold nanoparticles104. Using specific 
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targeting moieties with these nanospheres, several targets (beta4 integrin, CD4, HER2 receptor 
or EGFR) have been tested and imaged using CT, all demonstrating a significant CT contrast at 
the tumor site (Figure 1.15). Hainfeld et al103 showed that specific targeting of HER2 results in an 
accumulation of the nanospheres in the tumor periphery. Hereby, specific targeting resulted in a 
slightly better accumulation of particles compared to passive targeting 103. Other particle shapes 
such as nanorods and nanostars have been less elaborately studied in either in vitro proof of 
principle studies or in in vivo targeting studies100,105–107. Next to tumor imaging, AuNPs have been 
mainly used as a blood-pool contrast agent, visualizing the kidneys and liver of the mouse108.   
  
1.3.4 Photothermal therapy 
 
Gold nanoparticles can efficiently turn light into heat by the LSPR effect.  Since tumor cells are 
rapidly growing cells compared to ‘healthy’ cells, they are more sensitive to external factors. One 
of these external factors is temperature, where an increase in temperature has shown a decrease 
in tumor growth. Gold nanoparticles can be used as a specific therapeutic agent for PTT.  
 
An important factor is the upper limit of temperature applied to these tumor cells. When a 
temperature higher than 46°C is applied, thermoablation occurs which causes necrosis, 
coagulation and carbonization109. As a side effect to necrosis, the immune system will be 
activated. At temperatures between 41 and 46 °C, moderate hyperthermia is applied. This is a 
more favorable scenario for hyperthermia since cells undergo heat stress within this temperature 
range and will not induce an immune reaction.  It is still debated what the specific cause of this 
cell death after heat stress is. Hypotheses includes scenrario’s of lipid melting, protein 
denaturation, folding and aggregation, DNA cross linking16. Lately, protein denaturation has been 
shown as the major cause for late cell apoptosis after thermal stress. Here, the protein denatures 
and exposes its hydrophobic groups. These groups will interact, forming protein aggregates and 
disturbing crucial cellular pathways such as DNA metabolism, which will result in DNA damage. 
Nonetheless, this effect has been seen for all cells within this temperature range at in vitro level110.    
 
The effectiveness of tumor hyperthermia is more apparent on tissue level. Tumors show an altered 
vascularization where tumor blood flow has been shown to be lower than healthy cells 111. During 
Chapter 1: Introduction 
 
 
 
Antoine D’Hollander   29 
 
 
 
hyperthermia, the heat cannot be dissipated as efficient as it does from healthy tissue with regular 
vasculature, leading to higher temperatures reached in the tumors. Consequently tumors are more 
sensitive to elevated temperatures leading to an effective hyperthermia-induced ablation and 
therapy.    
 
Within the field of hyperthermia treatment, several techniques have been studied ranging from 
magnothermia, bases on switching magnetic fields, to PTT. PTT is based on therapeutic agents 
that convert laser light into heat. In this field, a substantial amount of concepts have been 
published using different types of gold nanoparticles for either passive or active targeting. A short 
overview of the main nanostructures will be discussed briefly.   
 
Nanorods have been extensively studied as photothermal therapeutic agents in the last decade due 
to their large absorption cross section. Dickerson et al. have performed a first in vivo proof of 
principle study using either intratumoral injection or passive targeting112. After exposure to the 
NIR laser (808 nm, 1-2 W/cm2, 10 min), tumor growth was significantly reduced for both treated 
groups. Still, the intravenously injected animals showed a less effective PTT compared to the 
animals were particles were injected directly into the tumors due to a lower nanorod concentration 
inside the tumor112. Other groups have shown effective therapy after passive targeting, resulting 
in a temperature increase of up to 70 °C during laser irradiation where controls without particles 
only showed an increase of up to 40 °C. Even after 50 days, no tumor recurrence has been 
observed for these treated animals (Figure 1.16)105. Bioconjugated nanorods have been used 
extensively for in vitro PTT using different biological ligands and irradiation powers (28; 10; 4; 
0.05 W/cm2). The variation in laser power is due to differences in incubation time, nanorod 
concentration etc. Also in vivo active PTT has been shown using different laser powers ranging 
from 24 until 4 W/cm2 showing effective tumor eradication105,112,113.  
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Figure 1.16. Overview of in vivo PTT experiments using nanorods. Top. Thermographic surveillance 
of photothermal heating in nanorod injected (top) and saline-injected (bottom) mice. Bottom. 
Volumetric changes in MDA-MB-435 tumor sizes are plotted over time after PTT irradiation (810 
nm, 2 W/cm2, 5 min using nanorods after i.v. injection. On the right, the survival of mice after 
irradiation is plotted versus time after irradiation. 
 
Nanocages have been described as successful photothermal therapeutic agents due to their equally 
large absorption cross section as nanorods75. Passive targeting studies show an effective treatment 
using a laser power of 0.7 W/cm2 inducing a temperature increase of 14 °C. Specific targeting has 
been shown in vitro by targeting HER2 using monoclonal antibodies114,115. Due to the hollow 
shape of these nanocages, they could be combined with drug delivery which is released during 
PTT. As a consequence a more effective treatment is realised41. 
 
 Also, nanostars have gained interest in the last years as a photothermal agent against cancer. Van 
de Broek et al. have shown, for the first time, specific in vitro PTT after active targeting of the 
nanostars using a nanobody recognizing the HER2 receptor. Using the same irradiation 
conditions, either non-labeled tumor cells or cells incubated with non- biofunctionalized nanostars 
do not show any therapeutic effects after photothermia116. Yuan et al. have reported the first in 
vivo PTT using nanostars with a passive targeting strategy. Using a window chamber, the nanostar 
accumulation around the tumor vasculature could be visualized using multiphoton microscopy. 
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After 48 hours, the tumor was irradiated (785 nm, 1.1 W/cm2, 10 minutes) and localized oozing 
of blood could be seen due to disruption of the vasculature at the irradiation spot117.  
 
1.3.5      Nanotheranostics   
 
The goal for future clinical applications in cancer treatment is to combine diagnostic and 
therapeutic capabilities into one gold nanoparticle. Several combinations have been studied from 
Raman/ PAI, fluorescence/ PAI, CT imaging/ PTT using different shapes of gold 
nanoparticles80,100,105,106,118–123. A crucial criterion within nanotheranostics is to choose the right 
multimodal approach with the largest benefit for cancer patients in the future. Kircher et al. 
demonstrates this multimodal potential by designing gold nanoparticles for combined MRI, 
photoacoustic and Raman imaging, where all three imaging modalities are used for a specific 
goal124. While MRI is used to locate the tumor on a whole body scale after i.v. injection of these 
gold nanoparticles, photoacoustic and Raman imaging are used for intraoperative guidance during 
surgery (Figure 1.17) Hereby PAI will guide the surgeon to locate the tumor within the tissue. 
Raman imaging will provide more into detail information about the finger protrusions of the 
tumor. This last imaging modality is crucial to decrease the likelihood of tumor reoccurrence after 
surgical removal 124.  
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Figure 1.17. Left. The schematic drawing of the triple modality imaging concept for surgical removal 
of the brain tumor. Right. Two-dimensional axial MRI, photoacoustic and Raman images. The post-
injection images of all three modalities showed clear tumor visualization (dashed boxes outline the 
imaged area) 
 
1.4 Objectives 
 
Nanotheranostic agents hold great potential as a new tool in the diagnosis and treatment of cancer. 
Several theranostic agents have been examined ranging from radioactive tracers, magnetic 
nanoparticles, microbubbles to gold nanoparticles9,18. The latter hold great promise due to their 
unique capabilities based on the LSPR effect of gold nanoparticles. Currently, several shapes of 
gold nanoparticles have been examined regarding their theranostic potential ranging from 
nanorods, nanoshells to nanocages. Nanostars are the least examined particles, although they have 
unique properties for theranostics due to their high absorption coefficient. Within this thesis, we 
aim to validate and improve the theranostic capabilities of the nanostars in an effective in vivo 
targeting strategy. 
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To be functional as theranostic agents against cancer, nanostars need to fulfill several 
requirements for later (pre-) clinical applications, which include their plasmon band in the NIR 
region, a hydrodynamic diameter below 100 nm and stable behavior under physiological 
conditions. To determine the ability of these nanostars as theranostic agents, both their imaging 
(CT; PA; SERS) and therapeutic (photothermal) capabilities must be examined in different set-
ups. We have started from rather simplified settings studying the sensitivity or heat generation 
capacities of the nanoparticle solution to more complex arrangements in vitro and in vivo. Within 
these latter conditions, the stability of these nanostars in biological medium and absense to limited 
cytotoxicity are essential. The optimization of all imaging, hyperthermia and characterization 
techniques to study the theranostic potential are crucial for later targeting studies 
Optimizing tumor targeting of gold nanostars 
 
For reaching their final goal as a theranostic agent, the nanostars must be tailored to accumulate 
inside the tumor cells in vivo. Here, the efficiency of the two targeting strategies, passive and 
active, for the nanostars to reach a significant concentration in the tumor has been studied To 
achieve active targeting in vitro, the nanostars must be conjugated to a biological ligand. The 
influence of serum conditions on active targeting by the formation of a protein corona must be 
taken into account. Once optimized (non-) biofunctionalized nanostars are available, the in vivo 
targeting efficiency must be determined for both passive and active targeting for establishing 
ultimate targeting strategies.  In a final phase the imaging and therapeutic capabilities of the 
nanostars after specific tumor targeting should be validated. 
The mentioned goals, pursued during this PhD project, are presented in the following chapters.  
 
 In Chapter 1, general concepts of gold nanoparticles and their applications in cancer theranostics 
are introduced. 
 
In Chapter 2, the potential of gold nanostars, synthesized in this project, as a multimodal imaging 
and therapeutic agent against cancer was thoroughly validated by their characterization in vitro 
and in vivo. The nanostar's synthesis and functionalization was optimized to fulfill the in vivo 
required properties. Having an optimal cell targeting protocol established, their photoacoustic, 
CT and photothermal properties were assessed.   
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To employ these nanostars as a theranostic agent against cancer, their targeting properties are a 
crucial criteria. In chapter 3, their optimization to successfully target tumor cells passively is 
reported and discussed. Active targeting is described in chapter 4. Both these targeting 
capabilities are examined in vitro and in vivo using an ovarian cancer cell line having an 
overexpression for the HER2 receptor. In chapter 3, the effect of the SAM end group on passive 
targeting is studied by dark-field microscopy in vitro and in vivo and by an extra quantification in 
vivo using ICP-OES. The problems encountering passive targeting are unveiled within this 
chapter. Targeting described in chapter 4 is based on nanostars functionalized with a nanobody 
to actively recognize the HER2 receptors on these tumors.   
 
In chapter 5, the application of SERS-labeled nanostars as a diagnostic agent against cancer is 
studied. Hereby the functionalization of these nanostars with a Raman label is fully characterized 
using UV-Vis absorption spectroscopy, DLS and zetapotential. Based on these results, an optimal 
Raman label concentration is defined for sensitive detection. Contrast capabilities of the SERS-
labeled nanostars are studied in vitro and in vivo using a passive targeting strategy where they 
tend to accumulate in the liver and tumor.   
 
Finally, in chapter 6, the presented results are discussed, ultimate conclusions are drawn and 
suggestions for future research are made. 
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2 ASSESSMENT OF THE THERANOSTIC 
POTENTIAL OF GOLD NANOSTARS –  
A MULTIMODAL IMAGING AND 
PHOTOTHERMAL TREATMENT STUDY. 
 
2.1 Introduction 
 
‘Nanotheranostics’ – referring to the use of nanotechnology for combined imaging and treatment 
of diseases - is currently an active research field as combining diagnosis with therapy has several 
advantages. The knowledge of the biodistribution of therapeutic agents through imaging can 
improve the guidance and initiation of cancer therapy. This can, for example, help to decide on 
the best time point for applying PTT. In addition, therapy success can be assessed at earlier time 
points and follow-up of therapy efficiency can be improved drastically. In the clinic, this will 
ultimately result in earlier intervention, better patient management and improved prognosis9. 
Within the field of nanotheranostics, AuNPs that show a LSPR can have a significant impact, as 
the LSPR effect can be used for both imaging and therapy31. The LSPR effect can be explained 
by the collective oscillation of the conduction band electrons due to light.  This collective 
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oscillation induces an enhanced absorption and scattering of light27. The scattering properties of 
light can be exploited by various imaging techniques including SERS95 and darkfield 
microscopy31. The light energy that is not scattered by the particles but absorbed, is converted 
into heat. This specific heat generation is the basis for both PAI and PTT 3,125.  
 
PAI is based on the acoustic waves generated by the thermo-elastic expansion that occurs when 
a specific compound absorbs a pulsed electromagnetic wave72. Exogenous contrast (e.g. carbon 
nanotubes, AuNPs) have shown to generate higher PAI contrast compared to endogenous 
molecules (e.g. hemoglobin)75. Due to the negligible scattering of ultrasound in tissue compared 
to light, a relatively high imaging depth of approximately 5 cm is possible with PAI71. PTT on the 
other hand is also based on the heat conversion of AuNPs during irradiation with a continuous 
laser74. Since cancer cells are more sensitive to heat than other cell types, a temperature increase 
above 43°C is lethal due to the inability to remove the heat in poorly vascularized tumor tissue111.  
For PAI and PTT, the ratio between the light scattering and absorption properties per AuNP is 
crucial. Hereto, several shapes of AuNPs have been studied ranging from nanorods, nanoshells, 
nanocages to nanostars75. Usually, nanostars have higher absorption vs. scattering coefficients 
compared to nanorods and nanoshells, but similar to nanocages74,116. This higher absorption 
coefficient is the crucial parameter for efficient heat conversion, important for PAI and PTT. 
Several studies have examined the use of gold nanorods as a contrast agent for PAI in tumors76–
79,82. However, only non-quantitative in vitro data 100 and in vivo mapping of the lymphatic system 
has been shown for nanostars85. For PTT of tumors, several groups have reported on nanostars as 
an effective in vitro PTT agent100,116,117 , but many questions remain regarding the PTT efficiency 
using these nanostars in vivo21,117. 
 
Alternatively, AuNPs can also be imaged with computed tomography (CT), since they absorb X-
rays more efficiently compared to frequently used contrast agents such as iodine based 
compounds105,126. In general, heavy atoms are frequently used as a contrast agent for X-ray based 
CT for diagnostic imaging in the clinic and for preclinical research 105. Nonetheless, relatively 
high local AuNP concentrations are needed to generate sufficient contrast for CT, in particular 
for small voxel sizes as required for preclinical imaging applications 127. AuNPs, such as nanorods 
or spheres, have shown their effectiveness as blood-pool and tumor-targeting contrast agent using 
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CT 105,128. However, for nanostars, quantitative in vitro and in vivo studies regarding their potential 
as contrast agents for CT are lacking100. 
 
Several routes have been explored to administer AuNPs as a theranostic agent against cancer, but 
many questions remain.  Intratumoral administration is the most straight forward way for 
theranostic application, while i.v. injection has shown mixed results in terms of tumor 
accumulation112,129. Few reports showed reasonable tumor accumulation where the charge of the 
nanoparticles played a crucial role for tumor targeting105,130. Even functionalizing the 
nanoparticles with biological ligands gave different outcomes in terms of intra-tumor 
accumulation57,58. Active targeting, suggested to overcome problems with low intra-tumor 
accumulation after intravenous delivery, may have no influence on tumor uptake but it does affect 
the distribution of AuNPs within the tumor 58. 
 
 AuNPs have to fulfill some essential requirements to be applicable for in vivo theranostic 
photothermal approaches. First, the absorption band of the AuNP must be tuned to the near 
infrared region (NIR) frequency range for having maximal contrast generation and therapy 
efficiency due to its relative high depth penetration44. Second, the diameter of the AuNPs has to 
be around or below 100 nm to cross leaky blood vessels and being retained in the tumor. Third, 
charged particles are favored since such particles show better retention after intra-tumor injection 
because of immediate interaction with the tumor cells131. 
 
Nanostars have been defined as promising nanoparticles due to their high LSPR absorption 
coefficient per particle which have a significant effect on the theranostic efficiency of gold 
nanostars75. A mathematical model was developed to predict the absorption coefficient of gold 
nanostars117. The morphology of the star-shaped AuNPs can be approximated as a spherical core 
with several small nanorods, where these small nanorods have the highest impact on the LSPR 
effect. Hereby, the nanostars seem to have a higher absorption vs. scattering coefficient compared 
to nanorods and nanoshells, but similar as nanocages65. This higher coefficient may lead to a 
better heat conversion, which is important for PAI and PTT. 
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Given the limited data available in the literature, set out to further explore and validate the 
promising theranostic applications of nanostars. Exploiting the advantage of the specific high 
absorption capacity of nanostars, we have studied the potential of nanostars for PAI/CT and PTT 
in vitro and in vivo. In this study, we first optimized the synthesis and functionalization of 
nanostars for efficient uptake by tumor cells and assessed their PAI and PTT capabilities in vitro 
using an ovarian cancer cell line (SKOV3). For the in vivo validation, gold nanostars were 
intratumoral injected in a xenograft mouse model and their local distribution in the tumor assessed 
with CT and PAI. Finally, PTT was performed and its potential was evaluated using 
bioluminescence imaging (BLI), magnetic resonance imaging (MRI) and histology.  
2.2 Materials and methods 
2.2.1 Synthesis and chemical functionalization of nanostars 
Gold nanostars were prepared based on the procedure described by Hao et al.132 and further 
optimized by Van de Broek et al.65. In brief, 2 mg bis (p-sulfonatophenyl) phenylphosphine 
dihydrate dipotassium (BSPP; Strem Chemicals,  Massachusetts, USA) and 100 μL H2O2 (30% 
v/v, Air Products, Vilvoorde, Belgium) were added to a 50 mL 6.8 mM aqueous sodium citrate 
solution (Acros Organics, Geel, Belgium). Next, 100 μL of 0.075 M HAuCl4 (Acros Organics) 
was added slowly under constant stirring at room temperature. By using an Atlas Syringe Pump 
(Syrris, Ruisbroek, Belgium) a slower addition rate of 12.5 µL/min was used in comparison to 
previously published articles in order to achieve the desired shape and size65. The 50 mL AuNP 
suspension was centrifuged at 4500 rpm for 1 h and the pellet was re-suspended in 10 mL of 
water. The star-shape of the AuNPs was stabilized using a disulfide molecule, according to Lin 
et al.133. Hereby, 1 mL of an 1.2 mM disulfide (S-(CH2)11-(O-CH2-CH2)6-O-CH2-CO-NH-(CH2)2-
maleimide)2 (Prochimia, Sopot, Poland) solution was added to 10 mL of the AuNP suspension 
mixed with 100 μL 0.5 M NaOH (Merck, Overijse, Belgium). After 90 min of shaking, the 
mixture was centrifuged at 4000 rpm for 60 min and re-suspended in water resulting in an optical 
density of ~ 1 at their maximum plasmon band. These nanostars were characterized in water and 
cell culture medium using UV-Vis absorption spectroscopy (Shimadzu UV-1601PC, Brussels, 
Belgium), dynamic light scattering (DLS; Malvern Nanosizer, WR, United Kingdom) and 
transmission electron microscopy (TEM; Tecnai F30, FEI company, Eindhoven, The 
Netherlands). 
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2.2.2 Dynamic light scattering and zeta protocol 
For dynamic light scattering (DLS), the hydrodynamic diameters of the nanostars under 
investigation were measured using a Zetasizer Nano ZS90 DLS system equipped with a red (633 
nm) laser and an Avalanche photodiode detector (APD) (quantum efﬁciency > 50% at 633 nm) 
(Malvern Instruments Ltd., England). A 1.5 mL semi-micro cuvette was used as sample container. 
The ‘DTS applications 5.10’ software was used to analyse the data. All sizes reported here were 
based on intensity average where the intensity was observed using a non-negative least squares 
(NNLS) analysis method. For each sample, two DLS measurements were conducted with a ﬁxed 
15 runs and each run lasts for 10 s. A detection angle of 173° was chosen for the size measurement.  
For determining the zeta potential an average was taken on three distinct measurements where the 
nanostars were dissolved in water. A U-shaped polycarbonate flow cell with embedded electrodes 
at either end, referred to as ‘clear disposable zeta cell’, was used during these measurements. As 
with the size experiments the ‘DTS applications 5.10’ software was used to process the data. 
2.2.3 Transmission Electron Microscopy 
We used a transmission electron microscopy (TEM) protocol as previously described134. In more 
detail, tumor tissue was collected after sacrificing the animals. Tissue was cut into cubes of 2mm3 
and fixed overnight in 2% glutaraldehyde and 0.05 M sodium cacodylate buffer (pH 7.3) at 4°C. 
Tissue samples were post-fixed in 2% OsO4 in 0.05 M sodium cacodylate buffer (pH 7.3) for 1 h 
and stained with 2% uranyl acetate in 10% acetone for 20 min. Next, samples were dehydrated in 
graded concentrations of acetone and were embedded in epoxyresin (Araldite). Semi-thin slices 
(500 nm) were cut, stained with toluidine-blue and used for selecting regions of interest. Ultra-
thin sections were mounted on 0.7% formvar coated grids, contrasted with uranyl acetate followed 
by lead citrate and examined with a Philips EM 208 transmission electron microscope operated 
at 80 kV. Digital images were taken with the MORADA 10/12 camera (Olympus, Hamburg, 
Germany). TEM analysis was performed with a Philips EM 208 S electron microscope (Philips, 
Eindhoven, The Netherlands). The microscope was provided with a Morada Soft Imaging System 
camera to acquire high resolution images of the evaluated samples. The images were processed 
digitally with the iTEM-FEI software (Olympus SIS, Münster, Germany). 
Gold nanostars as a specific theranostic agent against HER2 expressing tumor cells 
 
 
 
40  Antoine D’Hollander  
 
 
 
2.2.4 Cell culture 
SKOV3 cells (ATCC® HTB77, Cedex, France) were cultured in Roswell Park Memorial Institute 
medium (RPMI) 1640 medium supplemented with 10% fetal calf serum, 50 units/L penicillin, 50 
µg/mL streptomycin and 2 mM  L-glutamine. Cells were incubated at 37°C in a 5% CO2 
environment. All cell culture reagents were obtained from Life Technologies (Gent, Belgium). 
The SKOV3 cells were transduced with a lentiviral vector (LV-CMV-eGFP-T2A-fLuc) to stably 
express eGFP and firefly luciferase135.  
 
2.2.5 Inductively coupled plasma optical emission spectroscopy (ICP-OES)  
For uptake confirmation, 100 000 cells per well were seeded in a 12-well plate. After 24h, 
nanostars (2.3x1010 particles in 1 mL) were added to the cells and incubation continued for 
different time periods  (1, 3, 6, 12 and 24h). Next, cells were washed with PBS and again 
incubated overnight with fresh medium. After trypsinization, 100 000 cells were acid-digested 
with kingswater (HCl/ HNO3 at a ratio of 3:1) and diluted with de-ionized water to a volume of 
10 mL for ICP-OES (3300 DV, Perkin-Elmer, Waltham, United States). Reference standards were 
prepared by dissolving HAuCl4 to final concentrations between 0.1 and 2 ppm.  
 
2.2.6 In vivo xenograft model and nanostar administration  
Female Hsd:Athymic Nude-Foxn1nu  mice were used (8 weeks,  Harlan, Horst, The Netherlands) 
during these experiments. All animal experiments were approved by the local animal ethics 
committee of the KU Leuven and were performed according to the national and European 
regulations. Animals were kept in individually ventilated cages with food and water ad libitum. 
A total number of 1 x 107 SKOV3 tumor cells suspended in 100 µL were injected into each hind 
limb of the mice and left for two weeks to grow into solid tumors136.  
 
After formation of tumors (size > 200 µm3), 100 µL containing 9.2 x 1011 NPs/mL were injected 
into the tumor on the left hind limb. For controls, 100 µL PBS was injected into the right tumor 
in all animals (sham control). During all imaging experiments, tumor cell and nanostar injections, 
the animals were anesthetized with 1.5 % isoflurane in 100 % O2. The body temperature and 
respiration rate was monitored and maintained at 37°C and 80-120 min-1, respectively. For the 
Chapter 2: Assessment of the theranostic potential of gold nanostars –  
a multimodal imaging and photothermal treatment study. 
 
 
 
Antoine D’Hollander   41 
 
 
 
imaging experiments, three mice were used per condition while for the therapy experiments, six 
animals were used per condition. 
2.2.7 Photoacoustic imaging 
PAI was performed with a Vevo® Lazer 2000 (Fujifilms Visualsonics, Amsterdam, The 
Netherlands) using a 10 ns pulse laser (680-900 nm) with an energy fluence of 20 mJ/cm2 and 21 
MHz central frequency. These conditions were maintained for the in vitro and in vivo 
experiments. For in vitro PAI, 200 000 cells were suspended in 100 μL PBS and mixed with 100 
μL warm agar (Sigma, Diegem, Belgium). This solution was added and solidified in a bigger agar 
block. During in vivo PAI, ultrasound imaging is used to determine the tumor location, after which 
PAI was performed to validate nanostar injection.  
2.2.8 Computed tomography (CT) 
In vivo and in vitro CT images were acquired using an in vivo microCT scanner (Skyscan 1076, 
Bruker microCT, Kontich, Belgium) with the following settings: 50 kV x-ray source, 200 µA 
source current, 0.5 mm Al filter, 120 ms exposure time, 22 x 29 mm field of view, 0.7° rotation 
step over a total angle of 180°, which results in a tomographic dataset with a 35 µm isotropic 
resolution. The data has been processed using software from the manufacturer (NRecon, 
Dataviewer, CTvox and CTan). Sample preparation was similar for CT as for PAI. 
2.2.9 Photothermal therapy (PTT) 
In vitro and in vivo PTT experiments were performed using a home-built laser setup116. For in 
vitro PTT, nanostars (2.3 x 1010 particles in 1 mL) were added to a 12-well plate containing 100 
000 cells/ well that were pre-incubated overnight. The cells were then incubated with the 
nanostars for 24 h or with fresh medium as a control sample and washed twice with PBS. Next, 
the incubated cells were exposed to laser irradiation (690 nm, 20 W/cm2, 5 min) and incubated 
for an additional 2 h at 37 °C. Afterwards, the cells were washed with PBS. The cell viability was 
assessed using a live/dead staining (Calcein AM/Hoechst; Life Technologies Europe B.V., Gent, 
Belgium). After staining, the cells were imaged using a fluorescence microscope with 5 x 
objective (CellR system, Olympus, Aartselaar, Belgium). During the in vivo experiments, the 
mice were irradiated for five minutes with a laser (λ = 690 nm; 2 W/cm2), inducing PTT one day 
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after nanostar administration. During this laser treatment, the mice were anesthetized with 
ketamine/ domitor137 
2.2.10 Magnetic resonance imaging (MRI) 
MRI data acquisition and processing was similar to previous reports138. In brief, in vivo MRI was 
performed using a 9.4 T small animal MRI system (BioSpec, Bruker Biospin, Ettlingen, 
Germany) equipped with a gradient insert with a maximum gradient strength of 600 mT m-1. A 
quadrature transmit-receive coil (Bruker Biospin) with an inner diameter of 7 cm was used for 
data acquisition. The MRI protocol included a spin echo sequence with TR = 6000 ms, TE = 15.8 
ms, matrix = 200 x 200 mm, field of view 40 x 40 mm, slice thickness = 0.5 µm and 40 slices. 
2.2.11 Bioluminescence imaging (BLI) 
BLI experiments were performed with an IVIS 100 imaging system (Perkin Elmer, 
Massachusetts, United States). The mice were injected intravenously (i.v.) with D-luciferin (126 
mg/kg body weight, Promega) dissolved in PBS (15 mg/kg). Afterwards, they were placed in the 
IVIS 100 imaging system and one image frame per second was acquired until a signal intensity 
plateau was reached. The following settings were used: 1 s exposure time, FOV of 10 cm, binning 
of 4 and an f/stop of 8. For in vivo quantification of fLuc reporter gene activity, the data were 
analyzed as photon flux per second (p/s) from an 1 cm2 circular ROI located on the tumor using 
the Living Image software (version 2.50.1, Perkin Elmer). The signal intensity values at different 
time points (day 0, 1, 5, 8 and 15) were presented relative to the BLI signal of the same mouse at 
day 0.  
2.2.12 Histopathology 
Mice were sacrificed and transcardially perfused with 4% paraformaldehyde (PFA) in PBS 15 
days after treatment. The tumors were dissected and post fixed overnight in 4% PFA. The tumor 
tissue was embedded in paraffin and sectioned into 5 μm slices, stained with hematoxylin and 
eosin (H&E) and visualized with a Mirax desk scanner (Zeiss, Jena, Germany). In addition to 
histopathology, TEM analysis was performed on the tumor tissue following the protocol supplied 
in the supplementary information of Trekker et al.139. 
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2.2.13 Data analysis 
For quantification of CT and PAI data, contrast to noise ratios (CNR = (SI0-SI1/ σ(noise)) were 
calculated.  Statistical analyses were executed on the quantitative data using a paired t-test where 
the degree of significance is indicated with *: p < 0.05; **: p < 0.01; ***: p < 0.001.  
2.3 Results 
2.3.1 Synthesis and functionalization of nanostar-shaped AuNPs optimized 
for in vivo use 
 
 To be able to use nanostars as a theranostic agent in vivo, they need to be stable under 
physiological conditions, preferably absorb the light in the NIR-range and have a size around 100 
nm for optimal retention in tumors. To meet these requirements, we optimized a two-step method 
of Van de Broek et al. by changing the flow rate of the HAuCl4 from 50 μL/min to 12,5 μL/min 
during synthesis. As seen in Figure 2.1, the decrease in the flow rate shifted the LSPR band to the 
NIR region from an average value of 635.2 ± 5.7 nm to 665 ± 9.7 nm. Hereby no hydrodynamic 
diameter change of the nanostars was observed using DLS and by TEM the shape of the nanostars 
was visualized. However slight changes occurred at the morphology of the nanostars by using 
different flow rates. These images suggest that nanostars synthesized with lower flower rates of 
HAuCl4 have less but longer branches. Nanostars synthesized at a low rate of 12,5 μL/min will be 
used throughout this manuscript.  
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These nanostars are unstable in physiological conditions, and to maintain their specific shape, 
they have to be functionalized with a SAM116. After SAM functionalization, the resulting 
nanostars showed a shift in their plasmon absorption band by 9.0 ± 2.5 nm (Figure 2.2). This red 
shift indicated a successful chemical functionalization with the disulphide, resulting from a local 
refractive index change due to the chemisorption of the disulphide onto the nanostars. These 
results were confirmed by DLS, showing an average diameter of 66.3 ± 7.8 nm for the freshly 
synthesized nanostars and 75.0 nm ± 5.6 nm for the SAM functionalized nanostars. After 
functionalization, the zeta potential was -41.3 ± 1.2 mV, indicating anionic nanostars (Figure 2.3). 
Incubating the nanostars in biological medium for 1 week did not show any indication for 
instability as confirmed by the absence of peak broadening of the LSPR band or increase in 
diameter of the nanostars over time (Figure 3). Still, an increase in diameter to 100.6 ± 1.8 nm 
was noticed immediately upon incubation of the nanostars in cell culture medium due to the 
formation of a protein corona. As a consequence, these optimized nanostars are suitable for in 
vitro and in vivo theranostic applications. 
 
Figure 2.1. UV-Vis absorption spectroscopy of nanostars using different flow rates for HAuCl4, with 
a shift of the LSPR band to the NIR region with lower flow rates. TEM images of the nanostars from 
top to bottom that were generated with flow rates of 50 μL/min, 25 μL/min and 12.5 μL/min, 
respectively. 
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Figure 2.2. UV-Vis absorption spectroscopy of nanostars, normalized to absorbance of 1 a.u., either 
after synthesis (Nanostars) or after SAM functionalization (Nanostars SAM). 
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After functionalization, the capability of the nanostars to generate image contrast was studied in 
water using a concentration of 1.55 mg Au/mL. A PAI signal of 0.33 ± 0.04 a.u. was measured 
for the nanostars while water shows a signal of 0.13 ± 0.01 a.u. Figure 2.4). For CT, a signal of 
175.67 ± 2.74 and 57.33 ± 0.17 for the nanostars and water was respectively measured. As a 
consequence, both imaging modalities showed almost an equal contrast to noise ratio (CNR) of 
32.85 for PAI and 32.53 for CT. 
Figure 2.3. A. UV-Vis absorption spectroscopy of nanostars for 1 and 7 days in either water or cell 
culture medium. B. DLS intensity plots of the nanostars in water for 1 and 7 days showed no increase 
or decrease in diameter. C. DLS intensity plots of the nanostars in cell culture medium for 1 and 7 
days. D. The zeta-potential of the nanostars functionalized with the SAM in water with an average 
value of -41.3 +/- 1.2   nanostars are stable in water and cell culture medium. 
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Figure 2.4 Left. PAI images of nanostars and water in tube, which were quantified by plotting the 
signal amplitudes. Right. CT images of micro centrifuge tubes either filled with water or nanostars 
suspension. The corresponding signal amplitudes were used for quantification. (n=3) 
 
2.3.2 PAI and CT confirm efficient nanostar uptake by tumor cells 
In order to test whether tumor cells efficiently take up the nanostars, SKOV3 cells were incubated 
for different times (1, 3, 6, 12 and 24 h) with these nanostars and the uptake of nanostars by tumor 
cells was examined using ICP-OES, CT and PAI.  ICP-OES measurement shows for the first 
incubation time slots an almost linear increase of intracellular gold concentration while over time 
this seems to change into a plateau phase as visualized by the fitting curve (Figure 2.5). After 24h 
an intracellular gold concentration was measured of 11.28 ± 0.82 pg Au/cell was observed. TEM 
visualized the intracellular uptake of the nanostars inside vesicular structures of the cells where 
no nanostars were found at the cell membrane.  
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We next evaluated whether this uptake was sufficiently high to follow-up by PAI and CT. Hereby 
the tumor cells labeled with different amount of gold nanostars were homogenously suspended in 
an agar phantom at 1000 cells/μL. PA images in Figure 2.6 shows the increased PA signal (red 
pixels) over incubation time, where an exponential correlation was found between the PA signal 
and intracellular gold concentration. After 24h a PAI signal 1.93 ± 0.42 a.u. was measured 
compared to a PA signal of 0.19 ± 0.02 a.u. for the unlabeled cells. This successful nanostars-
labeling results in a CNR of 180.73 for PAI and a LOD of 3,5 pg Au/cell (17 μM).  
 
Figure 2.5. Intracellular gold concentration of different incubation time slots determined by ICP-OES. 
As inset a TEM images visualizing the nanostars inside the tumor cells. 
Chapter 2: Assessment of the theranostic potential of gold nanostars –  
a multimodal imaging and photothermal treatment study. 
 
 
 
Antoine D’Hollander   49 
 
 
 
 
Figure 2.6 Left. PA images of a phantom loaded with tumor cells (n=3) incubated for different times 
with the nanostars.  Right. PA signal plotted for the different gold masses per cell, where the dotted 
line suggests an exponential relation between those 2 variables. 
 
For CT, the contrast visualized by grey intensity is shown in Figure 2.7 where an increase of 
density was noticed over time. When plotting these density values over the different intracellular 
gold concentrations, an exponential fit was deducted. After 24h a CT signal 161.33 ± 1.42 was 
measured for the 24h-labeled nanostars compared to 130.28 ± 3.25 for unlabeled cells. These CT 
imaging capabilities results in a CNR of 7.36 for CT and a LOD of 5.5 pg Au/cell (28 μM) . 
 
Figure 2.7 Left. CT images of a phantom loaded with tumor cells (n=3) incubated for different 
timeswith the nanostars.  Right. CT signal quantified as density (grey values) plotted for the different 
gold masses per cell, where the dotted line suggests an exponential relation between those 2 variables.   
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2.3.3 Effective in vitro photothermal tumor cell ablation using gold 
nanostars 
Since tumor cells were effectively labelled with nanostars, we investigate if the in vitro nanostar 
uptake in the tumor cells was sufficient to eradicate tumor cells by PTT. First, the potential of 
nanostars for heat generation necessary for PTT (2 W/cm2) was measured where the temperature 
of the nanostars suspension increases to a plateau phase of 25°C, while no temperature increase 
for water was measured (Figure 2.8). Once the laser was turned off, the nanostars suspension 
immediately cooled down to room temperature, the same temperature as the water sample. For 
all next PTT experiments this same temperature profile was measured during laser irradiation. 
 
 
Figure 2.8 A. Temperature profile of tubes that were filled with either gold nanostars (4.6 x 1010 
nanostars/mL) or water and were irradiated with a continuous laser (2 W/cm2). 
 
A crucial parameter for determining the effectiveness of PTT is to calculate the cell killing 
capacity (IC50 value). To determine this value, the tumor cells have been labelled with the 
nanostars using the same conditions as for the imaging experiments. After PTT, their cell death 
was visualized by calcein AM living cells staining and quantified by calculating the total green 
pixels. As visualized by fluorescence microscopy a radius increase of non-living cells at the laser 
spot indicates a higher PTT effectiveness with an increasing intracellular gold concentration 
(Figure 2.9). By plotting the relative green fluorescence signal compared to the fluorescence 
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signal of the control cells, a sigmoidal curve was fit where an IC50 of 4.8 pg Au/cell (23 μM) was 
calculated.  
 
Figure 2.9 Left. Fluorescence images of the living cells stained with calcein AM for tumor cells (n=3) 
incubated for different times with the nanostars after PTT.  Right. Relative green pixel numbers 
plotted for the gold mass per cell where the fluorescence signal is relatively calculated to the control 
sample (0h). 
 
2.3.4 In vivo CT and PAI confirms nanostar delivery into tumors  
 
We evaluated if nanostar injected into tumors can be visualized by in vivo imaging. Tumor-
bearing mice (n=3) were imaged with CT and PAI before and one day after gold nanostar injection 
into the tumor. Before injection, only the contrast between the skeleton and the soft tissue was 
visible using CT (Figure 4, panel A). After injection of the nanostars, an intense contrast of 94.63 
± 6.77 was observed at the left side of the tumor, corresponding to the place of the tumor (Figure 
10). No significant change in contrast was generated in the PBS-injected control tumor with a 
signal of 74.11 ± 1.43 (Figure 10). A CNR increase of 25.31 was calculated after intratumoral 
injection of gold nanostars, indicating that intratumoral delivery of nanostars can be monitored 
with CT in vivo.  
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Alternatively, we evaluated whether intratumoral nanostar delivery can also be followed up with 
PAI.  Hereby, both ultrasound and photoacoustic images were overlaid as shown in Figure 2.10. 
Although some background photoacoustic contrast due to hemoglobin is present before nanostar 
injection, PAI could be used to visualize of the nanostars as indicated by the significant increase 
in signal intensity compared to the background (1.20 ± 0.17 a.u. compared to the control 0.44 ± 
0.05 a.u.) with a CNR of 80.31. 
 
2.3.5 Gold nanostars mediate in vivo photothermal therapy 
 
Before executing in vivo photothermal treatment, some parameters have to be defined, like the 
laser power and the correlation of nanostar concentrations with the temperature during treatment. 
Figure 2.10 A. CT images before and after injection of nanostars into the tumor. An increased 
contrast is noticed at the tumor site after gold nanostars injection (arrow) B. In vivo PA images before 
and 24 h after nanostar injection. The PAI signal (red pixels) is overlaid over the anatomical 
ultrasound images (grey pixels). 
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As a basic rule for using laser in cancer treatment, no skin damage may occur after irradiating. 
The laser power may not be too strong, but still strong enough to heat the nanostars sufficiently. 
Changing the diameter of the irradiated surface and the optical density filter can vary the power 
density. Second, the tumor size must be taken into account when choosing the diameter of the 
laser spot. Crucially the laser spot has to cover the whole subcutaneously located tumor. 
Consequently by controlling these factors, the ideal power can be chosen.  
To examine these factors, the laser was focused on the skin of the abdomen of a mouse which 
was not injected with nanostars. 18 different powers were measured using six different optical 
density filters (2 mm, 1.5 mm, 1 mm, 0.5 mm, 0.04 mm and no filter) in combination with three 
different diameters of irradiated surface (2 mm, 5 mm, 8 mm). During the 5 min irradiation, the 
skin temperature and the body temperature were monitored with a thermocouple and a NIR 
camera, respectively.  
 
Table 2.1 Temperature difference of the irradiated skin compared to the body temperature shown 
for different powers and irradiation surfaces 
  30 mm2 200 mm2 500 mm2 
7 mW 0.22 0.04 0.01 
12 mW 0.38 0.06 0.02 
66 mW 2.10 0.34 0.13 
194 mW 6.17 1.00 0.39 
540 mW 17.20 2.76 1.08 
615 mW 19.58 3.14 1.22 
 
Table 2.1 shows the maximum temperature difference between the skin at the laser spot and body 
temperature is shown for the different irradiation conditions. General higher temperatures were 
measured for higher powers and decreasing irradiation diameter. For further experiments a 
maximum powers must be defined where no skin damage was visible, usually around a 
temperature difference of 4oC.  Depending on the size of the tumor no filter with a laser spot size 
of 0.5 cm could be used. This corresponds to a maximum power of 3.14 W/cm2.  
Besides choosing the laser power, the minimum temperature increase during treatment must be 
correlated to the injected nanostars concentration for later PTT after intratumoral nanostars 
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administration. To have an efficient treatment, a temperature difference of minimally 6°C is 
necessary110.  
For studying this temperature increase, different molar concentrations of nanostars were 
subcutaneously injected which were suspended in matrigel. By using the NIR-camera, their 
temperature was followed during laser irradiation for 5 minutes and 1 minute afterwards. In the 
meantime their body temperature was measure by a thermocouple. The highest temperature 
during irradiation is shown in Figure 2.11, where for all concentration a temperature increase was 
visualized. The relative temperatures during this measurement are visualized as a function of time 
where a temperature increase during the first 60 seconds was visible reaching a plateau. When the 
laser was switched off, the subcutaneous nanostars/matrigel cooled down to normal body 
temperature of the mouse. During irradiation significant temperature increase was found for the 
molar gold concentrations of 2.25 μM and 4.50 μM compared to the control. 
 
Figure 2.11 Top. NIR images of the subcutaneous injected nanostar/matrigel concentration solution 
for different concentrations Left. Temperature difference compared to the body temperature during 
PTT of different nanostars/matrigel concentration solutions. Right. The maximum temperature 
plotted per gold concentration where the dotted line suggest a logarithmic correlation between those 
two variables.  
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When plotting the maximum temperature by gold concentration, the temperature increase 
effectiveness could be deducted by using a logarithmic fit. For smaller concentrations an 
extensive temperature increase was noticed while for larger concentrations this reaches a plateau. 
As a consequence a minimum concentration of 2.25 μM is needed for later effective PTT.   
The efficacy of nanostars to mediate PTT was studied in a xenograft mouse model (n = 6). The 
left tumor was used for injection with gold nanostars, while the right tumor acted as control after 
PBS sham injection. 24h after nanostar injection, both tumors were irradiated with a continuous 
laser (5 min, 690 nm and 2 W/cm2). Therapy efficacy was assessed in vivo by using MRI and BLI 
to evaluate tumor regression and viability. For quantification of the tumor cell viability, the BLI 
signal was monitored one day before and 0, 1, 5, 8 and 15 days after PTT where day 0 is the 
baseline. The day before PTT and after imaging, nanostars/PBS were injected into the tumors. 
One day after PTT, a significant decrease in relative BLI signal intensity to 10.13 ± 1.41 % was 
observed for the nanostars-injected tumor compared to the tumor at day 0, indicating a decrease 
in viable tumor cells or vessel patency (Figure 2.12). After 5 days, an increase of the BLI signal 
intensity was noticed to a relative value of 45.78 ± 10.02 %, which indicates partial re-growth of 
the PTT treated tumor as probably not all tumor cells were photothermal ablated. Although, a 
significant difference in signal intensity was maintained when compared to the tumor at day 0. 
Additionally, the right control tumor showed a constant increase in BLI signal intensity over time 
until a relative BLI signal of 440.24 ± 51.14 % after 15 days, confirming that the viability of the 
control tumor was not affected by laser irradiation. When comparing the nanostars-injected with 
the control tumor, a significant difference in BLI signal intensity was detected at day 1, 5 and 8, 
indicating a significant effect of PTT on tumor growth. 
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Figure 2.12 A. In vivo BLI before (day 0) and after PTT (days 1, 5, 8) illustrated in a color-coded 
intensity map. A  quantification of the BLI signal intensity relative to day 0 (set at 100% per mice) is 
plotted for both nanostar-injected and control (PBS-injected) tumors (RT) B. MR images of the 
tumor-bearing hind limbs taken at corresponding time points (days) after nanostar- or PBS-
injection. The yellow arrow indicates the tumor damage (hypointense area) after PTT at the 
nanostar-injected tumor. The relative mass volumes were quantified relative to day 0 (set at 100% 
per mice). (For both BLI and MRI graphs the Error bars represent SD; n = 6) 
 
For providing more information on the therapeutic effect, MR images were acquired on day 0, 1, 
8 and 15 to monitor tumor size, anatomy and heterogeneity. After 8 and 15 days, a relative tumor 
volume of 68.64 ± 18.45 % and 55.25 ± 30.1 % was observed for the left tumor compared to day 
0, indicating effective PTT (Figure 2.12). This was confirmed by the significant difference 
between this volume and the volume of the control tumor (PBS injection), where a relative tumor 
volume of 142.27 ± 28.49 % at day 5 and 184.12 ± 39.13 % at day 8 was measured, respectively. 
MRI also showed that the nanostars injected tumors were not affected evenly by PTT, indicating 
local differences due to inhomogeneous distribution of the nanostars (Figure 2.12). 
For validation, mice (n=3) were sacrificed after the first (day 1) and last (day 15) imaging time 
point following PTT. Tumors were resected and histologically examined. After one day, a distinct 
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blue color was seen on these histological slices coming from the nanostars with an LSPR band of 
679 nm, which were visible in the tumor. These nanostars were only noticed in the tumor region 
where also necrotic cells were visible ( Figure 2.13). As can be seen on the H&E stained images, 
the nuclei were either defragmented or darkened in comparison to the healthy cells (Figure 2.14). 
For the PBS-injected control tumors, the blue colour due to the nanostars was absent and the 
majority of cells appeared healthy. At the last imaging time point, no necrotic cells were visible 
on the histology sections for both the PBS- and nanostars-injected tumors (Figure 2.14). 
 
Figure 2.13 A complete overview of the histological section of either the tumor injected with nanostars 
(top) or PBS (bottom) after therapy. The blue ‘cloud’ in the tumor is caused by the gold nanostars, 
which is absent in the control tumor 
Using TEM, the presence of nanostar clusters inside vesicles of the cells was confirmed (Figure 
2.14). At the ultrastructural level, tumor cells were identified based on their pleomorphic aspects, 
increased nuclear/cytoplasmic ratio and distinct anaplasia. The latter was typically represented by 
nuclear hyperchromatism, thereby confirming that the tumor cells took up the nanostars. These 
nanostars were present in the cytoplasm and typically stored in membrane-bound compartments 
(endosomes, Figure 2.14). As the endosomes were packed with nanostars, it was difficult to 
identify single nanostars, demonstrating efficient intracellular uptake in vivo upon intratumoral 
injection.   
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Figure 2.14 A. Bright field microscopy images of control (right) and nanostar (left) injected H&E 
stained tumor sections. Defragmented nuclei of the tumor cells could be visualized after therapy. B. 
Ex vivo TEM images of tumor cells that indicate the presence of nanostars clusters in endosomes.  
The right panel shows a zoomed section of these endosomes with vesicular structures visible around 
the nanostars. 
2.4 Discussion  
 
We report the use of gold nanostars as theranostic agent against cancer using their photoacoustic 
and CT imaging capabilities to guide PTT after intratumoral injection. This strategy has clinical 
potential for the ablation of superficially localized tumor masses, or to aim for complete tumor 
cell eradication during tumor resection surgery. The clinical potential for a similar approach was 
already shown using magnetic nanoparticles 109,129. 
 
Crucial for PTT and PAI, is to synthesize nanostars with their LSPR band in the NIR-region. The 
aspect ratio of the tips at the nanostars plays a crucial role of LSPR band position 42. In our 
synthesis set-up, a variability on the LSPR band was noticed using different gold salt flow rates. 
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By decreasing this flow rate of gold salt, a red shift of the LSPR band was noticed due to the 
formation of longer but less tips. We surmise the role of BSPP, the shape-determining detergent, 
in respect to the lower starting gold salt volume is the cause of these longer tips. Since tips will 
only grow on surfaces with poor surfactant binding as BSPP, this increase in BSPP compared to 
the starting gold salt volume will lead to less tips created on the nanostars. Since only the flow 
rate has changed and not the total volume of gold salt during, these tips could grow to longer tips. 
To use these nanostars for in vivo conditions, their nanostars shape must be maintained over time 
in different physiological conditions. Hereby citrate was replaced by the SAM molecule as 
indicated by a shift in the LSPR band due to a change in the refractive index 116, and an increase 
of hydrodynamic diameter due to SAM formation on the nanostars surface. With this SAM layer, 
the nanostars are stable in cell culture conditions due to an electrostatic and steric repulsion24. 
Moreover proteins have absorbed on the nanostars forming a protein corona which increases the 
stability 140. 
 
Hereby, the efficient cellular uptake of nanostars into tumor cells is important for later in vivo 
applications. A first criterion is the size where two processes need to be considered: (1) optimal 
NP/cell interaction and (2) optimal tumor retention141,142. Nanoparticles having a hydrodynamic 
diameter above 100 nm are shown to have better tumor retention after intratumoral injection 
compared to smaller sized particles. In vitro studies, on the other hand, have shown that 
nanoparticles of around 50 nm diameter have the ideal size for cell interaction, while the cell 
uptake is less efficient for larger nanoparticles141. We have optimized our nanostars to have a 
hydrodynamic diameter of around 100 nm in serum conditions, which is the cut-off-value for 
optimal tumor retention and efficient tumor cell interaction. Second, the protrusions of the 
nanostars with a small curvature potentially increase cellular uptake by increasing their membrane 
interaction142. Third, our anionic particles show a much higher stability compared to cationic 
particles and still result in high cellular accumulation due to electrostatic interactions with the cell 
membrane141. Consequently, we were able to demonstrate that the nanostars were taken up 
reaching a gold concentration 11.28 ± 0.82 pg Au/cell after 24 h incubation, indicating that they 
are suitable for efficient passive labeling of tumor cells.  
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Given their right properties for cell labeling, we showed for the first time that nanostars can be 
used as an in vitro and in vivo theranostic agent combining both dual-modality imaging (PAI & 
CT) and PTT. Pure nanostar suspensions resulted in an almost equally high CNR for both imaging 
modalities.  In vitro these CNR’s could change since the nanostars will end up in acidic vesicles 
like lysosomes, where they could aggregate and may be depicted as one mass of gold nanostars. 
The exponential increase in signal for both PAI and CT with increasing intracellular gold 
concentration may be due to this aggregation. For CT this aggregation results in higher density of 
gold masses where the X-rays have to penetrate through, which increases the contrast. For PAI 
on the other hand, this aggregation results into a red shift of the LSPR band. Thereby the LSPR 
band will overlap more with the laser (700 nm) used for the PAI. When comparing the two 
imaging techniques a lower LOD and higher CNR was measured for PAI due to a higher optical 
sensitivity compared to CT. Still these in vitro experiments were performed in agar phantoms, 
creating a higher background for CT.  
 
Effective PTT was possible for nanostar labeled tumor cells, whereas unlabeled cells remained 
unaffected by laser treatment. Hereby an IC50 of 4.8 pg Au/cell (23 μM Au) was shown, which 
lies between the LOD of PAI and CT. Since in a theranostic approach, the gold nanostars are first 
used as a diagnostic agent it is preferable that the LOD is lower than the IC50. As a consequence 
it shows the potential of PAI as a theranostic imaging technique compared to CT. For comparing 
PTT effectiveness between different nanoparticles, the irradiation power that is needed to cause 
cell death is used as an indicator. The radiation power of 2 W/ cm  used in our study is in the 
same range as similar experiments performed with nanorods (10 W/cm2)143, nanoshells (35 
W/cm2)13,  and nanocages (5 W/cm2)115. The low radiation power used for our nanostars indicates 
their efficacy when compared with many nanostars reported in the literature (15 W/cm , 38 W/cm  
and 0.2 W/cm2)79,111,116. In addition to the inherent characteristics of the nanoparticles (absorption 
coefficient, size and wavelength), other factors like cellular labeling conditions, 
biofunctionalization of the AuNPs, etc. are equally important when comparing AuNPs regarding 
the irradiation power for PTT142. Consequently, there is a need for more in-depth and standardized 
studies for comparing different shapes of AuNPs and their theranostic potential.  
 
In addition to the in vitro experiments, we evaluated the use of in vivo imaging modalities (CT 
and PAI) to monitor intra-tumor nanostar delivery and their corresponding contrast generating 
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capabilities. With the nanostars having the optimal dimensions for intratumoral delivery, efficient 
nanostar accumulation in the tumor after injection was confirmed by PAI and CT and TEM. These 
nanostars were densely packed in endosomes, as visualized by TEM. Looking at the contrast 
generation of these nanostars in vivo, for PAI a significantly higher CNR (80.21) was observed 
compared to CT (25.31). This already high sensitivity of PAI could potentially be further 
improved by coating the nanostars with a silica shell 81. An additional advantage of PAI over CT 
is its high temporal resolution, while CT provides higher anatomical content. We were able to 
demonstrate that both imaging techniques can be used for intratumoral nanostar detection if high 
local concentrations can be achieved. By combining CT and PAI in a dual-modality approach 
using highly sensitive gold nanostars, PAI could provide rapid and detailed information on local 
nanostar distribution and their temporal changes, while CT could provide a full body scan with 
more detailed anatomical information.  
 
We have also confirmed the efficiency of the nanostars for PTT. Due to their star shape, they have 
a high absorption coefficient resulting in a large temperature increase of 25 °C when irradiated 
with a laser power of only 2 W/cm2. Reaching a local temperature higher than 43 °C will result 
in necrosis of tumor cells127,144.  After determining the right laser power and gold nanostars 
concentration, in vivo necrosis was shown in this study after tumor irradiation (2 W/cm2), while 
the control tumors did not show any side effects of laser irradiation. During laser treatment a 
temperature increase of 15oC was measured which corresponded to the gold nanostar 
concentration experiment. Using laser powers higher than the prescribed laser norm of 0.2 W/cm2  
defined by the American Laser Institute did not damage tissue when irradiating the control sample 
as confirmed by histology (Figure 6) 145. Compared to nanoshells (4 W/cm2) 13 and nanorods (2 
W/cm2) 112, the nanostars require the same magnitude of laser power to induce ablation after 
intratumoral injection. However, comparisons between different nanoparticles to assess their 
therapeutic efficiency are difficult due to the different experimental condition. Hereby, the 
combination with imaging techniques that provide information on the nanostar distribution and 
therapy outcome is of utmost importance. Additional treatment options to improve outcome are a 
combination of PTT with chemotherapy, photodynamic therapy or the introduction of tumor-
targeting moieties to the nanostars17,146. 
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2.5 Conclusion 
We have demonstrated an optimized synthesis and use of nanostars as a theranostic agent for 
combined multimodal imaging using CT, PAI and PTT. Due to the red shift of the LSPR band 
and the high absorption coefficient, these nanostars could have a better theranostic outcome 
compared to other shaped nanoparticles. The gold nanostars created significant contrast in both 
CT and PAI and proved to be an effective therapeutic agent for PTT, due to a successful passive 
uptake by the tumor cells. Future work should focus on the intravenous delivery of gold nanostars 
(passively or actively) leading most likely to further improvements in the nanotheranostics field, 
aiming for imaging and therapy of specific tumor types, which has also the potential to target and 
treat tumor metastases 
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3 UNREVEALING THE REASONS FOR THE 
INEFFECTIVENESS OF PASSIVE TARGETING 
USING NANOSTARS. 
3.1 INTRODUCTION 
 
In the previous chapter, the potential of the nanostars was studied using an intratumoral injection 
approach. To enable more practical clinical applications, e.g.  for diagnosing the tumor, the 
nanostars must accumulate inside the tumor after systemic administration. These particles 
spreading through the whole body via the bloodstream can either actively target the tumor or 
passively enter it by the specific characteristics of the tumor. Within this chapter the passive 
targeting will be studied in vitro and in vivo. 
 
A crucial factor is the optimization of the nanoparticle-cell interaction where the nanoparticles 
tend to enter the tumor cells. Generally nanoparticles uptake inside the cell is facilitated by a 
clathrin mechanism147. More specific, when NPs approach the cell surface and bind to the cell 
surface by ligand-receptor interaction, clathrin molecules intracellular will facilitate the NP 
uptake by inducing invagination of the membrane. These nanoparticles end up in endosomal 
structures within the cell, which will fuse with lysosomes to degrade the nanoparticles or excrete 
them by exocytosis148. 
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Different factors may influence the nanoparticles uptake such as size, shape and charge141. 
regarding size it has been shown that spherical nanoparticles around 50 nm are favored in terms 
of uptake compared to larger or smaller nanoparticles149. The exact reason is still not clear but it 
is suggested that the number of contact sites between the membrane and the nanoparticle play a 
crucial role for cellular uptake ref. It will take longer for the cell membrane to wrap a large particle 
and finally internalize it. Small particles below 50 nm however will form clusters that favor 
uptake142. Another factor is the charge of the nanoparticles, where cationic nanoparticles show a 
better intercellular uptake in vitro due to the electrostatic interaction with the negatively charged 
cell membrane. As a result, anionic nanoparticles are less taken up by these tumor cells. However 
some groups claim that they interact with the few cationic places on the cell membrane150. A last 
aspect is the shape of the nanoparticles where an increase in roughness already increases 
intracellular uptake151. For more atypical shapes it was suggested that rod like structures will 
experience longer wrapping times since the cells have to induce a bigger engulfment. On the 
contrary, in vitro experiments show a higher uptake of these rod-like structures favoring 
engulfment152.   
 
Nanoparticles can be used to target the tumor after i.v. injection using a passive targeting strategy. 
Here, the nanoparticles will accumulate inside the tumor due to the EPR effect where the tumor 
vasculature is more leaking, favoring diffusion of these nanoparticles inside the tissue (enhanced 
permeability). Hereby the particles should have a diameter between 40-600 nm to diffuse through 
the tumor’s pores.  When these nanoparticles diffuses inside the tumor tissue, they will have a 
low probability to circulate back into the blood mainly due to a defective lymphatic system45,153 
(enhanced retention). This EPR effect is dependent on either the tumor biology such as the 
vasculature and tumor extravascular environment and on the nanoparticles properties.  
 
As with the in vitro nanoparticle-cell interaction the same aspects (size, charge and shape of the 
particles) play an essential role for the intratumoral accumulation and distribution19. Here, the 
diameter of the nanoparticles needs to be smaller than the cut-off size of the fenestrations in order 
to be able to diffuse inside the tumor. Moreover, this size will also affect the extravasation of the 
nanoparticles within the tumor. On average, nanoparticles with a size smaller than 50 nm show a 
preferential accumulation inside the tumor, and the smaller the better the extravasation in the 
tumor154,155. Still, if the particles are too small, they show a more wide spread distribution in 
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different organs, increasing possible toxicity47. Also the presence of a charge on the nanoparticles 
has a profound effect on the nanoparticle accumulation in the tumor. Overall, neutral 
nanoparticles will show better accumulation within the tumor compared to charged 
nanoparticles53. However, in literature mixed results are shown with these charged nanoparticles 
where some have seen tumor accumulation with charged nanoparticles where others did not,156,157. 
In general, cationic particles show the least accumulation in the tumor. Hereby the effect of the 
charge on the blood retention time must be taken into account19. As for tumor cells, charges will 
increase the recognition by the RES, decreasing the blood retention time. As a last factor the shape 
of the nanoparticles may play a crucial role. Discoidal elongated shapes will show a higher 
accumulation in the tumor with a high penetration within the tumor compared to spherical 
particles with the same size51.  
 
Due to these specific and complex interactions of nanomaterials with living organisms, 
differences in efficacy of passive targeting have been shown the last years. While some observed 
reasonable accumulation in the tumor58,154,158, others reported almost no accumulation within the 
tumors95. When nanoparticles accumulate inside the tumor, most of them are found in the tumor 
peripheries103 and could be used for theranostic purposes20.  
In this part of the study, the passive interaction of the nanostars with the tumor cells will be studied 
in vitro and in vivo. Nanostars with a different end group on their self-assembled monolayer 
(SAM) will be evaluated regarding the difference in their cellular uptake. The biodistribution after 
i.v. injection of both nanostars with a high and low in vitro cellular uptake will be examined for 
different organs. As a final step, the photothermal capacities of these nanostars will be tested after 
i.v. injection.  
 
3.2 MATERIALS & METHODS 
 
3.2.1 Nanostars synthesis and functionalization 
Nanostars synthesis and chemical functionalization have been executed as explained in chapter 
2. For the functionalization three different molecules have been used ‘SAM MAL’ ( (HS–
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(CH2)11–(O–CH2–CH2)6–O–CH2–MAL)2, ‘SAM MALOH’ (HO-CH2–O-(O–CH2–CH2)6–
(CH2)11–S-S–(CH2)11–(O–CH2–CH2)6–O–CH2–MAL) and ‘SAM COOH’ (HS–(CH2)11–(O–
CH2–CH2)6–O–CH2–MAL). After functionalization, the nanostars were characterized using UV-
Vis absorption spectroscopy, DLS and zetapotential, in either water or cell culture medium with 
serum.  
 
3.2.2 Darkfield microscopy analysis of cell/ nanostar interaction. 
As in chapter 2, tumor cells (SKOV3) were seeded by 150 000 cells per well in a 12-well plate to 
study the cell-nanostars interaction. After 24h, nanostars with different SAMs (2.3x1010 particles 
in 1 mL) were added to the cells and incubated for 24h. After washing with PBS, these cells were 
again incubated overnight with fresh medium. After trypsinization, 300 µL of the cell suspension 
were plated on a coverslip in 1mL of fresh medium in a 12 well plate and incubated overnight.  
After fixation with 4-paraformaldehyde (4% PFA), these coverslips were mounted on a glass slide 
and visualized with darkfield microscopy.  Darkfield microscopy images were quantified by using 
CoralPaint Software where yellow pixels (nanostars) and green pixels (tumor cells) were detected 
from the images and converted into white pixels. The amount of white pixels was calculated for 
both conditions where afterwards the amount of nanostars pixels was divided by the amount of 
cell pixels to result in the nanostars/cell mean signal density.  
 
3.2.3 In vivo biodistribution using ICP-OES and darkfield microscopy.  
Athymic nude mice were, as in chapter 2, inoculated with tumor cells to let a tumor grow for 2-3 
weeks. Afterwards PBS or the nanostars (2,3 mg Au /ml) were injected via the tail vein (n=4 for 
each condition).  After 1 or 24h the mice were perfused with 4-PFA and the heart, the liver, the 
spleen, the kidneys and the tumors were dissected and stored in PBS with 0,1% sodiumazide 
(Sigma).  For ICP-OES, the organs were homogenized (Omni International Tm 125-220) in 1 ml 
distilled water. At each sample, 3 ml HCl and 1ml HNO3 were added. These samples were shaken 
for at least 48h. Afterwards, the samples were filtered using a 0.2 µm acrodisc syringe filter with 
HT tuffryn membrane (PALL Life Sciences) before measurement of the Au-content using ICP-
OES. For these measurements, standard Au Bibliography were used ranging from 1 – 100 ppm. 
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For darkfield microscopy and histology, the dissected organs were embedded in paraffin to make 
sections of 7 mm thickness with a microtome (HM360, Prosan). The sections were placed on 
microscope slides and deparaffinized for the darkfield microscopy slices and H&E staining.  
 
3.2.4 In vivo photothermal treatment and evaluation with BLI and MRI 
One day after nanostar injection, the tumors were all irradiated during five minutes with a 
monochrome NIR laser (λ = 690 nm; 1.00 W/ cm2) using a home-build laser setup, as described 
in chapter 1. To visualize the tumor viability and size evolution, BLI and MRI (protocol see 
chapter 1) were performed before treatment and three times a week until 12 days after irradiation.  
3.3 RESULTS 
 
3.3.1 SAM functionalization and characterization 
Nanostars were synthesized and functionalized as described in chapter 1 with a SAM molecule, 
either an alkanethiol or disulfide, all having a different end group. The alkanethiol is modified 
with a carboxyl end group (SAM COOH) while the disulfide is composed of either 50/50 
maleimide hydroxide (SAM MALOH) or complete maleimide (SAM MAL). This 
functionalization was thoroughly characterized and summarized in Table 3.1. For all three SAM 
molecules used, a red shift of the LSPR band and an increase in hydrodynamic diameter was 
observed, confirming the successful functionalization. After functionalization a small difference 
in zetapotential is measured where the nanostars SAM COOH have a slightly more negative 
zetapotential compared to the nanostars SAM MAL and SAM MALOH. When incubating these 
nanostars in serum conditions, an increase of the hydrodynamic diameter is measured of 21.2 +/- 
5.2 nm for the nanostars SAM MAL, 13.1 +/- 2.1 nm for the nanostars SAM MALOH and 4.5 
+/- 3.6 nm for the nanostars SAM COOH. 
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Table 3.1. LSPR shift, hydrodynamic diameter shift, zetapotential and protein corona increase for 
three different functionalization of the nanostars either, with SAM MAL, SAM MALOH or SAM 
COOH. Data represents mean values and standard deviations of 3 independent experiments. 
 
 
3.3.2 Difference in cellular uptake by changing the end group of the SAM. 
 
To study and compare the intracellular uptake of the nanostars by the tumor cells, we used 
darkfield microscopy to compare the difference in uptake over time. As for the MAL and 
MALOH SAM functionalized nanostars a gradual intracellular uptake over time was, resulting in 
fully packed tumor cells after 24h. Between the cells no nanostars were found indicating efficient 
intracellular uptake of these nanostars. On the contrary, we observed almost no accumulation over 
time for the COOH SAM modified nanostars even after 1h incubation1. An indication of the 
amount of nanostars per cell was deducted by calculating the nanostars/cell density using 
darkfield microscopy. Here the same trend was observed where no difference was quantified for 
the cellular uptake of the nanostars SAM MAL and SAM MALOH up to a nanostar/cell mean 
signal intensity of 15.69 ± 1.27 % after 24h for the nanostar SAM MAL and 18.93 ± 5.18 % for 
the nanostar SAM MALOH while only a value of 1.54 ± 0.99 % was deducted for the nanostar 
SAM COOH. As a consequence a significant difference in uptake could be confirmed between 
the nanostars SAM MAL(OH) and nanostars SAM COOH using a two way repeated measure 
anova test.  (1 These results were batch dependent) 
 
SAM MAL SAM MALOH SAM COOH
LSPR shift (nm) 9.4 ± 2.6 8.6 ± 3.5 9.6 ± 2.6
Hyrdrodynamic diameter shift (nm) 7.8 ± 3.4 7.5 ± 1.3 8.6 ± 2.9
Zetapotential (-eV) 41.3 ± 1.2 36.1 ± 1.9 44.5 ± 3.6
Protein corona increase (nm) 21.2 ± 5.2 13.1 ± 2.1 4.5 ± 3.6
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Figure 3.1. Nanostar/cell mean signal intensity deducted of darkfield microscopy images plotted of 
SKOV3 cells incubated either with nanostars SAM MAL, SAM MALOH and SAM COOH  for 
different time points (1, 3, 6, 12 and 24h; repeated measured two way ANOVA) 
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Figure 3.2. Darkfield microscopy images of SKOV3 cells incubated with either nanostars SAM MAL, 
SAM MALOH and SAM COOH for different time points (1, 3, 6, 12 & 24h) 
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3.3.3 In vivo biodistribution of nanostars after systemic administration 
 
An important criterion for an effective theranostic agent is a maximal accumulation of the 
nanostars inside the tumor and a minimal uptake in other organs of the host. Two invasive 
techniques, darkfield microscopy and ICP-OES, are used to study the biodistribution of the 
nanostars after i.v. injection.  
 
In Figure 3.3, a comparison of the relative gold concentration in the tumor is shown for two time 
points (1 and 24h after i.v. injection) compared to the injected amount of gold using ICP-OES. A 
high gold concentration of 9.2 ± 3.1% in the spleen and 74.8 ± 2.4% in the liver was measured 1h 
after i.v. injection compared to the injected amount gold. This gold concentration decreased over 
time (24h) by 47.8% for the spleen and 59.4 % for the liver. As for the tumor only small but non-
significant gold concentration was measured after 1h (1.3 ± 1.6%) while a non-significant gold 
concentration (0.3 ± 0.3%) was measured compared to the control (0.7 ± 0.7%) 24h after i.v. 
injection. For the other organs (heart and kidney) no gold was measured using ICP-OES.  
 
Figure 3.3. Left: Relative gold concentration of different organs at two time points (1 and 24h) after 
injection of either nanostars SAM MAL or PBS injection where the relative gold concentration is 
plotted in comparison to the injected amount of gold for the different tissues (one way Anova). Right: 
Nanostar/cell mean signal intensity of the different organs 24h after injection for either nanostars 
SAM MAL of PBS injection (t-test).  
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The distribution of these nanostars inside the organs was visualized 24h after injection using dark-
field microscopy. As with ICP-OES, no nanostars were visualized inside the kidney, heart and 
tumor, while for the liver and spleen significant accumulation was noticed (Figure 3.4). In liver, 
these nanostars were visualized between the hepatocytes (the bigger cells within the image). In 
contrast, the nanostars in the spleen are more randomly distributed inside the spleen. When 
quantifying the gold nanostars pixels compared to the area of the tissue (Figure 3.3), an estimation 
of nanoparticle density in the tissue was calculated. The highest density was found inside the 
spleen (9.08 ± 0.44 %) whereas less but still significant levels were noticed inside the liver (5.75 
± 1.43 %).  As expected for the tumor, heart and kidney no significant nanostar density was 
measured compared to the control. 
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Figure 3.4. Darkfield images of different organs after i.v. injection of either nanostars SAM MAL or 
PBS. 
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Similar to the nanostars SAM MAL, ICP-OES experiments were performed after i.v. injection of 
nanostars SAM COOH (Figure 3.5). As for the SAM MAL functionalized nanostars, no gold was 
measured in the tumor after 1h (0.3 ± 0.2 %) and 24h (0.1 ± 0 %). The nanostars accumulate to a 
lesser extent in the liver and this for both time points (1h - 32.3 ± 3.2%; 24h - 28.1 ± 2.5%) after 
injection. As for the spleen the same gold concentration (9.4 ± 1.4%) was measured compared to 
the SAM MAL functionalized nanostars for which also a small decrease was observed after 24h 
(5.7 ±1.6%). A small, but significant gold concentration was measured in the kidney and heart for 
even 1 and 24h after injection.  
 
 
Figure 3.5 Relative gold concentration of tissues either 1h after nanostars COOH, 24h after nanostar 
SAM COOH or PBS injection where the relative gold concentration is plotted in comparison to the 
injected amount of gold for the different tissues (one way ANOVA)  
3.3.4 In vivo PTT after passive targeting of the tumor 
 
Since ICP-OES and darkfield microscopy are invasive techniques which require a perfusion step, 
it could happen that the nanostars have flushed out of the respective organs before the 
biodistribution was measured. As a consequence, a PTT experiment may confirm the ineffective 
labeling of the tumor cells with the nanostars after i.v. injection. 
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One day after nanostar administration, the tumors were irradiated for 5 minutes with a NIR laser 
while the tumor temperature was monitored using a NIR camera.  For both the control and the 
nanostar-injected mice, a gradual increase of the temperature was recorded, reaching a plateau 
after 180 seconds (Figure 3.6). While in the nanostar injected animals this plateau value was at a 
temperature difference of 5.5°C, for the control mice around 2 °C.  No significant difference 
between the two conditions in this plateau phase was recorded. Once the laser was turned off the 
temperature decreased again to normal body temperature after 300 seconds.  
 
 
Figure 3.6 The temperature increase plotted over time where the tumor is irradiated at time point 0 
until 300 sec where no significance was measured (ANOVA; p ≤ 0.05) 
The PTT effectiveness was monitored for 13 days after therapy for both the control and nanostar 
administered animals using BLI and MRI. Figure 3.7 shows the BLI intensity after normalization 
where the same increasing trend was observed for both conditions. Next to the BLI signal, the 
tumor volume was monitored by MRI showing the same increasing trend as the BLI 
measurements, by tripling the size of volume after 13 days.  
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Figure 3.7. Relative BLI intensity (left) and tumor volumes (right) of the tumors after PTT for either 
i.v. injected nanostars or PBS mice. Treatment was executed at day 1 where no significance was 
shown over time for the nanostar and PBS administered mice (ANOVA; p≤0.05) 
For evaluating the possible toxic effect of the nanostars, the bodyweight of the mice was 
monitored during the follow up after PTT (Figure 3.8). No significant difference between the two 
groups was found over time where, both conditions started with almost the same weight 
19.7 ±0.7 g for the nanostars injected animals and 20.7 ±1.6 g for the control mice. At the last end 
point, the toxicology was evaluated on tissue level using H&E staining looking at inflammation 
or other tissue damage. No visual differences were detected between the nanostars and PBS 
injected animals and for all organs, focusing at the cell morphology and possible nucleus 
degradation (Figure 3.9). Also the vascularization of the tumor has been histological examined 
using a marker target CD31 which is found on endothelial cells in vascularized tumors and αSMA 
found on smooth muscle cells in the tumor. Both markers were clearly visualized (brown color) 
on the tumor sections (Figure 3.9).  
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Figure 3.8 Mean weight of the mice in each group during the follow up after PTT. No significant 
decrease in weight was measured (ANOVA; p≤0.05) 
 
Figure 3.9 Histology images of SKOV3 tumors either stained targeting CD31 or aSMA 
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Figure 3.10. Histology images after H&E staining of the tumor, spleen, liver, kidney and heart after 
either i.v. injection of the nanostars SAM MAL or PBS. 
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3.4 Discussion 
 
The nanoparticle characteristics have a huge influence on the intracellular uptake during passive 
tumor targeting. Hereby the size, shape and charge play a crucial role on this uptake but still big 
debates are ongoing about the efficacy of tumor targeting using anionic nanoparticles. To study 
this effect, we efficiently functionalized the nanostars with a SAM having different end groups 
(MAL, MALOH and COOH). We confirmed this by measuring a red shift of the LSPR band in 
the NIR region, due to a change in the refraction index, and a shift in hydrodynamic diameter 
since a SAM is formed on the nanostars’ surface. After functionalization, the negative 
zetapotential showed small differences between the three types of nanostars due to these different 
end groups. The nanostars SAM COOH gives a slightly more negative zetapotential while the 
nanostars SAM MALOH is more positive compared to the SAM MAL due to the alcohol 
groups159. 
 
For the intracellular uptake of the nanostars, we noticed a huge effect of changing the SAM’s 
chemical end group of the nanostar. While for the nanostars SAM MAL and MALOH a high 
intracellular uptake was visualized, almost no uptake was visualized using COOH SAM-
functionalized nanostars. This finding is contrary to the higher accumulation that was expected 
for the nanostars SAM COOH since they have a more negative charged zetapotential favoring 
cellular interaction with the cationic places on the cell membrane. Nevertheless, such small 
changes in zetapotential could not be the only reason for this significant difference in cellular 
uptake that we observed. 
 
To further explain the large difference in uptake among the tested nanostars, another effect must 
be taken into account, namely the creation of a protein corona around these nanostars in serum 
conditions140. The protein corona defines the adsorption of biological molecules on the 
nanoparticles, thereby changing the interface between the cells and the nanostars. We measured 
this effect by the difference in hydrodynamic diameter of the nanostars in cell culture medium 
with serum and water. While for nanostars with SAM MAL the largest protein corona is 
measured, this is lower for the nanostars with SAM MALOH and almost no protein corona for 
the nanostars SAM COOH. This protein corona formation could be due to the reactivity of the 
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maleimide end group which may bind to cysteine groups of proteins in the cell culture mediums 
as has been shown in literature160. 
Normally the protein corona reduces the uptake of the nanoparticles inside the tumor cells161,162, 
while we noticed a favored uptake within this case. We hypothesize that by shielding the negative 
surface of the nanostars SAM MAL and SAM MALOH by the protein corona, a favored uptake 
is observed compared to nanostars SAM COOH. Hereby there could be a threshold point of this 
protein corona between the hydrodynamic diameter shift of 13.1 nm for the nanostars SAM 
MALOH and 4.5 nm for the nanostars SAM COOH. Also the protein corona could change 
composition by using different end groups, which may have an effect on cellular uptake163. 
Another effect could be the reactivity of maleimide to thiols, which are abundant on cell receptors 
in  contrary to carboxyl groups which are mild reactive to proteins164. In general, this protein 
corona changes the identity of the nanostars and must be taken into account to predict the 
intracellular uptake of the nanostars. 
 
The high accumulation of negatively charged nanostars in the tumor cells that we observed in 
vitro, does not guarantees good accumulation inside the tumor.  Therefore, we studied the in vivo 
passive targeting capabilities of both the nanostars SAM MAL and SAM COOH, taking into 
account the effect of the presence of a protein corona around the nanostars in serum conditions. 
For both conditions no accumulation was observed 1h and 24h after i.v. injection of the nanostars. 
Several reasons could be considered regarding the unsuccessful accumulation of the nanostars 
inside the tumor. For instance this could be dependent on the tumor vasculature or the nanoparticle 
uptake by the RES19,130. Not all tumors have are well vascularized favoring the passive 
accumulation of the nanostars in the tumor by the EPR effect as has been shown for some tumor 
types. SKOV3 tumors with a vascularization have been observed and we visualized this by 
histology marking the cluster of differentiation 31 and alpha smooth muscle actin165. While 
CD31is a histological marker for vascularized tumors, αSMA is a marker for smooth muscles 
inside the tumor. As a consequence the failure of nanostars accumulation is not caused by a non-
vascularized tumor. Since our SKOV3 tumors showed clear visualization of these markers, we 
can conclude that the tumors are well vascularized, meaning that the passive targeting failure is 
not caused by the tumor vasculature. Another reasoning is the involvement of the RES which 
responsibility is filtration and phagocytosis of xenobiotic material such as the nanostars.  The 
result of the RES function of liver and spleen is decreasing the blood retention time, resulting in 
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a limitation of the nanoparticles that pass through the tumor. Due to this RES recognition the 
nanostars accumulated inside the liver and spleen. We indeed observed that within the liver the 
nanostars are located in the Kupffer cells between the bigger hepatocytes not showing any 
nanostar uptake. In the spleen the nanostars are more distributed over the whole organ. Next to 
the RES uptake, these organs are also characterized by fenestrae, where nanoparticles up to 100 
nm can pass through, such as our nanostars. 
 
The uptake of the RES system is dependent on different factor including the size, shape and charge 
of the nanoparticles. The RES will easily recognize bigger and spherical particles compared to 
smaller or more discoidal/nanorod shaped nanoparticles52,166. Since our nanostars can be 
described as a sphere with nanorods as branches, they may have a longer blood retention time.  
 
A last factor is the charge by the nanoparticle where the blood retention time decreases from 
cationic, anionic to neutral nanoparticles47. Hereby the opsonization process plays a crucial role 
where plasma proteins adsorb on the nanoparticle surface, facilitating the phagocytosis by the 
macrophages in the RES167.  This protein corona was mimicked using the cell culture medium 
with serum where the nanostars SAM MAL show a clear formation of the protein corona. As a 
consequence these nanostars are immediately recognized by the RES resulting in low tumor 
uptake and high liver and spleen uptake which is confirmed by ICP-OES and darkfield 
microscopy. For the nanostars SAM COOH this situation is different where almost no protein 
corona is noticed after incubating in cell culture medium conditions, resulting in probable longer 
blood retention time.  
 
This difference in protein corona could explain the subtle differences in the biodistribution of 
these nanostars having a different end group. The main difference was the small accumulation of 
the nanostars SAM COOH in the kidney and heart, which could be explained by a longer retention 
time in the blood. This was confirmed by the lower uptake in the liver due to a lower recognition 
of the nanostars SAM COOH by the RES system, while the nanostars SAM MAL are immediately 
recognized by the RES system due to the presence of a protein corona. Moreover macrophages 
are characterized with scavenger receptors which are loaded with cysteines, recognizing 
negatively charged molecules52. Since maleimide groups are reactive with thiols on these cysteine 
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groups, the nanostars SAM MAL could increase the recognition of these nanostars by the 
macrophages. 
 
Still, given the high concentration of nanostars inside the liver and spleen for the nanostars SAM 
MAL, no acute toxicity is noticed.  This is an encouraging observation, as it is an indication that 
systemic nanostar administration would not have harmful side effects for the mouse, and by 
extension, the patient. This non acute toxicity is supported by the weight of the animals that stays 
normal 13 days after nanostars administration and PTT.  Also, detailed histological evaluation of 
the tissues showed no nucleus degradation or cell morphology changes. Nonetheless, some studies 
have evaluated the possible long term toxicity of gold nanoparticles and observed a change in the 
upregulation of genes and the increase in volume of the Kupffer cells168. Aiming at the evaluation 
of the clinical applicability of NPs, the assessment of NP toxicity will remain a very important 
aspect in future in vivo studies.  
 
Given the inefficient nanostar uptake by the tumors upon passive delivery, it is not to our surprise 
that PTT performed 24h after i.v. nanostars-SAM-MAL injection remained ineffective.  This was 
indicated by the non-significant temperature increase during PTT compared to the temperature 
rise observed during PTT of tumors that were directly injected with nanostars.  That we could not 
observe any tumor viability and size decrease quantified by BLI and MRI was consistent with 
these results.  
 
This PTT effectiveness could be increased by a better tumor uptake where the nanostars have a 
decreased recognition by the RES system and potentially by actively target the nanostars using a 
biological ligand169,170. Hereby several biological ligands as antibodies, proteins, nanobodies have 
been used as an effective ligand to target overexpressed receptors on tumor cells.  
3.5 Conclusion 
 
In this chapter we examined the potential of passive targeting of tumors after systemic nanostars 
delivery.  We revealed the inefficiency of this approach and investigated possible reasons of the 
observed inefficiency of tumor targeting using a passive strategy with anionic charged nanostars. 
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A huge difference in intracellular uptake of the nanostars is shown related to the reduction of the 
protein corona by changing the end group of the SAM on the nanostars. A marginal uptake in the 
tumor is shown for both types of nanostars where they tend to accumulate in the spleen and liver. 
To increase possible tumor accumulation the nanostars, we propose that nanostars may be 
biofunctionalized for active targeting the tumor cells. This strategy we investigate in the next 
chapter.
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4 LIMITING THE PROTEIN CORONA: A 
SUCCESSFUL STRATEGY FOR IN VIVO ACTIVE 
TARGETING OF ANTI-HER2 NANOBODY-
FUNCTIONALIZED NANOSTARS. 
4.1 Introduction 
 
Finding an effective way to target tumors by using a theranostic nanoparticles is a big challenge 
up to now22. Hereby two targeting strategies, either passive or active, have been intensively 
studied171.  While passive targeting is based on the diffusion of the nanoparticles into the tumor 
tissue by the enhanced permeability and retention effect, active targeting makes use of biological 
ligands coupled onto the nanoparticles to recognize overexpressed receptors of tumor cells. 
However, these targeting approaches have had different outcomes due to several reasons ranging 
from the inappropriate tumor models to nanoparticle properties like their geometry, chemistry and 
many others57,95. 
During the last decade, many efforts have been made to optimize nanoparticle properties to 
succeed in targeting tumors172. Several criteria, such as size and charge, have been intensely 
discussed to enhance in vivo tumor uptake47. In essence, a poly-ethylene glycol (PEG) layer, a 
neutral charge and a nanoparticle diameter around 50 nm were found to be crucial53. Next to a 
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better tumor retention due to the EPR effect, these conditions are also linked to a longer blood 
retention time and by decreasing the recognition of the nanoparticle by the immune system56,173.  
The characteristics of the nanoparticles in water are completely different than the ones under in 
vivo conditions, which will determine the efficient targeting of the tumor cells by the 
nanoparticles15. Indeed, in vivo effects have to be taken into account when studying targeting 
efficiency such as the protein corona. This is generated on the nanoparticle surface in the presence 
of serum and consists in essence of different proteins where its composition is constantly changing 
over time10,11. The protein corona is composed of a ‘hard’ corona, consisting of tightly bound 
proteins, and a ‘soft’ corona of loosely bound interchangeable proteins12. The composition of the 
protein corona is also influenced by several factors that are unique for each type of nanoparticle, 
where surface charge and hydrophobicity are the most determining ones 13,14. As a consequence, 
efforts have been made during the last years to visualize and biologically validate the protein 
corona demonstrating important differences between in vitro and in vivo conditions. 
To maximize tumor targeting it is crucial to study the influence of the protein corona on the 
targeting efficiency of the tumor cells by the nanoparticles and how to manipulate this corona to 
achieve an efficient targeting. While specific, active targeting of tumor cells by nanoparticles may 
be shown under conditions without serum, the outcome could be completely changed by the 
formation of a protein corona in the presence of serum. It may even change over time such as in 
late-stage versus early-stage of disease16. Moreover, the protein corona also plays an important 
role for cell recognition during nanoparticle endocytosis, affecting the intracellular fate of 
nanoparticles17. As a consequence, the protein corona shows a crucial influence on the passive 
and active cell targeting and may lead to a complete loss of targeting capabilities 18,19. By using 
mathematical models to predict the protein corona composition and by tailoring the protein 
corona, first steps were taken to overcome this problem in order to generate active targeting 
compounds20–22.  
Here, we present a methodology to reduce the formation of a protein corona on gold nanostars 
that are functionalized with a self-assembled monolayer containing maleimide end groups. To 
prove the active targeting concept, the cancer cell receptor human epidermal growth factor 2 
(HER2), targeted by camel-derived nanobodies is used as a model23,24. The HER2-receptor was 
chosen because up to 30% of breast cancers show an overexpression of this receptor, while 
expression levels in normal tissues are close to absent, making it an interesting target for anti-
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cancer therapy25. Targeting has been optimized by using anti-HER2 nanobodies. Nanobodies 
consist of the antigen-binding domain of a heavy chain-only camelid antibody and bear intrinsic 
properties such as smaller size and higher stability than anti-HER2 monoclonal antibodies like 
Herceptin23. These nanobodies are covalently bound the gold nanostars with a self-assembled 
monolayer as the interface. Nanostars are chosen since they a promising type of gold nanoparticles 
due to their higher absorption coefficient crucial for photoacoustic imaging (PAI) and 
photothermal therapy (PTT) compared to other shaped nanoparticles 26,27. 
To test our approach under in vitro and in vivo conditions in a mouse model, two different cell 
lines were used throughout this study, an ovarian cancer cell line (SKOV3) showing high 
expression of HER2 receptors and a hamster ovarian cancer cell line (CHO) as a negative control. 
By using these two cell lines and three different types of nanoparticles (non-biofunctionalized or 
biofunctionalized with either anti-HER2 or control nanobodies, the specificity of active targeting 
was studied, both under non-serum and serum conditions. 
4.2 Material and Methods 
4.2.1 Nanostar synthesis, functionalization and characterization.  
Nanostar synthesis and functionalization with the SAM molecule (1.2mM, (HS–(CH2)11–(O–
CH2–CH2)6–O–CH2–MAL)2), have been previously described in chapter 2 resulting in batch of 
SAM functionalized nanostars solved in HEPES buffer (pH=7, 10 mM). Nanobodies (2Rb17c 
and cAbcII10) were synthesized with an end standing cysteine group as published by Massa et al. 
182. To attach these nanobodies onto the maleimide end group of the SAM-coated nanostars, the 
nanostar suspension was mixed with an identical volume of nanobodies dissolved in HEPES 
buffer.  A range of nanobody concentration has been added to the nanostar suspension to define 
an optimal concentration (monomer: 0; 0;25;0;5;1;2;5;5;10 µg/mL and reduced dimer: 0;0;01; 
0,05; 0,1; 0,5; 1;2 µg/mL). After overnight shaking, the suspension was centrifuged at 4000 rpm 
for 60 minutes. Subsequently, the supernatant was discarded and the pellet resuspended in the 
desired buffer. After each functionalization step, the absorbance, hence shift in plasmon resonance 
band of the nanostars was measured using UV-Vis absorption spectroscopy (Shimadzu UV-
1601PC, Brussels, Belgium). Their hydrodynamic diameter as well as zeta-potential was 
determined using dynamic light scattering (DLS; Malvern Nanosizer, WR, United Kingdom).  
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These nanoparticles are also examined on their stability in the respective cell culture mediums 
(with and without serum) for the SKOV3 and CHO cells using the same characterization 
techniques. All chemical compounds were purchased from Sigma Aldrich (Diegem, Belgium) 
For blocking experiments of the maleimide end groups, the same protocol was used for the 
biofunctionalized and non-biofunctionalized nanostars. Five different blocking agents were tested 
three different short molecules, namely 3-mercaptopropionic acid (‘SHCOOH’), 2-
mercaptoethylamine (‘SHNH’) and 2-mercaptoethanol (’SHOH’) and two molecules containing 
a poly-ethylene glycol (PEG) chain, namely O-(2-Mercaptoethyl)-O′-(2-
carboxyethy)heptaethylene glycol (‘PEGCOOH’) and O-(2-Mercaptoethyl)-O′-methyl-
hexa(ethylene glycol) (‘PEGCH’). For functionalizing the nanostars with these blocking agents, 
3 mL of the nanostars (6.9 1011 nanostars/mL) were mixed with 300 µL of the blocking agents at 
different concentrations (1.2, 2.4 and 12 mM). After 60 minutes of centrifugation at 4000 rpm, 
the nanostars were re-suspended in either MES buffer or cell culture medium either with or 
without serum to characterize this suspension by UV-Vis absorption spectroscopy and DLS. All 
chemical compounds were purchased from Sigma Aldrich (Diegem, Belgium). 
4.2.2 Cell culture.  
Both, SKOV3 and CHO cells (ATCC® HTB77, Cedex, France) were maintained at 37 °C and 
5% CO2 in 75 cm2 cell culture flasks. SKOV3 cells were cultured in a RPMI1640 medium and 
the CHO cells in DMEM medium both supplemented with 10% Fetal Bovine Serum, 1% 
Penicillin Streptomycin and 1% L-glutamine. All cell culture reagents were purchased from 
Invitrogen Life Technologies Life Sciences (Gent, Belgium). Darkfield microscopy for in vitro 
active targeting. 
4.2.3 Darkfield microscopy 
Tumor cells were seeded at a density of 150.000 cells/well in a 12 well plate and incubated 
overnight. Nanostars (5.7x109 nanostars/mL) were added to the suspension. After 6h of 
incubation, they were washed twice with cell culture medium. After an overnight incubation with 
fresh medium, tumor cells were trypsinized and seeded onto a coverslip. After another overnight 
incubation, the cells were fixed with 4% paraformaldehyde and washed three times with PBS. 
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After mounting the coverslip on a glass slice, the tumor cells were visualized using darkfield 
microscopy. The dark field measurements were performed using an Olympus BX51 microscope 
(Olympus, Berchem, Belgium) equipped with a dark field condenser and an objective (10×). The 
microscope was fitted with Soft Imaging System’s Colorview III camera and AnalySIS Life 
Sciences software (Olympus, Berchem, Belgium). 
 
Darkfield microscopy images were quantified using CoralPaint Software where the yellow pixels 
(nanostars) and green pixels (tumor cells) were deducted from the images and converted into 
white pixels. The number of white pixels was calculated for both conditions. The number of 
nanostars pixels was divided by the number of cell pixels to result in the nanostars/cell mean 
signal intensity 
 
4.2.4 In vivo tumor model and photoacoustic imaging of the nanostars in 
vivo.  
Female athymic nude mice (8 weeks, Harlan, Host, The Netherlands) were used during these 
experiments. All animal experiments were approved by the local animal ethics committee of the 
KULeuven and were performed according to the national and European Regulations. Animals 
were kept in individually ventilated cages with food and water ad libidum. A total number of 1 x 
107 SKOV3 tumor cells suspended in 100 µL cell culture medium were injected into each hind 
limb of the mice and left for two weeks to grow into solid tumors.    
 
After tumor formation (size > 200 mm3), 200 µL of nanostars (2.7 1012 nanostars/mL) were 
intravenously (i.v.) injected into animals (n=3). Three hours after nanostar injection, tumors were 
imaged by photoacoustic imaging (PAI) using a multi-wavelength approach. Hereby, a 
VevoLazer 2001 (Visualsonics, Amsterdam, The Netherlands) was used with the following 
parameters: 10 ns pulsed laser with a power of 20 mJ/cm2 and a 200 mHz frequency. To spectrally 
unmix the gold nanostar signal from the hemoglobine’s photoacoustic signal, the tumors were 
irradiated at different wavelengths (680, 700, 720, 750, 800, 850 nm). During in vivo PA imaging, 
ultrasound imaging was used to determine the tumor location. The PA signal intensity was 
measured over the complete region of interest (ROI), defined as the tumor volume, before and 
after nanostar administration. 
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4.2.5 Histopathology 
To confirm the location of the nanostars, animals were sacrificed and perfused with 4% PFA after 
the PAI experiments. The following tissues were removed: kidney, liver, tumor, heart and spleen. 
After embedding in paraffin and sectioning in slices of 7 µm width, the sections were de-
paraffinized before visualizing them with darkfield microscopy.  
4.2.6 Statistical analysis 
For quantification of the darkfield data, nanostars/cell mean signal intensity was 
calculated.  Statistical analyses were executed on the quantitative data using a paired t-test where 
the degree of significance is indicated with *: p < 0.05; **: p < 0.01; ***: p < 0.001.  
4.3 Results 
4.3.1 Nanostar biofunctionalization 
Nanostars are synthesized and maleimide functionalized having their plasmon band maximum at 
674.5 ± 10.7 nm and an average hydrodynamic diameter of 75.0 ± 5.6 nm as previously 
described26,29. Nanobodies (2Rb17c and cAbBcII10) with an end-standing cysteine group were 
chemically bound onto the maleimide end group of the nanostar’s coating by nucleophilic 
addition. As it was described by Massa et al. a spontaneous dimerization can occur during the 
nanobody’s synthesis (with Cysteine at C-terminal end), resulting in fractions of monomers and 
dimers of nanobodies24. To reduce the cystins and to avoid the formation of dimers, a mild 
reduction with 2-mercaptoethylamine was performed to have only monomers with an end-
standing cysteine group that can then react with the maleimide group. A difference in maximum 
nanobody concentration was measured for the monomer fraction (1 µg/mL) compared to the 
reduced dimer fraction (0.05 µg/mL). For both fractions, the nanostars were unstable at higher 
nanobody concentrations as shown by the broadening or disappearance of the plasmon band 
(Figure 4.1). At the optimal nanobody concentrations a non-significant plasmon band shift was 
noticed compared to the non-biofunctionalized nanostars. Using DLS, the same trend of increased 
hydrodynamic diameter was observed with a non-significant increase after biofunctionalization. 
For the determination of zetapotential, a less negative potential was measured for 
biofunctionalized compared to non-biofunctionalized nanostars (Table 4.1). This trend was 
Gold nanostars as a specific theranostic agent against HER2 expressing tumor cells 
 
 
 
90  Antoine D’Hollander  
 
 
 
observed for all batches of nanobodies. As a consequence in the continuing text no differences 
will be made between the reduced dimer or monomer fraction.  
 
Figure 4.1 UV-Vis absorption spectroscopy for nanostars functionalized with various concentrations 
of either monomer 2Rb17c (A), monomer cAbcII10 (monomer), reduced dimer 2Rb17c (C), reduced 
dimer cAbcII10 (C) 
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Table 4.1 For the different sets of nanostars functionalized with nanobodies, the LSPR band shift, 
hydrodynamic diameters and zetapotential are reported. Data represent mean values ± standard 
deviations for three independent experiments. 
 
 
Since the gold nanostars will ultimately be used under physiological conditions, their stability 
was examined in different cell culture media (with and without serum) and characterized by using 
UV-Vis absorption spectroscopy (data not shown). All bio-functionalized nanostars were stable 
in these different media as indicated by the absence of LSPR band broadening. Still, these 
characteristics only suggest a successful biofunctionalization, while we do not know if the 
nanobody concentration on the nanostars is high enough to succeed in active targeting and if the 
nanobodies are accessible to target the HER2 receptor once bound onto the nanostars.  
 
Since the gold nanostars are to be used under physiological conditions, their stability was 
examined in different cell culture media (with and without serum) and characterized by using 
UV-Vis absorption spectroscopy and dynamic light scattering (Figure 4.2). All bio-functionalized 
nanostars were stable in these different media as indicated by the absence of localized surface 
plasmon resonance (LSPR) band broadening. Still, an increase of the hydrodynamic diameter was 
observed when nanoparticles were exposed to standard SKOV3 cell culture medium. For the non-
biofunctionalized nanostars a hydrodynamic diameter of 27.3 ± 2.4 nm was noted, whereas the 
2Rb17c- and cAbBcII10-functionalized nanostars had a hydrodynamic diameter of 26.8 ± 3.2 nm 
and 25.4 ± 2.7 nm, respectively (Figure S7). In CHO cell culture medium with serum, the 
formation of a protein corona increased the hydrodynamic diameter to 20.4 ± 2.1 nm, 20.8 ± 3.9 
nm and 16.9 ± 3.1 nm for the non-biofunctionalized nanostars, the 2R17c and the cAbBcII10 
functionalized nanostars, respectively. These expansions are due to the formation of the protein 
2Rb17c 
monomer
cAbcII10 
monomer
2Rb17c 
reduced dimer
cAbcII10 
reduced dimer
LSPR band shift (nm) 1.5 ± 1.0 1.0 ± 1.0 1.5 ± 0.5 2.0 ± 1.0
Hydrodynamic diameter increase (nm) 5.3 ± 3.7 6.2 ± 4.2 4.8 ± 2.9 5.3 ± 3.9
Zetapotential (mV) -36.3 ± 3.5 -37.2 ± 2.9 -37.6 ± 2.6 -35.8 ± 3.2
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corona, which did not have an effect on the nanoparticle stabilities as no broadening of the 
plasmon band was measured compared to the plasmon band in water. Furthermore, these 
characteristics are only suggestive for a successful biofunctionalization, since at this stage we do 
not know if the nanobody concentration on the nanostars is sufficient to provoke an active 
targeting and if the nanobodies onto the nanostars are available for HER2 receptor recognition.  
 
 
Figure 4.2 UV-Vis absorption spectroscopy of the nanostars – biofunctionalized and/or blocked with 
SHOH - in  HEPES buffer (A), cell culture medium with serum (B) and cell culture medium without 
serum (C). 
4.3.2 In vitro visualization of active targeting using biofunctionalized 
nanostars.  
To verify if the 2Rb17c nanobody actively recognizes the HER2 receptor on the SKOV3 tumor 
cells, nanostars were incubated in medium not containing serum at a temperature of 4 °C. In 
general, under this non-physiological condition no protein corona is generated and passive 
targeting is inhibited since the receptor-mediated endocytosis pathway is blocked at this low 
Chapter 4: Limiting the protein corona: A successful strategy for in vivo active targeting of anti-her2 
nanobody-functionalized nanostars. 
 
 
 
Antoine D’Hollander   93 
 
 
 
temperature30,31. First, darkfield microscopy was used to image the interaction of the nanostars 
with the HER2-positive SKOV3 cells. As shown in Figure 4.3, , the nanostars functionalized with 
2Rb17c (POS) showed high accumulation in the SKOV3 cells while the other two control 
nanostars, the non-biofunctionalized nanostars (MAL) and nanostars functionalized with a non-
targeting control nanobody cAbBcII10 (NEG), showed minimal accumulation inside the tumor 
cells. (Figure 4.4). No statistically significant differences in uptake were noticed between the three 
types of nanostars for CHO cell labelling. Using quantitative darkfield microscopy data, the same 
trends were quantitatively confirmed with a higher uptake for the 2Rb17c functionalized 
nanostars (POS) under these non-serum containing culturing conditions (Figure 4.5) 
Exertion of these experiments at a temperature of 37 °C resulted in a different outcome (Figure 
3). No difference in targeting was observed between the three types of particles due to a higher 
passive uptake of the two control nanoparticles. Similarly, incubation of the nanostars with the 
tumor cells in standard medium (with serum) at 4 °C resulted in a diminished specific 
accumulation in HER-2 expressing SKOV3 cells compared to the conditions without serum: the 
2Rb17c functionalized nanostars showed similar uptake by the HER2 expressing tumor cells 
when compared with the control nanoparticles, which resulted in a slightly decreased intracellular 
nanostar concentration when compared to the uptake without serum, for both SKOV3 and CHO 
tumor cells (Figure 4.4). Also, at a temperature of 37oC, no active targeting was observed where 
a similar decreased uptake was observed as for non-serum containing conditions. Comparing the 
different conditions for the CHO cells, no significant difference in nanostar uptake was seen, 
indicated by the absence of the yellow colored nanostars. These trends are quantitatively shown 
in Figure 4.5. 
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..  
Figure 4.3 Darkfield microscopy images of SKOV3 cells (green) incubated with either non-
biofunctionalized nanostars (MAL), biofunctionalized with 2Rb17c (POS) and cAbcII10 (NEG) for 
different incubation conditions visualized by the yellow spots. 
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Figure 4.4 Darkfield microscopy images of CHO cells incubated with either non-biofunctionalized 
nanostars (MAL), biofunctionalized with 2Rb17c (POS) and cAbcII10 (NEG) for different 
incubation conditions. 
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Figure 4.5 Nanostar/ cell intensity for SKOV3 cells (A) or CHO cells (B)  incubated with either non-
biofunctionalized nanostars (MAL), biofunctionalized with 2Rb17c (POS) and cAbcII10 (NEG) for 
different incubation conditions. 
4.3.3 Reducing the size of the protein corona reduces passive targeting  
It was shown that nanoparticles with a functional maleimide end group have failed in active 
targeting due to the generation of a protein corona18. To overcome this problem, various 
compounds have been tested to block the maleimide serum interactions on nanoparticle surfaces32. 
We have examined three different short molecules (SHCOOH, SHNH and SHOH) and two 
molecules containing a PEG chain (PEGCOOH, PEGCH) to block the maleimide end groups. 
Each of these molecules has an end-standing thiol group, which will covalently bind to the 
maleimide group. In a first set of experiments, the blocking capabilities were examined on the 
non-biofunctionalized nanostars, while in a second step, nanostars functionalized with nanobodies 
were used. 
 
Three concentrations of the various blocking agent were tested in the same order as the SAM 
functionalization (1.2 & 2.4 mM) and an up to ten-time higher concentration (12 mM). Looking 
at the LSPR band shift for the concentrations of 1.2 and 2.4 mM, only a small red-shift of the 
LSPR band was measured for all blocking agents. For the highest concentrations (12 mM), a.blue 
shift of the LSPR band was detected for the small molecules (SHOH, SHCOOH and SHNH), 
while a red shift was noticed for the larger PEG molecules (Figure 4.6; Appendix 1). In addition, 
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a significant decrease of the hydrodynamic diameters in MES buffer was observed for all 
concentrations, when compared to the non-blocked nanostars.  
 
Figure 4.6 Normalized absorbance of the nanostars that are functionalized with the blocking agents 
SHNH (A), SHOH (B), SHCOOH (C), PEGCH (D) and PEHCOOH (E) for different concentrations 
(1,2 mM; 2,4 mM and 12 mM) in either MES-buffer or cell culture medium with serum. 
 
Gold nanostars as a specific theranostic agent against HER2 expressing tumor cells 
 
 
 
98  Antoine D’Hollander  
 
 
 
Based on these initial finding, we chose to use a concentration of 2.4 mM for all subsequent 
experiments. At this functionalization concentration, the zetapotential showed either an increase 
or decrease when compared to the non-blocked, functionalized nanostars, depending on the end 
group of the agent (Table 4.2). While for positive and neutral groups (-OH, CH3 and NH2) a less 
anionic zetapotential was measured, the nanostars were slightly more anionic for carboxyl end 
groups of the blocking agents. 
 
Table 4.2 Zetapotential given for the nanostars either non-blocked (MAL) or blocked with different 
types of molecules 
 
 
Figure 4.7 shows the increase of hydrodynamic diameter when these nanostars are dissolved in 
cell culture medium with serum. The nanostars blocked with a PEG-containing blocking agent 
did not show any significant reduction of the protein corona as compared to the non-blocked 
nanostars (control). On the other hand, the nanostars that were blocked with the shorter molecules 
showed significantly reduced hydrodynamic diameters. The most pronounced effect was seen for 
the nanostars blocked with SHOH, showing only a hydrodynamic diameter increase of around 9 
nm when comparing serum with non-serum containing medium 
Zetapotential (mV)
MAL -41.23 ± 2.13 
SHNH -34.92 ± 3.52
SHOH - 37.37 ± 1.73
SHCOOH -41.53 ± 1.53
PEGCOOH - 40.67 ± 0.97
PEGCH - 42.27 ± 1.25
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Figure 4.7 Hydrodynamic diameter difference shown for the difference nanostars - non-blocked or 
blocked – under serum-containing conditions compared to their hydrodynamic diameter in water 
(control) 
4.3.4 In vitro visualization of active targeting using biofunctionalized 
nanostars.  
To examine the effect of this blocking agent on the nanostar-cell interaction, the nanostars were 
incubated for 6 and 24h with the SKOV3 cells in medium containing serum. The darkfield images 
showed a reduced passive uptake for all blocked nanostars with subtle differences between the 
different blocking agents (Figure 4.8). The nanostars functionalized with SHCOOH or 
PEGCOOH showed the smallest reduction in uptake on the darkfield microscopy images, while 
SHOH showed the highest reduction in uptake after both 6 and 24h incubation (Figure 4.8). Using 
darkfield quantification, only a nanostar/cell mean signal intensity of 3.2 ± 1.2 % was measured 
for the SHOH functionalized nanostars compared to 8.8 ± 0.9 % for the non-blocked nanostars 
(Figure 4.9).  
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Figure 4.8 Darkfield images of SKOV3 cells incubated with the different (non-)blocked nanostars 
during 6 or 24 h of incubation 
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Figure 4.9 Nanostar/cell intensity plotted for different SKOV3 cells incubated with non-
biofunctionalized nanostars either non-blocked or in the presence of a blocking agent. 
4.3.5 In vitro visualization of active targeting using biofunctionalized 
nanostars.  
 
Since blocking the nanostars with SHOH resulted in reduced hydrodynamic diameters, mainly 
due to a reduced protein corona, the next step was to examine the active targeting properties of 
the biofunctionalized nanostars blocked with this molecule. Nanobody-functionalized nanostars 
blocked with SHOH remained stable in water and in medium containing serum, as no broadening 
or diminishing of the LSPR band was seen (Figure 4.2). Also further functionalization with 
nanobodies did not influence the inhibition of protein corona by SHOH in cell culture media for 
both the SKOV3 and CHO tumor cells (Figure 4.10). Overall, the thickness of the protein corona 
was significantly reduced to a maximum size of 9 nm. 
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Figure 4.10 Differences in hydrodynamic diameters measured for the nanostars – biofunctionalized 
and/or blocked with SHOH - in cell culture medium containing serum compared to the 
hydrodynamic diameter measured in water. Data is shown for SKOV3 cell  
 
When incubating tumor cells with these nanostars under serum-free conditions at a temperature 
of 4 °C, specific accumulation was seen using darkfield microscopy where a significant decrease 
of uptake was noticed for both the non-biofunctionalized and cAbBcII10 functionalized nanostars 
but not for the 2Rb17c functionalized nanostars (Figure 4.11). After incubating at a temperature 
of 37 °C in the absence of serum, the same specific intracellular uptake in the SKOV3 cells was 
observed for the 2Rb17-blocked nanostars. For the other two types of nanostars, almost no 
intracellular nanostar accumulation was observed. Performing the same experiments in medium 
containing serum, a specific accumulation of the 2Rb17c functionalized nanostars was seen inside 
the cells for both temperatures. The other two types of nanostars showed no accumulation inside 
the tumor cells, indicating a blocking of the formation of a protein corona which results in a 
successful active targeting. . As seen in Figure 4.12 almost no nanostar accumulation was detected 
in the CHO cells under none of the conditions tested (serum versus non-serum at a temperature 
of 4 and 37°C)., These results were confirmed after quantifying the intensities in the darkfield 
microscopy images (Figure 4.13).  
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Figure 4.11 Darkfield microscopy images of SKOV3 cells incubated with either non-
biofunctionalized nanostars (MAL), biofunctionalized with 2Rb17c (POS) or cAbcII10 (NEG). All 
nanostars were functionalized with the blocking agent SHOH. 
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Figure 4.12 Darkfield microscopy images of CHO cells incubated with either non-biofunctionalized 
nanostars (MAL), biofunctionalized with 2Rb17c (POS) or cAbcII10 (NEG). All nanostars were 
functionalized with the blocking agent SHOH. 
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Figure 4.13 Nanostar/ cell intensity for SKOV3 cells (A) or CHO cells (B) incubated with either non-
biofunctionalized nanostars (MAL), biofunctionalized with 2Rb17c (POS) and cAbcII10 (NEG) but 
all functionalized with blocking agent SHOH for different incubation conditions 
 
4.3.6 In vivo imaging of biofunctionalized nanostars.  
To verify the targeting capabilities in vivo, animals with a SKOV3 cell xenograft were 
intravenously injected with the blocked nanostars either biofunctionalized with 2Rb17c, 
cAbBcII10 or non-biofunctionalized as shown in Figure 4.14. By using PAI, the intratumoral 
accumulation of the nanostars (color coded in Figure 4.14 ; green pixels) was monitored and 
overlaid over the anatomical ultrasound image. Three hours after i.v. injection, some 
accumulation of the non-biofunctionalized nanostars (signal intensity: 0.042 ± 0.012 a.u.) was 
observed at the tumor border using PAI (Figure 4.14 . Top: Photoacoustic images overlaid on 
ultrasound images are shown for SKOV3 tumors before and after systemic injection (i.v.) of non-
biofunctionalized nanostars (MAL) or biofunctionalized with either 2Rb17c (POS) or cAbcII10 
(NEG). All nanostars were also blocked with SHOH. The PA signal of the nanostars is shown in 
green pixels. Bottom: Quantification of the PA signals. A much higher and also intratumoral 
accumulation was noticed for the 2Rb17c functionalized nanostars (signal intensity: 0.088 ± 0.023 
a.u.) showing the in vivo targeting capabilities of these nanostars. The cAbBcII10 
biofunctionalized nanostar showed almost no accumulation inside the tumor, even not around the 
tumor vasculature (0.006 ± 0.005 a.u.). As well some spatial overlap was noticed when 
distinguishing the overlapping nanostar and the oxyhemoglobin signal (Figure 4.15). 
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Figure 4.14 . Top: Photoacoustic images overlaid on ultrasound images are shown for SKOV3 tumors 
before and after systemic injection (i.v.) of non-biofunctionalized nanostars (MAL) or 
biofunctionalized with either 2Rb17c (POS) or cAbcII10 (NEG). All nanostars were also blocked with 
SHOH. The PA signal of the nanostars is shown in green pixels. Bottom: Quantification of the PA 
signals. 
To cross-validate the photoacoustic imaging results, the tumors and other organs (liver, spleen, 
heart and kidney) were isolated immediately after PAI. Organs were fixed and sectioned for 
darkfield microscopy.  As depicted in Figure 4.16, no nanostars were detectable in the tumor after 
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systematic injection of cAbBcII10 functionalized nanostars.  For the non-biofunctionalized 
nanostars, some nanostars could be visualized at the tumor border. For the 2Rb17c functionalized 
nanostars, some nanostars were present at the tumor border and even more were found in and 
around vesicular structures within the tumor. For the other studied tissues, no differences were 
observed in nanostar accumulation between the specifically labeled versus control nanostars 
(Figure 4.17). As expected, the liver and spleen showed high accumulation of nanostars, whereas 
almost no nanostars were detectable in the heart and kidney.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Photoacoustic image of the SKOV3 tumor after spectral unmixing to visualize 
oxyhemoglobine (red) and the 2Rb17c functionalized nanostars, blocked with SHOH (green). By 
spectral unmixing, a distinction between the oxyhemoglobine and nanostars signal was made 
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Figure 4.16 Representative ex vivo darkfield images of the tumor tissue section after systemic 
injection of the 2Rb17c functionalized nanostars (POS), cAbcII10 functionalized nanostars (NEG) 
and non-biofunctionalized nanostars (all functionalized with the blocking agent SHOH). The 
nanostars are visualized as yellow spots inside the tumor tissue 
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Figure 4.17 Ex vivo darkfield images of sections of different organs of mice that were systemically 
injected with the 2Rb17c functionalized nanostars (POS), cAbcII10 functionalized nanostars (NEG) 
and non-biofunctionalized nanostars (all were functionalized with the blocking agent SHOH). The 
nanostars are visualized as yellow spots inside the tumor tissue. 
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4.4 Discussion 
For future clinical applications in oncology with gold and other nanoparticles it will be crucial to 
demonstrate under in vivo conditions their ability of an effective tumor targeting. This remains 
still a huge hurdle in nanoparticle research where variable success for active targeting has been 
indicated3,9,18,33. While many properties of nanoparticles have been optimized over the years, ‘the 
biggest hurdle in the next years’ that has been identified is the formation of a protein corona in 
vivo19. We have developed here a viable strategy to decrease the thickness of the protein corona 
to overcome steric hindrance and to improve the active targeting.  
 
In this study, two different types of nanobodies, either 2Rb17c, targeting the HER2 receptor on 
the ovarian cancer cell line SKOV3, or cAbBcII10 as a control nanobody were used. For both, a 
maximum optimal biofunctionalization concentration was deducted where at higher 
concentrations the nanostars aggregated due to the osmotion depletion effect34. This effect 
describes that the nanostars exert a repellent force on the charged nanobodies in suspension due 
to the presence of the PEG units in the coating layer. Above a critical nanobody concentration, 
the nanostars will aggregate since the repellent force is too large, which induces attraction forces 
between the nanostars.  
 
Either the fraction of the monomer or the dimer nanobodies were used for nanostar 
biofunctionalization. Between these two different formats of nanobodies, a difference in 
maximum optimal biofunctionalization concentration was observed. With the monomer fraction, 
a higher biofunctionalization concentration could be added to the nanostar’s suspension compared 
to the reduced dimer fraction. This was probably due to the previously described capping of the 
monomer’s reactive thiol group during the nanobody synthesis, which resulted in less reactive 
monomers that could bind to the nanostars24. Since similar trends in the LSPR shift, hydrodynamic 
diameter changes and zetapotential were seen for the two different kinds of batches, we can 
assume that there was no difference between the nanostars that have been coupled either by the 
monomer or the reduced dimer nanobody coupling on these nanostars. The successful coupling 
of the nanobodies was confirmed by active targeting under serum-free conditions for the nanostars 
that were functionalized with 2Rb17c nanobodies.  
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For in vivo applications, it is crucial that the nanostars are able to specifically target HER2-
expressing tumor cells in the presence of serum. When incubating the nanostars in serum 
containing medium even at a low temperatures, which will block passive targeting, no active 
uptake could be detected in the tumor cells. This absence of active targeting in serum conditions 
has been attributed to the formation of a protein corona around these nanostars as seen by the 
hydrodynamic diameter increase. The biological ligands on the nanostars are believe to be 
completely capped by serum proteins, inhibiting the possibility to bind with receptors on tumor 
cells19.  
 
It has been shown that the maleimide end is responsible of the formation of a protein corona 
around the nanoparticles18. Maleimide end groups are highly reactive at neutral pH. By blocking 
the maleimide end groups using compounds with an end-standing thiol group, the formation of a 
protein corona could potentially be reduced. Different molecules were evaluated for their capacity 
to affect the thickness of the protein corona by changing the charge of the end group or the build-
in of a PEG-chain in the molecule13.  SHOH (2-mercaptoethanol) showed the strongest decrease 
in the hydrodynamic diameter of the gold nanostars, most likely due to their neutral end group 
and small size10. Compared to these neutral end groups, charged groups show a less significant 
decrease in protein corona thickness likely due to an electrostatic interactions with biomolecules 
present in serum35. However, compared to the non-blocked nanostars with a maleimide end group, 
a decrease in the protein corona is still visible due to a lower reactivity of these charged end 
groups. Unexpectedly, blocking ligands with a PEGylated back-chain showed less protein corona 
reduction compared to the shorter molecules. This could possibly be caused by the steric 
hindrance during functionalizing the nanostars with the PEGylated blocking agents where less 
blocking molecules may have reacted with the maleimide end groups. As a result, there could still 
be reactive maleimide end-groups on these nanostars.  
 
In vitro evaluation in SKOV3 cell culture allowed verifying whether the changed thickness of the 
protein corona had an effect on passive uptake. Indeed, uptake of nanostars blocked with the short 
molecules was lowest for the SHOH functionalized nanostars confirming the effect of a reduced 
protein corona 13,36 Similarly, the PEGylated molecules showed less reduction of uptake, probably 
due to the non-significant decrease of the protein corona. The optimal thickness may be subtle as 
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the total absence of a protein corona was reported to again increase the nanoparticle uptake16. 
Overall, the size of the protein corona may define the degree of passive uptake by tumor cells, 
which could also have an influence on the recognition by the reticuloendothelial system37. 
 
When using the optimal SHOH blocking strategy on the biofunctionalized nanostars, nanobody-
specific uptake was realized in both non-serum and serum conditions at both low and high 
temperatures. The successful active targeting is most likely due to combined effect of decreased 
passive targeting and a decreased protein corona thickness18. The latter avoids sterically hindrance 
of the nanobodies enabling receptor recognition on the tumor cells. Although the increase of the 
hydrodynamic diameter may predict failure of active targeting under in vitro conditions, the 
situation could be completely different in vivo where the reticuloendothelial system other serum 
proteins and the EPR effect must be taken into account30. 
 
We could demonstrate that reducing the size of the protein corona size and increasing in vitro 
targeting capabilities are indeed good predictors for active targeting of nanostars under in vivo 
conditions. PAI and ex vivo darkfield microscopy confirmed intratumoral accumulation of 
2Rb17c-functionalized nanostars, both inside the tumor and on the tumor periphery. The tumor 
periphery is characterized by high vascular density and lower intratumoral pressure, resulting in 
higher nanostars accumulation38. However, nanostars always accumulated near blood vessels due 
to the low penetration of these nanostars inside the tumor tissue. This is mainly caused by the 
relatively large size and anionic charges of the nanostars39. The non-biofunctionalized nanostars 
showed also a significant but lower uptake in the tumor periphery. Due to the blocking of the 
protein corona formation, nanostars are less recognized by the RES36, resulting in a longer blood 
retention time, which increases the possibility that nanoparticles accumulate into the tumor. The 
active targeting was further confirmed by cAbBcII10-functionalized nanostars that did not show 
any uptake inside the tumor. 
 
Several hurdles have yet to be overcome to improve active targeting and intratumoral 
accumulation compared to a passive targeting strategy. It has to be kept in mind that active 
targeting still depends on the EPR effect for the nanoparticles to diffuse into the tumor2. This also 
applies to the HER2 receptor targeted in this study. Only due to the EPR effect nanostars can  
reach the SKOV3 tumor cells. By targeting a receptor on the vasculature like the vascular 
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epidermal growth factor (VEGFR), an enhanced uptake of the nanoparticles inside the tumor is 
possible since the EPR effect is no requirement40. Another important factor for a successful 
therapy is to minimize the nanoparticle uptake by the RES, which resulted in high concentrations 
of gold nanostars inside the liver and spleen as also seen in our study41. This could potentially 
have a long-term toxic effect on these tissues, such as by changing the cell morphology or genetic 
alterations42,43.  
4.5 Conclusion 
Taken together, we show the specificity of the 2Rb17c-functionalized nanostars to HER2 
expressing tumor cells by decreasing the size of the protein corona using 2-mercaptoethanol as a 
blocking agent. Hereby, the biological identity of the nanostars was tailored so that active 
targeting could be achieved in vitro and in vivo making them an ideal candidate for later 
theranostic applications. Further research, including a better understanding of the nanoparticle-
RES interaction may help to transfer these nanostars to a clinical theranostic application in the 
future
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5 DEVELOPMENT OF RAMAN-LABELED 
NANOSTARS AS A BIOCOMPATIBLE TUMOR 
CONTRAST AGENT FOR IN VIVO SERS 
IMAGING. 
 
 
5.1 Introduction 
 
Diagnosing cancer at an early stage by improving imaging approaches is key to increase the 
survival of cancer patients. Optical imaging techniques such as SERS have gained interest in this 
field where the optical selectivity is used for better tumor tissue discrimination. SERS exploits 
the enhanced Raman scattering by bringing a Raman molecule close to a metal surface such as 
on gold nanoparticles. Hereby an enhancement by 1010-12 of the Raman signal could be realized. 
As a consequence, SERS has made its introduction into the biomedical field since the technique 
enables the very sensitive detection of molecules and easy discrimination based on a fingerprint 
spectrum.  
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On one hand, SERS has been introduced for the detection of analytes in a label-free manner where 
they interact with the metal surface. On the other hand, SERS-active structures that have the 
Raman label is already coupled to the surface, are used to follow the interaction of these structures 
up to the level of single molecule detection. Examples of the successful use of the Raman labeling 
approach are the discrimination of different cell types, viruses and other lab-on-a-chip 
applications. Also in vivo, these SERS-active structures, such as nanorods or nanospheres have 
shown his potential to discriminate these labels inside different tissues119,193–19776,95. 
 
Aiming at cancer diagnosis with the aid of SERS, gold nanoparticles have been extensively 
studied as potential ideal  SERS contrast agents 76,95,96,99,195,198–200.  The criteria for an ideal SERS 
contrast agent is to have a high enhancement factor of the Raman signal by creating locally high 
electric fields. Hereby several shapes have been introduced ranging from nanorods, nanostars, 
dimers etc76. All these nanoparticles are equipped with sharp tips generating these high electric 
fields upon irradiation201. In particular, nanostars have several sharp tips, and are as a consequence 
efficient surfaces / carriers for SERS labels which enables detection down to the pM level202,203. 
In vitro applications of sensitive SERS imaging using nanostars have been demonstrated for the 
study of cellular pathways, intracellular pH sensing or the detection of specific cells in histology 
sections93,94,98. Despite their high potential, nanostars have not been used as an in vivo SERS 
contrast agent despite their higher sensitivity compared to nanorods or nanospheres. 
 
In our approach, we aim to use the high sensitivity of these nanostars as an in vivo cancer 
diagnostic agent. Hereto, the nanostars have to be decorated with SERS reporters. This is not 
straightforward since changing the stabilizing coating of the nanostars may affect their stability 
in physiological conditions. Using in vitro experiments, we evaluate the properties and the 
potential of SERS-labeled nanostars to passively target tumor cells as described in chapter 2. By 
an in vivo passive targeting strategy blocking the protein corona with 2-mercapto ethanol as in 
chapter 4, SERS used to evaluate tthe nanostars will end up in the tumor by the EPR effect19,153. 
Using SERS, the passive uptake of nanostars in the tumor and biodistribution is evaluated which 
is crucial for later theranostic purposes.  
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5.2 Materials and methods 
 
5.2.1 Nanostars synthesis and functionalization 
Nanostars synthesis has been executed as explained in chapter 2. After synthesis the nanostars 
were suspended in 10 mL and functionalized with 1 mL of the desiring DTNB concentration after 
adding 100 μL NaOH (0.5 M). After 1,5h of shaking, the nanostars suspension was centrifuged 
for 60 min at 4500 rpm, the supernatans discarded and the nanostars pellet resuspended in water. 
Then the nanostars were functionalized with the SAM (HS–(CH2)11–(O–CH2–CH2)6–O–CH2–
MAL)2 according to the protocol in chapter 2. After functionalization, the nanostars were 
characterized using UV-Vis absorption spectroscopy, DLS and Zetapotential measurement, in 
water. To evaluate their SERS imaging capabilities, the nanostars were either dried on a silica 
wafer overnight or loaded into an agar phantom (as described in chapter 2).   
5.2.2 Darkfield microscopy analysis of cell- nanostar interaction. 
As in chapter 2, tumor cells (SKOV3) were seeded by 150 000 cells per well in a 12-well plate to 
study the cell-nanostars interaction. After 24h, nanostars with different SAMs (2.3x1010 particles 
in 1 mL) were added to the cells and incubated for 3h, 6h and 24h. After washing with PBS, these 
cells were again incubated overnight with fresh medium. After trypsinization, 300 μL of the cell 
suspension were either acid digested for ICP-OES or plated on a coverslip in 1 mL of fresh 
medium in a 12 well plate and incubated overnight.  After fixation with 4% paraformaldehyde in 
PBS (4% PFA), these coverslips were mounted on a glass slide and visualized with darkfield 
microscopy or the Raman microscope type alpha 300R, WITec, Ulm, Germany). Darkfield 
microscopy images were quantified by using CoralPaint software where yellow pixels (nanostars) 
and green pixels (tumor cells) were detected from the images and converted into white pixels 
(Figure M1). The amount of white pixels was calculated for both conditions where afterwards the 
amount of nanostars pixels was divided by the amount of cell pixels to result in the nanostars/cell 
density. These glass slides were also imaged using the Raman microscope (785 nm, 40mW, 5 sec 
integration time, raster of 40x40 µm).  
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5.2.3 Evaluation of in vivo biodistribution using ICP-OES and darkfield 
microscopy.  
Athymic nude mice were, as in chapter 2, injected subcutaneously with tumor cells. We let the 
tumors grow for 2-3 weeks. Afterwards, nanostars (200 µl, 2,3 mg Au/ml) were injected via the 
tail vein (n = 4 for each condition).  After 24h the mice were imaged with Raman microscopy. 
After this imaging slot the animals were sacrificed, transcardially perfused with 4%PFA and the 
heart, the liver, the spleen, the kidneys and the tumors were dissected and stored in PBS with 
0,1% sodiumazide (Sigma). These organs and tumors were ex vivo visualized using the Raman 
Witeq microscope using the same settings as in vivo. For darkfield microscopy, the dissected 
organs were embedded in paraffin to make sections of 7 µm thickness with a microtome (HM360, 
Prosan). The sections were placed on microscope slides and deparaffinized before darkfield 
microscopy. 
5.3 Results 
 
5.3.1 Nanostar synthesis and functionalization with SERS label 
 
The nanostars are designed as described previously in chapter 2, resulting in nanostars absorbing 
the light in the NIR region. As a SERS label, DTNB was chosen, since it has a high Raman cross 
section and is used extensively in literature204–208. To find the optimal DTNB concentration for 
functionalizing the nanostars with this label, a concentration range (10 mM; 1 mM; 0.1 mM; 0.01 
mM and 0.001mM) was added on these nanostars. An optimal concentration of 0.1 mM was 
chosen since it did not affect the stability of the nanostars and it showed a stable LSPR peak shift 
and hydrodynamic diameter increase. A broadening and decrease of intensity of the LSPR band 
occurred at higher concentrations, indicating instability of the nanostars (Figure 5.1). This 
instability was confirmed by a too large hydrodynamic diameter increase of 21.04 ± 0.84 nm 
when functionalizing the nanostars with 10 mM DTNB (Table 5.1). Moreover starting at a 
functionalization concentration of 0.1 mM a second band appeared in the absorption spectrum 
around 412 nm due to the creation of 3-thio-6-nitrobenzoate (TNB-) molecules in the solution. 
The successful functionalization of these nanostars with the DTNB molecule was confirmed by a 
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red shift of this absorption band and increase in the hydrodynamic diameter by 8.14 ± 0.63 nm. 
With only the DTNB label on the nanostar surface, the nanostars are only stable in salt 
concentrations up to 0.03 M NaCl. 
 
 
 
Figure 5.1 Left: UV-Vis of the nanostars functionalized with a concentration range of DTNB. A 
second band is appearing due to the formation of TNB-. Right: LSPR band of the nanostars 
functionalized with 0.1 mM DTNB for different salt concentrations, showing the nanostar instability 
by a decrease in intensity. 
Table 5.1. For a given set of DTNB concentration the LSPR band shift, hydrodynamic diameter 
increase is reported together with the maximum salt concentration where the nanostars remain in 
suspension.  
DTNB (mM) LSPR peak shift 
Hydrodynamic 
diameter increase (nm) 
Maximum salt 
concentration (M) 
0.001 1.33 ± 0.58 6.35 ± 1.77 0.06 M 
0.01 2.33 ± 0.59 9.39 ± 1.49 0.06 M 
0.1 3.67 ± 1.15 8.14 ± 0.63 0.03 M 
1 4.33 ± 1.53 7.04 ± 0.61 0.03 M 
10 4.67 ± 1.53 21.04 ± 0.84 0.03 M 
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For increasing the stability in physiological conditions, the nanostars were afterwards 
functionalized with the SAM as described in chapter 2. As with the DTNB functionalization, a 
red-shift in the LSPR band (5.30 ± 1.66 nm) and increase in hydrodynamic diameter (6.12 ± 1.57 
nm) was measured after SAM functionalization (Figure 5.2). These nanostars with a SAM 
molecule, the nanostars are stable up to a concentration of 1M NaCl (Figure 5.2). After 
functionalization the nanostars had an anionic zetapotential of -33.3 ± 3.4 mV. 
 
Figure 5.2 Left: UV-Vis spectrum of the ‘naked’ nanostars, nanostars functionalized with 0.1 mM 
DTNB and with a SAM. As inset the LSPR band shift to the NIR region due to the binding of these 
molecules to the nanostar surface. Right: LSPR band of the nanostars functionalized with DTNB and 
SAM for different salt concentrations showing no instability. 
 
Due to the SAM functionalization, the SAM’s molecules could replace the Raman labels on the 
nanostars. Therefore the SERS contrast generation (785 nm, 40 mW and 10 sec integration time) 
was measured of dried nanostars on a silica wafer using either nanostars functionalized with 
DTNB and SAM or nanostars only functionalized with the SAM. As shown in Figure 5.3, a clear 
DTNB spectrum could be deducted from the nanostars functionalized with DTNB and SAM with 
the highest intensity at 1333 cm-1. This confirms that the SAM molecule has not replaced all the 
DTNB molecules on the nanostars. Conversely, for the nanostars SAM no SERS signal could be 
measured.   
 
Gold nanostars as a specific theranostic agent against HER2 expressing tumor cells 
 
 
 
120  Antoine D’Hollander  
 
 
 
 
Figure 5.3 Left: Brightfield microscopy images of the nanostars dried on a silica wafer where the 
SERS signal intensity at 1333 cm-1 is visualized in the zoom picture. Right: SERS spectrum of the 
corresponding nanostars either labeled with DTNB and SAM or only functionalized with the SAM 
molecule.  
 
To evaluate the SERS capabilities of the nanostars for later in vivo applications, the sensitivity of 
SERS detection for the different nanostars concentrations (250, 125, 62.5, 31.3, 15.7 µM Au) has 
been evaluated after loading them into an agar phantom. During SERS imaging they are irradiated 
with a continuous laser (785 nm, 40 mW and 60 sec integration time). Within the phantom, for 
all nanostar concentrations, a detectable DTNB spectrum was measured with the maximum 
intensity at 1333 cm-1 (Figure 5.4). When plotting the intensity at 1333 cm-1 for the different gold 
concentrations, a LOD a linear relation was deducted between the Raman intensity and gold 
concentration. Using a linear fit, a LOD of 13 μM was calculated.  
 
Chapter 5: Development of Raman-labeled nanostars as a biocompatible tumor contrast agent for in vivo 
SERS imaging. 
 
 
 
Antoine D’Hollander   121 
 
 
 
 
Figure 4. SERS spectrum for different concentration (µM Au) of the SERS labeled nanostars 
embedded 2mm deep in in an agar phantom. As inset the intensity at 1333 cm-1 plotted for the 
different concentrations. 
 
5.3.2 SERS to visualize the in vitro uptake in tumor cells 
Prior to using these nanostars in vivo, the in vitro uptake by the tumor cells was studied. After 3, 
6 and 24h incubation, the increase in intracellular uptake of the nanostars was visualized by dark-
field microscopy and quantified by ICP-OES. The gold quantification increased over time, going 
from 0.3 ± 0.9 pg Au/cell after 3h, 4.4 ± 0.68 pg Au/cell after 6h, up to 8.05 ± 1.1 pg Au/cell 
measured after 24h, 2, compared to 0.1 ± 0.05 pg Au/cell for the control cells using ICP-OES. 
Darkfield microscopy confirmed the intracellular uptake of nanostars, by visualizing nanostars 
inside the cells (Figure 5.4).  
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Figure 5.4 Left: Darkfield microscopy pictures where an increase of gold nanostars inside the tumor 
cells is visualized over time Right: SERS spectrum of the corresponding cells labeled with nanostars, 
showing the highest intensity peak at 1333 cm-1 
 
On these time points, we collected the SERS spectra of the cultured cells by a raster scan with a 
resolution of 1 µm. At these conditions only SERS spectrums were measured since no normal 
Raman spectrum was measured with the control cells. When acquiring the SERS spectra of the 
cells labeled for 6 and 24h with the nanostars, a clear SERS signal was measured (Figure 5.4). 
For these two a distinct peak at 1333 cm-1 was detected that was absent for the control spectrum. 
After 24h labeling, the highest SERS peak was observed. Together with the higher Au 
concentration measured after 24h of incubation, this indicates that the SERS label did not detach 
from the nanostars after intracellular uptake. After 3h, no distinct Raman peak was measured, 
however having some nanostars inside the tumor cells as indicated by the dark field microscopy 
picture. Moreover, for all conditions a significant background signal is observed between 1300-
1400 cm_1 that can be contributed to the glass coverslip. This background signal could be reduced 
by using quartz coverslips, thereby increasing the potential in vitro sensitivity. Since the nanostars 
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are located in specific endosomes as shown in chapter 2, these spots of the nanostars could be 
mapped inside the cells, confirming the intracellular uptake (Figure 5.5). 
5.3.3 SERS as an in vivo imaging tool using nanostars as contrast agents 
 
To validate the in vivo SERS imaging capabilities of these nanostars as a cancer diagnostic agent, 
the Raman labeled nanostars were i.v. injected to passively target the tumor. 3h after i.v. injection 
of these nanostars, the SERS spectrum of the tumor, liver and control tissue were deducted with 
the Witec microscope. Both the SERS spectrum of the liver and tumor are shown after background 
and control tissue deduction in Figure 5.6. For both of them a clear SERS band at 1333 cm-1 was 
visualized showing the accumulation of these nanostars in the respective organs. Due to the 
recognition of the nanostars by the RES a high SERS signal was observed in liver with an intense 
peak at 1333 cm-1. Next to the liver, some of the nanostars accumulated in the tumor with a 
corresponding DTNB SERS spectrum. However due to the inhomogeneous accumulation of the 
nanostars inside the tumor, not at all points a detectable SERS spectrum was observed.  
Figure 5.5 Brightfield image of a tumor cell overlaid by a SERS intensity image where at high 
intensities at the wavenumber of 1333 cm-1 yellow spots are visualized. 
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Figure 5.6 SERS spectrum of the liver and tumor 3 hours after i.v. injection of the nanostar where 
the background and control tissue have been subtracted. For both a clear peak at 1333 cm-1 was 
visible. 
 
After sacrificing the animals, several organs were examined to evaluate their nanostar 
accumulation and corresponding SERS signal ex vivo (Figure 5.7). By ex vivo darkfield imaging 
of the organs, a clear nanostar accumulation was observed in the liver, spleen and tumor 
confirming the ex vivo SERS signal observations (Figure 5.7). No nanostars were visualized in 
the kidney and heart, corresponding to a background SERS spectrum. Regarding the tumor, the 
nanostars seem to preferentially accumulate in its periphery due to a higher vascular density. As 
a consequence, only at these locations a SERS signal was measured while in the tumor mass itself 
almost no SERS signal was measured.  
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Figure 5.7 Left: Darkfield images of the different tissues where nanostars (gold spots) were clearly 
visualized inside the liver, spleen and in less amount at the tumor border. Right: SERS spectra of the 
different tissues where a DTNB spectrum was observed for the spleen, liver and tumor border. 
5.3.4 Discussion 
 
Due to its unique fingerprint Raman spectra, SERS is recently emerging as one of the most 
promising tools for in vivo biosensing and imaging. By changing the shape, different types of 
SERS labeled gold structures have been introduced and described in the literature. However the 
focus for in vivo use has been mainly on the use of nanorods and nanospheres. To the best of our 
knowledge, the use of gold nanostars as an in vivo diagnostic agent for cancer have never been 
addressed before. In this manuscript we proved applicability of these nanostars as an in vivo 
diagnostic agent using SERS. By functionalizing the nanostars with the DTNB label, these 
nanostars could be followed intracellular in vitro and on tissue level in vivo. 
 
Realizing this opportunity of SERS imaging using nanostars, the functionalization condition of 
the nanostars with the Raman label must be examined. An important criteria is the maximum 
DTNB concentration of 0.1 mM where we proved that at higher concentrations the nanostars 
became unstable due to the osmotion depletion effect ref.  Starting from this functionalization 
concentration we believe that the nanostars are fully covered with DTNB, resulting in negative 
charged 3-thio-6-nitrobenzoate (TNB-) in the solution. As has been discussed in chapter 4, these 
negative molecules in the suspension will induce osmotic depletion inducing the instability of the 
nanostars. The creation of TNB- molecules is confirmed by an absorbance band around 412 nm 
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that we measured starting from a concentration of 0.1 mM. An extra SAM functionalization step 
made this nanostars applicable for SERS detection in physiological conditions. 
 
A crucial parameter for high sensitive imaging is the LOD of these nanostars in phantom 
conditions. Hereby they showed a LOD of 13 μM which is higher compared to previous reported 
LODs64,209,210. Several reasons must be taking into account fort his higher concentration such as 
the embedding under an agar phantom layer of 2 mm agar layer mimicking the in vivo conditions, 
which decreases the irradiation effectiveness. Another reason is the mismatch between the laser 
wavelength and the plasmon absorption band (785 vs 680 nm). In this way the field at the tips of 
the nanostars is not the strongest resulting in a smaller enhancement of the DTNB Raman signal. 
Moreover, this sensitivity could be increased by incorporating the SERS label itself into the 
molecule of the SAM, covering the complete nanoparticle with this Raman label205. Another 
strategy is to have built-in hot spots in the particle itself, which can increase the SERS signal by 
103-4 211–213. 
 
However, with this LOD, the nanostars could be easily intracellularly visualized using SERS as 
confirmed by ICP-OES and darkfield microscopy. Hereby we established that a minimum 
concentration of 4.4 pg Au/cell is necessary to visualize the nanostars inside the cells. At higher 
concentrations a non-linear relation was noticed between the gold concentration and SERS signal 
intensity. While for ICP-OES an increase of 82 % gold per cell was measured between 6 and 24h, 
a higher SERS signal increase of 135 % was measured. As the nanostars concentrations show a 
linear relationship with the Raman signal, this non-linear relation is due to the creation of hot 
spots of the nanostars194. The nanostars will aggregate inside the acidic endosomal structures 
inside the cells, which will create these hot-spots structures. Looking at the nanostars 
accumulation itself a lower intracellular nanostars concentration was measured compared to the 
results in chapter 1 and 2. Hereby the less anionic zetapotential could have an influence on this 
decrease in intracellular uptake.  
 
The use of nanostars has been shown as an in vivo diagnostic agent for cancer. Still, not at all 
locations of the tumor, a detectable SERS signal was measured due to a low extravasation of these 
nanostars inside the tumor. Hereby the anionic charges and size decreases the penetration of these 
Chapter 5: Development of Raman-labeled nanostars as a biocompatible tumor contrast agent for in vivo 
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nanostars inside the tumor tissues. By functionalizing these nanostars with a biological ligand as 
in chapter 4, their tumor accumulation could be enhanced inside the tumor.  
 
Since SERS is limited by a light penetration depth of only 1-2 cm, this imaging modality can be 
used for tumor detection after i.v. injection76,100,118. SERS can be combined with CT or PAI in a 
multimodal imaging approach. By using these other techniques a full body and 3D image of the 
tumor with the nanoparticle signal could be provided, which is not possible with SERS alone. 
Still new techniques are envisioned to use SERS as a 2D imaging tool having fast scanning times 
by using a Raman microscope. For theranostic purposes these nanostars could be used as a 
therapeutic agent for either PTT, by increasing the tumor temperature to a lethal level for the 
tumor, or photodynamic therapy, by creating singlet oxygen atoms which are toxic for tumor cells 
92,99,100,212,214. SERS may Even be used as an aid for surgical removal benefitting from the high 
Raman contrast imaging capabilities.  SERS shows a high potential for applicability during 
surgery to define the tumor boundary, which is perfectly feasible within the 1-2 cm light 
penetration limits of SERS imaging124. Moreover, nanostars will accumulate preferentially at the 
tumor periphery delineating the tumor border during imaging as we showed.  
 
Conclusion 
 
In summary, physiological stable SERS-labeled nanostars show stable SERS signal in agar 
phantoms down to a concentration of 12 µM. In vitro these nanostars are easily taken up by tumor 
cells where they end up intracellularly in endosomal structures.  SERS imaging confirms this 
intracellular specific uptake inside cells where a minimum concentration of 4.4 pg Au/cell could 
be detected. Using these unique properties, SERS signal from the nanostars could be detected in 
the liver and tumor after simple i.v. injection. The presence of the nanostars has been confirmed 
by ex vivo SERS measurements combined with darkfield imaging. Taken together, based on our 
first in vivo results, we demonstrate that nanostars can be used as a diagnostic agent for cancer 
using SERS as a cheap optical imaging technique, with future applications in guidance for surgical 
removal.   
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6 CONCLUSION 
 
For the development of new therapeutic and diagnostic techniques of tumor masses, 
bionanotechnology and more specifically the novel nanoparticles is rapidly evolving as a 
promising technique169. One of the driving forces towards nanoparticles is the possibility to 
combine imaging and therapeutic capabilities on one specific nanoparticle3. Although many 
hurdles still have to be overcome before these nanoparticles may be used as a clinical agent in 
oncology. 
  
A huge variety of nanoparticles is currently studied with a focus on a better theranostic agent 
against cancer. A well-known class of nanoparticles are gold nanoparticles with their specific 
plasmonic properties29. These local plasmonic capacities are the basis for their theranostic 
potential. Dependent on the shape of gold nanoparticles, the plasmonic capacity changes as for 
nanorods, nanostars or nanocages compared to nanospheres74,201. While nanocages and nanorods 
are well described in literature, nanostars as a theranostic agent against cancer are still not fully 
developed. However, these nanostars shows a much more intense plasmonic effect compared to 
other particles, resulting in better imaging and therapeutic capabilities209.  
 
Within the field of gold nanoparticles, some are already in the clinical trial phase, but still many 
questions remain unanswered to predict the success of these nanoparticles as a theranostic agent3. 
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One of the main hurdles is the cell/ receptor-specific targeting efficiency of the nanoparticles due 
to the formation of a protein corona in vivo. 
  
The goal of this work was to establish a nanobody-functionalized gold nanostar targeting HER2-
positive tumor cells to overcome the protein corona problem. Using the intense plasmonic 
properties of nanostars, this could result in an effective theranostic agent for CT, PAI and SERS 
imaging as well as for PTT. In a first part of this work, it was our goal to study the effectiveness 
of the nanostars as a theranostic agent using CT, PAI, SERS and PTT (Chapter 2 and 5). In a 
second part, we studied the passive and active targeting capabilities of these nanostars in vitro 
and in vivo (Chapter 3 and 4). Here, we showed that the interaction of the nanostars with 
surrounding proteins to form a protein corona plays a crucial role for targeting efficiency.   
 
In Chapter 2, gold nanostars were successfully synthesized and functionalized with a stabilizing 
SAM layer. Crucial is that these nanostars fulfill the in vivo requirements as their plasmon band 
must be in the NIR region, their hydrodynamic diameter size has to be below 100 nm and they 
must maintain their stability under physiological conditions. It was shown by reducing the gold 
salt addition rate to 12.5 µL/min, that synthesized nanostars fulfilled these first requirements 
(plasmon band around 674.3 ± 8.3 nm and hydrodynamic diameter of 75.0 ± 5.6 nm).  After 
functionalization with the SAM molecules, these nanostars had an increased stability under 
physiological conditions.  
 
The imaging capabilities and therapeutic effectiveness of nanoparticles depends on their 
interactions with the targeted cells. In chapter 2, we showed that the gold nanostars showed a 
linear intracellular uptake by time, reaching to a plateau phase after 12h. After 24h, an 
intracellular gold concentration of 11.28 ± 0.82 pg Au/cell was measured, with particles ending 
up in vesicular structures, which was visualized by TEM.  These results clearly demonstrate that 
anionic charged nanostars with a hydrodynamic diameter below 100 nm are easily taken up by 
the targeted tumor cells.  
 
Due to this high cellular uptake, the nanostars can be used as a contrast agent using CT or PAI 
and as a photothermal therapeutic agent as demonstrated in chapter 2. Their capabilities to 
generate contrast in CT and PAI correlated exponentially with the intracellular gold concentration 
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where a higher LOD was calculated for PAI then for CT.  This exponential growth in contrast-to-
background is not only due to a higher intracellular gold concentration but also due to the 
aggregation of the nanostars inside the tumor cells. For therapy, the IC50 value is the most sensitive 
parameter to determine the therapeutic effectiveness. Our gold nanostars showed an IC50 of 5.8 
pg Au/cell, which corresponds to 150 k nanostars/cells. Another parameter to determine the 
therapeutic effectiveness is the laser power used to induce specific PTT. Here our power of 2 
W/cm2 is slightly lower than those determined for nanorods, or nanocages, again demonstrating 
the effectiveness of gold nanostars105,115. As a consequence, we can propose that nanostars shows 
slightly better theranostic capabilities. Still this also depends on the cellular interaction, 
combination with different therapeutic techniques etc.  
 
The ultimate test of theranostic properties of nanoparticles has to be performed in vivo since the 
situation from a physiological and cellular point is completely different compared to in vitro 
validations. This was performed by a proof of concept study where the nanostars were 
intratumoral injected. After injection, the nanostars showed an intense contrast in the tumor using 
both PAI and CT. Still a higher CNR was measured for PAI compared to CT, showing the higher 
sensitivity of this imaging method. For in vivo PTT, the laser conditions were optimized where a 
maximum laser power of 3.14 W/cm2 and a minimum gold concentration of 2.5 µM was necessary 
to result in an effective PTT. Using BLI, MRI and histology, a significant PTT was confirmed 
but regrowth of the tumor occurred after several days. This indicates that combination with other 
therapeutic approaches might be necessary. 
 
In the last chapter, the SERS imaging capabilities of the nanostars were studied using DTNB-
labeled nanostars. SERS is based on the enhanced inelastic scattering by a Raman-active label 
close to the gold surface88. As a consequence, this technique could be used as a new optical 
imaging technique for monitoring the formation and therapy of tumors using gold nanoparticles. 
Compared to PA and CT, no LOD could be calculated due to the imaging set-up. Still, SERS can 
be used as an imaging tool to visualize the location of the nanostars with high precision inside the 
cells, showing the specificity of this imaging technique. After i.v. injection of nanostars, SERS 
signal was measured in the liver and tumor region, confirming the location of the nanostars. Since 
the technique is based on optical imaging with a low penetration depth, it will have potential for 
translation into the clinic mainly as an imaging tool for tumor resection during surgery76. 
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Having the imaging and therapeutic properties optimized and quantified, a next step was to 
determine the targeting efficiency of functionalized gold nanostars in vitro and in vivo. Two 
targeting strategies have been described in the literature, either passive targeting using the 
inherent characteristics of the tumor, or active targeting. In Chapter 3, passive targeting has been 
studied using anionic nanostars with a different end group (MAL, MALOH or COOH). Using 
these nanostars under physiological conditions, an increase in hydrodynamic diameter was 
measured due to the formation of a protein corona on the nanostar’s surface. The protein corona 
is composed of several biological molecules dependent on the serum and nanoparticle 
characteristics as described before215. Moreover, we measured a difference in the thickness of the 
protein corona with the largest corona formed for nanostars with a maleimide end group and the 
lowest for nanostars with a COOH end group. This further supports the hypothesis that the 
thickness of protein corona depends on the reactivity of the end group. In contrary to literature, 
we see the highest uptake for nanostars with a thick protein corona compared to the nanostars 
with almost no protein corona161. The reason for this is still unclear to us, indicating the need for 
a more into detail research on the protein corona. The difference in the end group of the SAM 
layer has also an effect on the in vivo biodistribution of the gold nanostars. Due to the protein 
corona, the nanostars SAM MAL were immediately taken up by the RES and ended up in the 
liver and spleen, whereas the nanostars SAM COOH showed a lower uptake in the liver/spleen. 
Almost no nanostars were observed in the tumor, showing a non-effective PTT after i.v. 
administration. 
 
In Chapter 4, the active targeting of tumor cells with nanobody functionalized nanostars was 
studied. After biofunctionalization, these nanostars showed no specific cell uptake in vitro where 
the protein corona inhibited the interaction of the nanobodies with the HER2 receptors on the 
tumor cells. We believe this protein corona was generated due to the free maleimide end groups 
on the nanoparticles. Different agents were studied to chemically block the free maleimide groups 
where 2-mercaptoethanol showed the best inhibition on the formation of a protein corona. These 
nanostars showed less passive uptake by tumor cells, proving our theory that the protein corona 
may induce an inhibition of cell specific uptake. Also due this reduced protein corona, these 
nanostars are also less anionic resulting in a less favored cell uptake.  Using 2-mercaptoethanol 
to block the free maleimide groups after biofunctionalization, a specific uptake inside the tumor 
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cells expressing HER2 receptors was noticed. No specific uptake was noticed when the nanostars 
were biofunctionalized with the control nanobody or on a negative cell line with no HER2 
receptors. As a consequence, the protein corona is the limiting factor for active targeting of 
nanostars to tumor cells. This theory was also tested in vivo. Using PAI, specific active targeting 
was confirmed, where HER2-targeting nanostars are located close to the vasculature of the tumor. 
As a consequence, these nanostars may be used as a specific theranostic agent for HER2 
expressing tumor masses. 
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7 FUTURE PERSPECTIVES. 
 
With this multidisciplinary research, we aimed to improve the potential of gold nanostars as a 
theranostic agent for HER2 expressing tumor masses. Although, substantial progress has been 
made, there are still some remaining hurdles in order to implement this technique as a standard of 
care technique for cancer diagnosis and treatment. 
 
The synthesis of the nanostars is still batch dependent where several factors like time procedure 
to the compound masses play a big role on the resulted synthesized nanostars. Taken together 
with the functionalization, it takes approximately three days to produce a biofunctionalized 
nanobody where the free maleimide groups are blocked with 2-mercaptoethanol. Changing the 
synthesis set-up by using a flow reactor could result in a higher production yield and better defined 
batches. Also the follow-up of functionalization could be done in a different order by adding extra 
molecules one by one on the nanostar surface. By linking the nanobody, the SAM molecule and 
2-mercaptoethanol beforehand could increase the functionalization efficiency due to a higher 
nanobody loading on the nanostar surface. Before clinical testing, an automated synthesis and 
functionalization of the nanostar production under possibly GMP conditions must be realized, 
resulting in nanostars with less variability on size. 
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As stated in this thesis, the biggest hurdle is to optimize the right targeting strategies of the 
nanoparticles to the tumor. As have shown in the thesis, these targeting capabilities are dependent 
on so many factors as the nanoparticles characteristics (diameter, charge and material), to the set-
up of the experiment. These nanoparticle can show in vitro high tumor accumulation where this 
situation can be completely different in vivo with almost no tumor uptake after i.v. administration.  
. Here the biological identity in serum, due to the protein corona, have a huge influence on 
targeting efficiency140. Several strategies have been studied to overcome this problem. While we 
developed a way to inhibit the formation of a protein corona, other studies showed that tailoring 
the protein corona may result in a better nanoparticle uptake by the tumor cells179. By studying 
the effect of the nanoparticle characteristics on the protein corona and the cellular uptake, a 
strategy per particle could be defined to overcome this problem. In addition to experimental data, 
the focus is changing to also include results from modelling the protein corona178. This could 
potentially result to a simulation method to design the most optimal nanoparticle. After the 
assessment of targeting strategies in xenograft models, it will also be necessary to validate them 
in allograft models to better simulate the situation in patients and hereby better predict outcome 
once moving to clinical trials 
 
By overcoming the blockage of targeting ligands by the protein corona, the active targeting 
capacities also depends on the right choice of targeting molecule for active targeting. We have 
chosen the well characterized HER2 receptor of tumor cells. However, this receptor has the 
disadvantage that the particles still need to pass the blood barrier to reach the tumor cells. Here, 
the possibility of finding other target molecules should be considered in future studies. By 
choosing a vascular target as the vascular epidermal growth factor, the targeting efficiency could 
potentially be improved57. Still this targeting efficiency is dependent on the vascularization of the 
tumor. By promoting the vascular growth within the tumor, this targeting efficiency could be 
improved as has been showed for other drug molecules216. Not only reaching the target/ tumor 
should be taken into account, also the intratumoral distribution is an important criteria217. Here, 
the nanoparticle dimension and charge will play an important role. The mechanisms of 
intratumoral distribution of nanoparticles are not well understood and need to be evaluated 
further, as they will have an effect on the imaging and therapeutic effectiveness. The distribution 
of nanoparticles within a tumor is of some importance for tumor diagnosis but even more 
important for potential applications as theranostic agents. Crucial is to choose the right 
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combination of therapy and imaging technique for the specific tumor types. Among others, this 
will depend on the LOD and the depth penetration of an imaging or therapy technique. For 
example, the low depth penetration of SERS will only permit clinical applications like the intra-
operative use during tumor resection. On the other hand, imaging sensitivity and contrast could 
be further increased by changing the design of the gold nanoparticles. Here, combining different 
materials on one nanoparticle could potentially increase the range of imaging techniques. For 
example, an iron nanoparticle with a gold layer could be potentially also used as a MRI contrast 
agent. On the therapeutic side, we are limited to tumors located under the skin or exposed during 
surgery due to the low laser penetration depth. To increase the therapeutic effectiveness, 
photodynamic therapy could still be combine with other therapies, such as temperature sensitive 
drug release14,17.  
 
 
Next to studying the targeting and theranostic capabilities, two important criteria’s have not been 
touched in this thesis, namely possible long term toxicity and possible excretion of nanoparticles. 
As these nanoparticles are not biodegradable, they will stay in the tumor site. As a consequence, 
gold nanoparticles are to single time point applications. While the properties of nanoparticles used 
in this thesis have the right diameter for targeting and theranostic applications, they are less 
favorable to avoid excretion. Nanoparticles with a diameter larger than 10nm will not be excreted 
by the kidneys, but will mainly accumulate inside the liver and spleen48. Within the liver, they are 
taken up by the Kupffer cells, where most studies showed no short term toxicity within these cells. 
Still on long-term toxicity, more studies were generated that showed alteration in the genotype 
expression of these Kupffer cells loaded with gold nanoparticles218. As a consequence, these 
nanoparticles should be further intensively studied for long-term effects on different cell 
morphologic and gene expression parameters before clinical studies can be considered. The 
outcome of these studies will have a huge influence on the optimal nanoparticle characteristics 
for tumor targeting and therapy.  
 
In conclusion, this PhD study emphasized on the theranostic capabilities of the gold nanostars and 
tried to overcome problems associated with the protein corona to achieve active targeting of tumor 
cells. More in depth research is needed on toxicity and long term distribution and stability to 
evaluate if these nanostars could be used as a theranostic agent in the clinic. Looking at the bigger 
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picture, more coordinated research is needed between centers to study the potential of (gold) 
nanoparticles as a theranostic agent. Every research center is trying to develop their own ‘optimal’ 
nanoparticle while huge questions about metal nanoparticles still need to be solved before 
developing a new theranostic agent.  The next years will be crucial for nanoparticle research if 
they will have a potential as a standard of care technique for cancer diagnosis and treatment.
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APPENDIX 1 
 
 
1.2 mM 2.4 mM 12 mM 1.2 mM 2.4 mM 12 mM 1.2 mM 2.4 mM 12 mM 1.2 mM 2.4 mM 12 mM 1.2 mM 2.4 mM 12 mM
LSPR band shift (nm) 2.33 ± 0.29 2.67 ± 0.76 -0.50 ± 0.50 1.17 ± 0.29 2.00 ± 0.50 -0.83 ± 0.28 1.50 ± 0.50 1.67 ± 0.29 -0.17 ± 0.76 1.83 ± 0.29 2.00 ± 0.50 3.17 ± 0.76 1.67 ± 0.29 2.17 ± 0.29 1.67 ± 0.29
Hydrodynamic diameter change (nm) -3.75 ± 0.86 -4.06 ± 1.09 -4.75 ± 0.54 -4.19 ± 1.50 - 3.85 ± 1.50 -4.04 ± 2.26 -3.45 ± 1.24 -4.05 ± 2.24 - 4.43 ± 2.02 -3.32 ± 1.15 -3.07 ± 0.87 -2.16 ± 2.60 -2.89 ± 1.17 -3.70 ± 1.07 -3.57 ± 1.81
SHNH SHOH SHCOOH PEGCOOH PEGCH
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